000083436512-312024Q3falseP3YP1YP1YP4YP1Yhttp://fasb.org/us-gaap/2024#PrimeRateMember311311xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesblfs:reportable_segmentblfs:reporting_unitxbrli:pureblfs:employeeblfs:lawsuitblfs:peer00008343652024-01-012024-09-3000008343652024-11-0500008343652024-09-3000008343652023-12-310000834365us-gaap:SeriesAPreferredStockMember2023-12-310000834365us-gaap:SeriesAPreferredStockMember2024-09-300000834365us-gaap:ProductMember2024-07-012024-09-300000834365us-gaap:ProductMember2023-07-012023-09-300000834365us-gaap:ProductMember2024-01-012024-09-300000834365us-gaap:ProductMember2023-01-012023-09-300000834365us-gaap:ServiceMember2024-07-012024-09-300000834365us-gaap:ServiceMember2023-07-012023-09-300000834365us-gaap:ServiceMember2024-01-012024-09-300000834365us-gaap:ServiceMember2023-01-012023-09-300000834365blfs:RentalRevenueMember2024-07-012024-09-300000834365blfs:RentalRevenueMember2023-07-012023-09-300000834365blfs:RentalRevenueMember2024-01-012024-09-300000834365blfs:RentalRevenueMember2023-01-012023-09-3000008343652024-07-012024-09-3000008343652023-07-012023-09-3000008343652023-01-012023-09-300000834365us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2024-06-300000834365us-gaap:CommonStockMember2024-06-300000834365us-gaap:AdditionalPaidInCapitalMember2024-06-300000834365us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300000834365us-gaap:RetainedEarningsMember2024-06-3000008343652024-06-300000834365us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300000834365us-gaap:CommonStockMember2024-07-012024-09-300000834365us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300000834365us-gaap:RetainedEarningsMember2024-07-012024-09-300000834365us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2024-09-300000834365us-gaap:CommonStockMember2024-09-300000834365us-gaap:AdditionalPaidInCapitalMember2024-09-300000834365us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300000834365us-gaap:RetainedEarningsMember2024-09-300000834365us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2023-06-300000834365us-gaap:CommonStockMember2023-06-300000834365us-gaap:AdditionalPaidInCapitalMember2023-06-300000834365us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300000834365us-gaap:RetainedEarningsMember2023-06-3000008343652023-06-300000834365us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300000834365us-gaap:CommonStockMember2023-07-012023-09-300000834365us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000834365us-gaap:RetainedEarningsMember2023-07-012023-09-300000834365us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2023-09-300000834365us-gaap:CommonStockMember2023-09-300000834365us-gaap:AdditionalPaidInCapitalMember2023-09-300000834365us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300000834365us-gaap:RetainedEarningsMember2023-09-3000008343652023-09-300000834365us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2023-12-310000834365us-gaap:CommonStockMember2023-12-310000834365us-gaap:AdditionalPaidInCapitalMember2023-12-310000834365us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000834365us-gaap:RetainedEarningsMember2023-12-310000834365us-gaap:AdditionalPaidInCapitalMember2024-01-012024-09-300000834365us-gaap:CommonStockMember2024-01-012024-09-300000834365us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300000834365us-gaap:RetainedEarningsMember2024-01-012024-09-300000834365us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2022-12-310000834365us-gaap:CommonStockMember2022-12-310000834365us-gaap:AdditionalPaidInCapitalMember2022-12-310000834365us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000834365us-gaap:RetainedEarningsMember2022-12-3100008343652022-12-310000834365us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300000834365us-gaap:CommonStockMember2023-01-012023-09-300000834365us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300000834365us-gaap:RetainedEarningsMember2023-01-012023-09-300000834365blfs:CustomerAMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2024-01-012024-09-300000834365blfs:CustomerAMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2023-01-012023-12-310000834365blfs:CustomerBMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-09-300000834365blfs:CustomerBMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-09-300000834365blfs:CustomerCMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-07-012024-09-300000834365us-gaap:ProductConcentrationRiskMemberblfs:CryoStorProductsMemberus-gaap:SalesRevenueNetMember2024-07-012024-09-300000834365us-gaap:ProductConcentrationRiskMemberblfs:CryoStorProductsMemberus-gaap:SalesRevenueNetMember2023-07-012023-09-300000834365us-gaap:ProductConcentrationRiskMemberblfs:CryoStorProductsMemberus-gaap:SalesRevenueNetMember2024-01-012024-09-300000834365us-gaap:ProductConcentrationRiskMemberblfs:CryoStorProductsMemberus-gaap:SalesRevenueNetMember2023-01-012023-09-300000834365country:USus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-07-012024-09-300000834365country:USus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-07-012023-09-300000834365country:USus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-09-300000834365country:USus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-09-300000834365us-gaap:EMEAMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-07-012024-09-300000834365us-gaap:EMEAMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-07-012023-09-300000834365us-gaap:EMEAMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-09-300000834365us-gaap:EMEAMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-09-300000834365blfs:GeographicOtherMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-07-012024-09-300000834365blfs:GeographicOtherMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-07-012023-09-300000834365blfs:GeographicOtherMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-09-300000834365blfs:GeographicOtherMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-09-300000834365us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-07-012024-09-300000834365us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-07-012023-09-300000834365us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-01-012024-09-300000834365us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-09-300000834365blfs:OneSupplierMemberus-gaap:SupplierConcentrationRiskMemberblfs:SupplyPurchaseMember2023-07-012023-09-300000834365blfs:OneSupplierMemberus-gaap:SupplierConcentrationRiskMemberblfs:SupplyPurchaseMember2023-01-012023-09-300000834365blfs:OneSupplierMemberus-gaap:SupplierConcentrationRiskMemberus-gaap:AccountsPayableMember2024-01-012024-09-300000834365blfs:OneSupplierMemberus-gaap:SupplierConcentrationRiskMemberus-gaap:AccountsPayableMember2023-01-012023-12-310000834365srt:ScenarioPreviouslyReportedMember2023-12-310000834365srt:RestatementAdjustmentMember2023-12-310000834365blfs:GlobalCoolingMember2024-04-170000834365us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberblfs:GlobalCoolingMember2024-04-172024-04-170000834365us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberblfs:GlobalCoolingMember2024-04-170000834365us-gaap:EmployeeSeveranceMember2024-01-012024-09-300000834365blfs:StockCompensationExpenseMember2024-01-012024-09-300000834365us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberblfs:GlobalCoolingMember2023-12-310000834365us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberblfs:GlobalCoolingMember2024-07-012024-09-300000834365us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberblfs:GlobalCoolingMember2023-07-012023-09-300000834365us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberblfs:GlobalCoolingMember2024-01-012024-09-300000834365us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberblfs:GlobalCoolingMember2023-01-012023-09-300000834365blfs:SciSafeHoldingsIncMemberus-gaap:MeasurementInputDiscountRateMember2020-10-010000834365blfs:SciSafeHoldingsIncMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2020-10-010000834365blfs:SciSafeHoldingsIncMemberblfs:MeasurementInputAssetPriceVolatilityMember2020-10-010000834365blfs:SciSafeHoldingsIncMemberblfs:MeasurementInputRevenueVolatilityMember2020-10-010000834365blfs:SciSafeHoldingsIncMember2020-10-010000834365blfs:SciSafeHoldingsIncMember2023-07-012023-09-300000834365blfs:SciSafeHoldingsIncMember2023-01-012023-09-300000834365us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000834365us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000834365us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000834365us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000834365us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300000834365us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300000834365us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300000834365us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300000834365us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-09-300000834365us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-09-300000834365us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-09-300000834365us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-09-300000834365us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherDebtSecuritiesMember2024-09-300000834365us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherDebtSecuritiesMember2024-09-300000834365us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherDebtSecuritiesMember2024-09-300000834365us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherDebtSecuritiesMember2024-09-300000834365us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000834365us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000834365us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000834365us-gaap:FairValueMeasurementsRecurringMember2024-09-300000834365us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000834365us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000834365us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000834365us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000834365us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310000834365us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310000834365us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310000834365us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310000834365us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000834365us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000834365us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000834365us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310000834365us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherDebtSecuritiesMember2023-12-310000834365us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherDebtSecuritiesMember2023-12-310000834365us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherDebtSecuritiesMember2023-12-310000834365us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherDebtSecuritiesMember2023-12-310000834365us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000834365us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000834365us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000834365us-gaap:FairValueMeasurementsRecurringMember2023-12-310000834365blfs:ContingentConsiderationLiabilitiesMember2022-12-310000834365blfs:ContingentConsiderationLiabilitiesMember2023-01-012023-09-300000834365blfs:ContingentConsiderationLiabilitiesMember2023-09-300000834365us-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300000834365us-gaap:CorporateDebtSecuritiesMember2024-09-300000834365us-gaap:OtherDebtSecuritiesMember2024-09-300000834365us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310000834365us-gaap:CorporateDebtSecuritiesMember2023-12-310000834365us-gaap:OtherDebtSecuritiesMember2023-12-310000834365us-gaap:SeriesEPreferredStockMemberblfs:PanTHERACryoSolutionsInc.Member2023-12-310000834365us-gaap:SeriesEPreferredStockMemberblfs:PanTHERACryoSolutionsInc.Member2024-09-300000834365blfs:SeriesA1AndA2PreferredStockMemberblfs:IVexSolInc.Member2023-12-310000834365blfs:IVexSolInc.Member2024-01-012024-06-300000834365blfs:IVexSolInc.Member2024-09-300000834365blfs:RealEstateLeaseMembersrt:MinimumMember2024-09-300000834365blfs:RealEstateLeaseMembersrt:MaximumMember2024-09-300000834365blfs:VehicleAndOtherEquipmentMembersrt:MinimumMember2024-09-300000834365blfs:VehicleAndOtherEquipmentMembersrt:MaximumMember2024-09-300000834365us-gaap:LeaseholdImprovementsMember2024-09-300000834365us-gaap:LeaseholdImprovementsMember2023-12-310000834365blfs:FurnitureAndComputerEquipmentMember2024-09-300000834365blfs:FurnitureAndComputerEquipmentMember2023-12-310000834365us-gaap:ManufacturingFacilityMember2024-09-300000834365us-gaap:ManufacturingFacilityMember2023-12-310000834365us-gaap:ConstructionInProgressMember2024-09-300000834365us-gaap:ConstructionInProgressMember2023-12-310000834365us-gaap:CustomerRelationshipsMember2024-09-300000834365us-gaap:TradeNamesMember2024-09-300000834365us-gaap:TechnologyBasedIntangibleAssetsMember2024-09-300000834365us-gaap:NoncompeteAgreementsMember2024-09-300000834365us-gaap:CustomerRelationshipsMember2023-12-310000834365us-gaap:TradeNamesMember2023-12-310000834365us-gaap:TechnologyBasedIntangibleAssetsMember2023-12-310000834365us-gaap:NoncompeteAgreementsMember2023-12-310000834365blfs:The2023TermLoanMember2022-09-200000834365blfs:The2023TermLoanMember2022-09-202022-09-200000834365blfs:The2023TermLoanMemberblfs:VariableRateComponentTwoMember2022-09-202022-09-200000834365blfs:The2023TermLoanMember2024-09-300000834365blfs:SecondAmendmentTermLoanMember2024-04-170000834365blfs:GlobalCoolingAmendedTermNotesMember2024-09-300000834365blfs:GlobalCoolingAmendedTermNotesMember2023-12-310000834365blfs:TermLoanMember2023-12-310000834365blfs:TermLoanMember2024-09-300000834365blfs:FinancedInsurancePremiumMember2024-09-300000834365blfs:FinancedInsurancePremiumMember2023-12-310000834365blfs:FreezerEquipmentLoanMember2023-12-310000834365blfs:FreezerEquipmentLoanMember2024-09-300000834365blfs:ManufacturingEquipmentLoansMember2023-12-310000834365blfs:ManufacturingEquipmentLoansMember2024-09-300000834365blfs:FreezerInstallationLoanMember2024-09-300000834365blfs:FreezerInstallationLoanMember2023-12-310000834365blfs:OtherLoansMember2024-09-300000834365blfs:OtherLoansMember2023-12-310000834365blfs:TotalDebtMember2024-09-300000834365blfs:TotalDebtMember2023-12-310000834365blfs:ProductCellProcessingMember2024-07-012024-09-300000834365blfs:ProductCellProcessingMember2023-07-012023-09-300000834365blfs:ProductCellProcessingMember2024-01-012024-09-300000834365blfs:ProductCellProcessingMember2023-01-012023-09-300000834365blfs:ProductBiostorageServicesMember2024-07-012024-09-300000834365blfs:ProductBiostorageServicesMember2023-07-012023-09-300000834365blfs:ProductBiostorageServicesMember2024-01-012024-09-300000834365blfs:ProductBiostorageServicesMember2023-01-012023-09-300000834365blfs:ProductFreezerAndThawMember2024-07-012024-09-300000834365blfs:ProductFreezerAndThawMember2023-07-012023-09-300000834365blfs:ProductFreezerAndThawMember2024-01-012024-09-300000834365blfs:ProductFreezerAndThawMember2023-01-012023-09-300000834365blfs:ServiceBiostorageServicesMember2024-07-012024-09-300000834365blfs:ServiceBiostorageServicesMember2023-07-012023-09-300000834365blfs:ServiceBiostorageServicesMember2024-01-012024-09-300000834365blfs:ServiceBiostorageServicesMember2023-01-012023-09-300000834365blfs:ServiceFreezerAndThawMember2024-07-012024-09-300000834365blfs:ServiceFreezerAndThawMember2023-07-012023-09-300000834365blfs:ServiceFreezerAndThawMember2024-01-012024-09-300000834365blfs:ServiceFreezerAndThawMember2023-01-012023-09-300000834365blfs:RentalRevenueBiostorageServicesMember2024-07-012024-09-300000834365blfs:RentalRevenueBiostorageServicesMember2023-07-012023-09-300000834365blfs:RentalRevenueBiostorageServicesMember2024-01-012024-09-300000834365blfs:RentalRevenueBiostorageServicesMember2023-01-012023-09-3000008343652024-10-01blfs:RentalRevenueMember2024-09-3000008343652025-01-01blfs:RentalRevenueMember2024-09-3000008343652026-01-01blfs:RentalRevenueMember2024-09-300000834365blfs:RentalRevenueMember2024-09-3000008343652024-10-01blfs:ServiceRevenueMember2024-09-3000008343652025-01-01blfs:ServiceRevenueMember2024-09-3000008343652026-01-01blfs:ServiceRevenueMember2024-09-300000834365us-gaap:EmployeeStockOptionMember2024-09-300000834365us-gaap:RestrictedStockMember2023-12-310000834365us-gaap:RestrictedStockMember2024-01-012024-09-300000834365us-gaap:RestrictedStockMember2024-09-300000834365us-gaap:RestrictedStockMember2024-07-012024-09-300000834365us-gaap:PerformanceSharesMember2024-03-082024-03-080000834365us-gaap:PerformanceSharesMember2024-03-080000834365us-gaap:PerformanceSharesMember2024-07-012024-09-300000834365us-gaap:PerformanceSharesMember2024-01-012024-09-300000834365us-gaap:PerformanceSharesMember2024-09-300000834365us-gaap:PerformanceSharesMember2023-07-012023-09-300000834365us-gaap:PerformanceSharesMember2023-01-012023-09-300000834365blfs:MarketbasedRestrictedStockMember2023-12-310000834365blfs:MarketbasedRestrictedStockMember2024-01-012024-09-300000834365blfs:MarketbasedRestrictedStockMember2024-09-300000834365blfs:MarketbasedRestrictedStockMembersrt:ExecutiveOfficerMember2022-02-242022-02-240000834365blfs:MarketbasedRestrictedStockMember2024-03-082024-03-0800008343652022-02-242022-02-240000834365blfs:MarketbasedRestrictedStockMember2022-02-242022-02-240000834365blfs:MarketbasedRestrictedStockMembersrt:ExecutiveOfficerMember2023-01-032023-01-030000834365blfs:MarketbasedRestrictedStockMembersrt:MinimumMember2023-01-032023-01-030000834365blfs:MarketbasedRestrictedStockMembersrt:MaximumMember2023-01-032023-01-0300008343652023-01-032023-01-030000834365blfs:MarketbasedRestrictedStockMember2023-01-032023-01-030000834365srt:RestatementAdjustmentMember2023-01-012023-12-310000834365blfs:MarketbasedRestrictedStockMembersrt:ExecutiveOfficerMember2024-03-082024-03-080000834365blfs:MarketbasedRestrictedStockMembersrt:MinimumMember2024-03-082024-03-080000834365blfs:MarketbasedRestrictedStockMembersrt:MaximumMember2024-03-082024-03-0800008343652024-03-082024-03-080000834365blfs:MarketbasedRestrictedStockMember2024-07-012024-09-300000834365blfs:MarketbasedRestrictedStockMember2023-07-012023-09-300000834365blfs:MarketbasedRestrictedStockMember2023-01-012023-09-300000834365us-gaap:CostOfSalesMember2024-07-012024-09-300000834365us-gaap:CostOfSalesMember2023-07-012023-09-300000834365us-gaap:CostOfSalesMember2024-01-012024-09-300000834365us-gaap:CostOfSalesMember2023-01-012023-09-300000834365us-gaap:GeneralAndAdministrativeExpenseMember2024-07-012024-09-300000834365us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-300000834365us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-09-300000834365us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-300000834365us-gaap:SellingAndMarketingExpenseMember2024-07-012024-09-300000834365us-gaap:SellingAndMarketingExpenseMember2023-07-012023-09-300000834365us-gaap:SellingAndMarketingExpenseMember2024-01-012024-09-300000834365us-gaap:SellingAndMarketingExpenseMember2023-01-012023-09-300000834365us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300000834365us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300000834365us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300000834365us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300000834365blfs:ShareBasedPaymentArrangementOptionAndRestrictedStockAwardsMember2024-07-012024-09-300000834365blfs:ShareBasedPaymentArrangementOptionAndRestrictedStockAwardsMember2023-07-012023-09-300000834365blfs:ShareBasedPaymentArrangementOptionAndRestrictedStockAwardsMember2024-01-012024-09-300000834365blfs:ShareBasedPaymentArrangementOptionAndRestrictedStockAwardsMember2023-01-012023-09-300000834365blfs:SciSafeHoldingsIncMemberus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberus-gaap:SubsequentEventMemberblfs:SCIHoldingsMember2024-11-120000834365us-gaap:SubsequentEventMemberblfs:SCIHoldingsMember2024-11-122024-11-120000834365blfs:SciSafeHoldingsIncMemberus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberus-gaap:SubsequentEventMember2024-11-122024-11-120000834365blfs:SciSafeHoldingsIncMemberus-gaap:EmployeeSeveranceMemberus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberus-gaap:SubsequentEventMember2024-11-122024-11-120000834365blfs:SciSafeHoldingsIncMemberblfs:EarnOutPaymentMemberus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberus-gaap:SubsequentEventMember2024-11-122024-11-120000834365blfs:SciSafeHoldingsIncMemberblfs:StockCompensationExpenseMemberus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberus-gaap:SubsequentEventMember2024-11-122024-11-120000834365blfs:SciSafeHoldingsIncMemberus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberus-gaap:SubsequentEventMember2024-11-120000834365us-gaap:SubsequentEventMemberblfs:SiliconValleyBankSVBMember2024-11-11
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
____________________________________________________
FORM 10-Q
þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2024
o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the transition period from          to
Commission File Number 001-36362
____________________________________________________
BioLife Solutions, Inc.
(Exact name of registrant as specified in its charter)
Img 0.jpg
____________________________________________________
Delaware94-3076866
(State or other jurisdiction of
incorporation or organization)
(IRS Employer
Identification No.)
3303 Monte Villa Parkway, Suite 310, Bothell, Washington, 98021
(Address of registrants principal executive offices, Zip Code)
(425) 402-1400
(Telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbolName of exchange on which registered
Common stock, par value $0.001 per shareBLFS
The NASDAQ Stock Market, LLC
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (S232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit said files). Yes þ No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer þ Accelerated filer o Non-accelerated filer o Smaller reporting company o Emerging Growth Company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes o No þ
As of November 5, 2024, 46,387,214 shares of the registrant’s common stock were outstanding.
1

BIOLIFE SOLUTIONS, INC.
FORM 10-Q
FOR THE QUARTER ENDED SEPTEMBER 30, 2024
TABLE OF CONTENTS
2

PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
BioLife Solutions, Inc.
Unaudited Condensed Consolidated Balance Sheets
September 30,December 31,
(In thousands, except per share and share data)20242023
Assets
Current assets:
Cash and cash equivalents$23,977 $33,317 
Restricted cash184 31 
Available-for-sale securities, current portion10,211 16,288 
Accounts receivable, trade, net of allowance for credit losses of $955 and $1,707 as of September 30, 2024 and December 31, 2023, respectively
17,918 16,928 
Inventories32,179 32,208 
Prepaid expenses and other current assets4,914 6,463 
Current assets, discontinued operations 15,369 
Total current assets89,383 120,604 
Assets held for rent, net10,822 7,713 
Property and equipment, net17,709 20,930 
Operating lease right-of-use assets, net14,402 11,446 
Financing lease right-of-use assets, net30 94 
Long-term deposits and other assets271 270 
Available-for-sale securities, long-term4,884 548 
Equity investments995 5,069 
Intangible assets, net18,415 21,149 
Goodwill224,741 224,741 
Long-term assets, discontinued operations 150 
Total assets$381,652 $412,714 
Liabilities and Shareholders Equity
  
Current liabilities:  
Accounts payable$3,838 $3,573 
Accrued expenses and other current liabilities8,449 10,775 
Sales taxes payable4,351 4,962 
Warranty liability186 350 
Lease liabilities, operating, current portion2,788 2,534 
Lease liabilities, financing, current portion323 355 
Debt, current portion12,231 6,833 
Current liabilities, discontinued operations 12,796 
Total current liabilities32,166 42,178 
Lease liabilities, operating, long-term15,189 12,189 
Lease liabilities, financing, long-term913 1,158 
Debt, long-term7,823 18,311 
Deferred tax liabilities100 188 
Long-term liabilities, discontinued operations 1,027 
Total liabilities56,191 75,051 
Commitments and contingencies (Note 12)
Shareholders’ equity:  
Preferred stock, $0.001 par value; 1,000,000 shares authorized, Series A, 4,250 shares designated, and 0 shares issued and outstanding as of September 30, 2024 and December 31, 2023
- - 
3

Common stock, $0.001 par value; 150,000,000 shares authorized, 46,227,940 and 45,167,225 shares issued and outstanding, respectively, as of September 30, 2024 and December 31, 2023
46 45 
Additional paid-in capital673,183 652,880 
Accumulated other comprehensive loss, net of taxes(208)(345)
Accumulated deficit(347,560)(314,917)
Total shareholders’ equity325,461 337,663 
Total liabilities and shareholders’ equity$381,652 $412,714 
The accompanying notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.
4

BioLife Solutions, Inc.
Unaudited Condensed Consolidated Statements of Operations
Three Months Ended
September 30,
Nine Months Ended
September 30,
(In thousands, except per share and share data)2024202320242023
  
Product revenue$23,457 $17,137 $64,624 $63,444 
Service revenue4,660 4,377 14,173 12,573 
Rental revenue2,454 2,059 6,881 5,975 
Total product, rental, and service revenue30,571 23,573 85,678 81,992 
Costs and operating expenses:  
Cost of product revenue (exclusive of intangible assets amortization)8,765 6,572 25,163 29,223 
Cost of service revenue (exclusive of intangible assets amortization)3,401 3,937 10,247 11,624 
Cost of rental revenue (exclusive of intangible assets amortization)2,110 1,069 4,868 4,142 
General and administrative11,351 10,813 33,953 37,568 
Sales and marketing3,543 4,876 10,401 12,731 
Research and development2,050 3,739 6,827 10,772 
Asset impairment charges 8,310  8,310 
Intangible asset amortization910 1,312 2,734 4,135 
Change in fair value of contingent consideration (1,580) (1,778)
Total operating expenses32,130 39,048 94,193 116,727 
Operating loss(1,559)(15,475)(8,515)(34,735)
Other (expense) income:  
Change in fair value of equity investments  (4,074) 
Gain on settlement of Global Cooling escrow   5,115 
Interest expense, net(267)(449)(796)(1,216)
Other income95 235 417 1,002 
Total other (expense) income, net(172)(214)(4,453)4,901 
  
Loss before income tax benefit (expense)(1,731)(15,689)(12,968)(29,834)
Income tax benefit (expense)28 (115)(93)(209)
Net loss from continuing operations(1,703)(15,804)(13,061)(30,043)
Discontinued operations:
Loss from discontinued operations (13,328)(19,572)(22,999)
Income tax expense  (10)(3)
Loss from discontinued operations (13,328)(19,582)(23,002)
Net loss$(1,703)$(29,132)$(32,643)$(53,045)
  
Loss from continuing operations, attributable to common shareholders:
Basic and Diluted$(1,703)$(15,804)$(13,061)$(30,043)
Loss from discontinued operations, attributable to common shareholders:
Basic and Diluted$ $(13,328)$(19,582)$(23,002)
Loss per share from continuing operations, attributable to common shareholders:
Basic and Diluted$(0.04)$(0.36)$(0.28)$(0.69)
5

Loss per share from discontinued operations, attributable to common shareholders:
Basic and Diluted$ $(0.31)$(0.43)$(0.53)
Net loss attributable to common shareholders:
Basic and Diluted$(1,703)$(29,132)$(32,643)$(53,045)
Net loss per share attributable to common shareholders:
Basic and Diluted$(0.04)$(0.67)$(0.71)$(1.22)
Weighted average shares used to compute loss per share attributable to common shareholders:
Basic and Diluted46,175,34543,570,43845,871,71543,348,412
The accompanying notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.
6

BioLife Solutions, Inc.
Unaudited Condensed Consolidated Statements of Comprehensive Loss
Three Months Ended
September 30,
Nine Months Ended
September 30,
(In thousands)2024202320242023
Net loss$(1,703)$(29,132)$(32,643)$(53,045)
Other comprehensive income (loss):  
Foreign currency translation adjustment, net of tax282 (165)91 (25)
Unrealized gain on available-for-sale securities, net of tax65 4 46 44 
Comprehensive loss$(1,356)$(29,293)$(32,506)$(53,026)
The accompanying notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.
7

BioLife Solutions, Inc.
Unaudited Condensed Consolidated Statements of Shareholders Equity

Three Months Ended September 30, 2024
(In thousands, except share data)Series A
Preferred
Stock
Shares
Series A
Preferred
Stock
Amount
Common
Stock
Shares
Common
Stock
Amount
Additional
Paid-in
Capital
Accumulated
Other
Comprehensive
Income
Accumulated Deficit
Total Shareholders’ Equity
Balance, June 30, 2024-$- 46,104,888$46 $667,808 $(555)$(345,857)$321,442 
Stock-based compensation--5,329 5,329 
Stock option exercises-22,50046 46 
Stock issued – on vested RSUs-100,552
Foreign currency translation--282 282 
Unrealized loss on available-for-sale securities--65 65 
Net loss--(1,703)(1,703)
Balance, September 30, 2024-$- 46,227,940$46 $673,183 $(208)$(347,560)$325,461 


Three Months Ended September 30, 2023
(In thousands, except share data)Series A
Preferred
Stock
Shares
Series A
Preferred
Stock
Amount
Common
Stock
Shares
Common
Stock
Amount
Additional Paid-in Capital
Accumulated
Other
Comprehensive
Loss
Accumulated
Deficit
Total Shareholders’ Equity
Balance, June 30, 2023-$- 43,442,250$43 $623,412 $(499)$(270,828)$352,128 
Stock-based compensation--9,117 9,117 
Stock option exercises-31,00064 64 
Stock issued – on vested RSAs-358,1011 1 
Foreign currency translation--(165)(165)
Unrealized gain on available-for-sale securities--4 4 
Net loss--(29,132)(29,132)
Balance, September 30, 2023-$- 43,831,351$44 $632,593 $(660)$(299,960)$332,017 
The accompanying notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.
8

BioLife Solutions, Inc.
Unaudited Condensed Consolidated Statements of Shareholders Equity



Nine Months Ended September 30, 2024
(In thousands, except share data)Series A
Preferred
Stock
Shares
Series A
Preferred
Stock
Amount
Common
Stock
Shares
Common
Stock
Amount
Additional
Paid-in
Capital
Accumulated
Other
Comprehensive
Income
Accumulated Deficit
Total Shareholders’ Equity
Balance, December 31, 2023-$- 45,167,225$45 $652,880 $(345)$(314,917)$337,663 
Stock-based compensation--20,231 20,231 
Stock option exercises-58,750137 137 
Stock issued – on vested RSUs-1,001,9651 1 
Common stock shares issued-(65)(65)
Foreign currency translation--91 91 
Unrealized gain on available-for-sale securities--46 46 
Net loss--(32,643)(32,643)
Balance, September 30, 2024-$- 46,227,940$46 $673,183 $(208)$(347,560)$325,461 

Nine Months Ended September 30, 2023
(In thousands, except share data)Series A
Preferred
Stock
Shares
Series A
Preferred
Stock
Amount
Common
Stock
Shares
Common
Stock
Amount
Additional Paid-in Capital
Accumulated
Other
Comprehensive
Loss
Accumulated
Deficit
Total Shareholders’ Equity
Balance, December 31, 2022-$- 42,832,231$43 $611,739 $(679)$(246,915)$364,188 
Stock-based compensation--23,337 23,337 
Stock option exercises-175,043369 369 
Stock issued – on vested RSAs-923,1281 1 
Contingent consideration shares issued-116,9732,263 2,263 
Settlement of Global Cooling escrow-(216,024)(5,115)(5,115)
Foreign currency translation--(25)(25)
Unrealized loss on available-for-sale securities--44 44 
Net loss--(53,045)(53,045)
Balance, September 30, 2023-$- 43,831,351$44 $632,593 $(660)$(299,960)$332,017 
The accompanying notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.
9

BioLife Solutions, Inc.
Unaudited Condensed Consolidated Statements of Cash Flows
Nine Months Ended
September 30,
(In thousands)20242023
Cash flows from operating activities
Net loss$(32,643)$(53,045)
Adjustments to reconcile net loss to net cash used in operating activities
Impairment of intangible assets- 5,758 
Impairment of long-lived assets- 9,727 
Settlement of Global Cooling escrow- (5,115)
Depreciation4,223 5,646 
Amortization of intangible assets2,734 4,266 
Amortization of loan costs- 13 
Stock-based compensation20,231 23,337 
Non-cash lease expense265 494 
Deferred income tax (benefit) expense(88)36 
Change in fair value of contingent consideration- (1,778)
Change in fair value of equity investments4,074 - 
Accretion of available-for-sale investments(407)(1,049)
(Gain) loss on disposal of property and equipment, net(62)227 
Loss on disposal of assets held for rent, net458 443 
Loss on disposal of Global Cooling8,897 - 
Change in operating assets and liabilities, net of effects of acquisitions
Accounts receivable, trade, net(1,666)9,437 
Inventories2,124 (8,450)
Prepaid expenses and other assets1,514 (1,045)
Accounts payable(1,139)(3,380)
Accrued expenses and other current liabilities(96)(1,692)
Warranty liability(478)(97)
Sales taxes payable(889)1,330 
Other(266)128 
Net cash provided by (used in) operating activities6,786 (14,809)
Cash flows from investing activities
Purchases of available-for-sale securities(16,014)(22,688)
Proceeds from sale of available-for-sale securities2,609 2,971 
Maturities of available-for-sale securities15,600 42,450 
Purchases of assets held for rent(2,028)(3,453)
Purchases of property and equipment(2,465)(5,400)
Payments on divestiture of Global Cooling(13,039)- 
Net cash (used in) provided by investing activities(15,337)13,880 
Cash flows from financing activities
Payments on equipment loans(682)(383)
Proceeds from exercises of common stock options137 370 
Payments on term loans(2,500)(300)
10

Proceeds from financed insurance premium2,094 2,639 
Payments on financed insurance premium(1,730)(1,653)
Other(16)77 
Net cash (used in) provided by financing activities(2,697)750 
Net decrease in cash, cash equivalents, and restricted cash(11,248)(179)
Cash, cash equivalents, and restricted cash – beginning of period35,438 19,473 
Effects of currency translation on cash, cash equivalents, and restricted cash(29)(28)
Cash, cash equivalents, and restricted cash – end of period$24,161 $19,266 
Non-cash investing and financing activities
Purchase of property and equipment not yet paid$97 $4,064 
Assets acquired under operating leases$5,302 $880 
Assets acquired under financing leases$- $1,682 
Unrealized (losses) gains on currency translation$3 $(11)
Unrealized gains on available-for-sale securities$(46)$(44)
Cashless issuance of SciSafe earnout shares$- $2,263 
Cash interest paid$1,236 $1,394 
Returned shares from settlement of Global Cooling escrow$- $(5,115)
The accompanying notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.
11

BioLife Solutions, Inc.
Notes to Unaudited Condensed Consolidated Financial Statements
1.    Organization and significant accounting policies
Business
BioLife Solutions, Inc. (“BioLife”, “us”, “we”, “our”, or the “Company”) is a developer, manufacturer, and supplier of a portfolio of bioproduction tools and services including proprietary biopreservation media, automated thawing devices, cloud-connected shipping containers, and biological and pharmaceutical materials storage. Our CryoStor® freeze media and HypoThermosol® hypothermic storage media are optimized to preserve cells in the regenerative medicine market. These novel biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. Our Sexton cell processing product line includes human platelet lysates (“hPL”) for cell expansion, reducing risk and improving downstream performance over fetal bovine serum, human serum, and other chemically defined media, CellSeal® cryogenic vials that are purpose-built rigid containers used in cell and gene therapy (“CGT”) that can be filled manually or with high throughput systems, CryoCase™ cryo-compatible transparent rigid containers designed for closed-system fill and retrieval, and automated cell processing machines that bring multiple processes traditionally performed by manual techniques under a higher level of control to protect therapies from loss or contamination. Our ThawSTAR® product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. These products help administer temperature-sensitive biologic therapies to patients by standardizing the thawing process and reducing the risks of contamination and overheating, which are inherent with the use of traditional water baths. Our evo® shipping containers provide cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. Our biological and pharmaceutical materials storage services provide facilities that allow for real-time tracking of biologic materials and vaccines that can be stored at a wide range of temperatures.
On April 17, 2024, the Company sold all of the issued and outstanding shares of common stock of Global Cooling, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Global Cooling”), to GCI Holdings Company, LLC, an Ohio limited liability company (“GCI Holdings”) pursuant to a Stock Purchase Agreement (the “Purchase Agreement”), by and between the Company and GCI Holdings (the “Global Cooling Divestiture”). Upon the execution of the Purchase Agreement, on April 17, 2024, the Global Cooling business is presented in the accompanying unaudited condensed financial statements as a discontinued operation for all periods presented. See Note 3: Discontinued operations for further details regarding the divestiture.
On November 12, 2024, the Company entered into a Stock Purchase Agreement (the “Purchase Agreement”), by and among the Company, Subzero Purchaser Corp., a Delaware corporation (“Buyer”), SciSafe, Inc., a Delaware corporation and an indirect, wholly owned subsidiary of the Company (“Seller”), and SciSafe, Inc., a New Jersey corporation and an indirect wholly owned subsidiary of the Company (“SciSafe”), for the sale by Seller of all of the issued and outstanding shares of common stock (the “Shares”) of SciSafe to Buyer. The divestiture of SciSafe was considered a subsequent event to the financial results presented as of September 30, 2024. SciSafe is therefore presented as a part of our continuing operations as of the three and nine months ended September 30, 2024. For additional information on the divestiture of SciSafe, see Note 19: Subsequent events.
Use of estimates
The preparation of financial statements in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Significant estimates and assumptions by management affect the Company’s net realizable value of inventory, sales tax liabilities, valuation of market-based stock awards, valuations, fair value of marketable debt securities, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, estimated fair values of intangible assets and goodwill, amortization methods and periods, warranty reserves, certain accrued expenses, stock-based compensation, contingent consideration from business combinations, and provision for income taxes.
12

The Company regularly assesses these estimates; however, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.
Basis of presentation

The Unaudited Condensed Consolidated Financial Statements and related footnote disclosures as of and for the three and nine months ended September 30, 2024 are unaudited, and are not necessarily indicative of the Company’s operating results for a full year. The Unaudited Condensed Consolidated Financial Statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial results for the three and nine months ended September 30, 2024 in accordance with U.S. GAAP, however, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the U.S. Securities and Exchange Commission (the “SEC”) rules and regulations relating to interim financial statements. These Unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Audited Consolidated Financial Statements and accompanying notes thereto included in the Company’s Annual Report on Form 10-K as of and for the fiscal year ended December 31, 2023, filed with the SEC on February 29, 2024 (the “Annual Report”).
The Unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries, SAVSU Technologies, Inc. (“SAVSU”), Arctic Solutions, Inc. doing business as Custom Biogenic Systems (“CBS”), SciSafe Holdings, Inc. (“SciSafe”), BioLife Solutions B.V, and Sexton Biotechnologies, Inc. (“Sexton”). All intercompany accounts and transactions have been eliminated in consolidation.
Discontinued operations
On April 17, 2024, the Company sold all of the issued and outstanding shares of common stock of Global Cooling and the accounting requirements for reporting the Global Cooling subsidiary as a discontinued operation were met. Unless otherwise noted, amounts and disclosures throughout these Notes to Unaudited Condensed Consolidated Financial Statements relate to the Company's continuing operations. Refer to Note 3: Discontinued operations for further details.
In the opinion of management, the accompanying Unaudited Condensed Consolidated Financial Statements include all adjustments, consisting of only normal, recurring adjustments necessary for a fair presentation of the financial position, results of operations, and cash flows. The results of operations for the interim periods presented are not necessarily indicative of results to be expected for the entire year.
Foreign currency translation
The Company translates items presented on its Unaudited Condensed Consolidated Financial Statements into U.S. dollars. For the Company’s subsidiaries that operate in a local currency functional environment, all assets and liabilities are translated into U.S. dollars using current exchange rates at the balance sheet date; revenue and expenses are translated using average exchange rates in effect during each period. Resulting translation adjustments are reported as a separate component of Accumulated Other Comprehensive Loss in the Unaudited Condensed Consolidated Statements of Shareholders' Equity.
Segment reporting
The Company views its operations and makes decisions regarding how to allocate resources and manages its business as one reportable segment and one reporting unit. The Company’s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.
Significant accounting policies
The following describes an update to the Company’s accounting policies for discontinued operations during the three and nine months ended September 30, 2024. For a full discussion of significant accounting policies, refer to the Notes to the Consolidated Financial Statements described in Part II, Item 8 of our Annual Report.
In accordance with ASC 205-20: Presentation of Financial Statements: Discontinued Operations, a disposal of a component of an entity or a group of components of an entity is required to be reported as discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results. In
13

the period in which the component meets held-for-sale or discontinued operations criteria, the major current assets, non-current assets, current liabilities, and non-current liabilities shall be reported as components of total assets and liabilities separate from those balances of the continuing operations.
Our operations related to Global Cooling met the definition of a discontinued operation as of April 17, 2024. Accordingly, we retrospectively classified the results of our Global Cooling operations as discontinued operations in the Unaudited Condensed Consolidated Statements of Operations for all periods presented. The results of all discontinued operations, less applicable income taxes, are reported as components of net loss separate from the net loss of continuing operations. Certain assets and liabilities associated with our Global Cooling operations were classified as assets and liabilities of discontinued operations in the Unaudited Condensed Consolidated Balance Sheets for the periods presented. Additionally, the cash flows and comprehensive loss of our Global Cooling operations have not been segregated and are included in the interim Unaudited Condensed Consolidated Statements of Cash Flows and Unaudited Condensed Consolidated Statements of Comprehensive Loss, respectively, for all periods presented. All amounts included in the notes to the unaudited condensed consolidated financial statements relate to continuing operations unless otherwise noted. For additional information, see Note 3: Discontinued operations.
Liquidity and capital resources

On September 30, 2024 and December 31, 2023, we had $39.3 million and $50.2 million in cash, cash equivalents, and available-for-sale securities, respectively, in our continuing operations. Based on our current expectations with respect to our future revenue and expenses, we believe that our current level of cash, cash equivalents, and other liquid assets will be sufficient to meet our liquidity needs for at least the next twelve months from the date of the filing of this Quarterly Report on Form 10-Q (this “Form 10-Q”).
Risks and uncertainties
The preparation of financial statements requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities at the reporting date and revenues and expenses during the reporting periods. These estimates represent management's judgment about the outcome of future events. The global business environment continues to be impacted by cost pressure, the overall effects of economic uncertainty on customers' purchasing patterns, high interest rates, and other factors. It is not possible to accurately predict the future impact of such events and circumstances. Actual results could differ from our estimates.
For additional information, see caption “Risk Factors” identified in Part I, Item 1A of our Annual Report and in Part II, Item 1A of this Form 10-Q.
Concentrations of credit risk and business risk
Significant customers are those that represent more than 10% of the Company’s total revenue or gross accounts receivable balances for the periods and as of each balance sheet date presented. For each significant customer, revenue as a percentage of total revenue and gross accounts receivable as a percentage of total gross accounts receivable as of the periods presented were as follows:
Accounts ReceivableRevenue
September 30,December 31,Three Months Ended
September 30,
Nine Months Ended
September 30,
202420232024202320242023
Customer A16 %17 %****
Customer B****11 %11 %
Customer C**11 %***
*less than 10%
Revenue from foreign customers is denominated in United States dollars or euros.
14

The following table represents the Company’s products representing more than 10% of the Company’s total revenue:
Three Months Ended
September 30,
Nine Months Ended
September 30,
Product revenue concentration2024202320242023
CryoStor52 %46 %51 %53 %
The following table represents the Company’s total revenue by geographic area (based on the location of the customer):
Three Months Ended
September 30,
Nine Months Ended
September 30,
Revenue by customers geographic locations(1)
2024202320242023
United States(2)
76 %81 %77 %82 %
Europe, Middle East, Africa (EMEA)19 %15 %18 %14 %
Other5 %4 %5 %4 %
Total revenue100 %100 %100 %100 %
(1) As of the year ended December 31, 2023, the Company updated its methodology for determining the country of origin for its sales. Sales are now recorded by shipping country rather than billing country. The Company updated the methodology retrospectively, adjusting the prior year presentation for all regions presented.
(2) The line item presented above previously bifurcated sales between the United States and Canada. Due to the updated methodology for determining the country of origin for sales, it was noted that Canada no longer was a material location to separately disclose. Canada sales have been included within the "Other" line item in the table above and United States sales have been retained as a single line item to more accurately reflect origin of sales for material regions.
In the three and nine months ended September 30, 2024, no suppliers accounted for greater than 10% of purchases. In the three and nine months ended September 30, 2023, one supplier accounted for 19% and 16% of purchases, respectively.
As of September 30, 2024, one supplier accounted for 11% of our accounts payable. As of December 31, 2023, one supplier accounted for 11% of our accounts payable.
Recent accounting pronouncements
In March 2024, the SEC adopted final rules on the enhancement and standardization of climate-related disclosures of public companies. The final rules require disclosure of, among other things, material climate-related risks and their impact; activities to mitigate or adapt to material climate-related risks; governance and oversight of climate-related risks; and material Scope 1 and/or Scope 2 greenhouse gas emissions with an accompanying assurance report required following an initial transition period, at a limited assurance level, and then following an additional transition period, at a reasonable assurance level. In addition, the effects of severe weather events and other natural conditions, subject to certain thresholds, and amounts related to carbon offsets and renewable energy credits or certificates are required to be disclosed in the notes to the audited financial statements in certain circumstances.
On April 4, 2024, the SEC voluntarily stayed the implementation of the final rules pending the completion of judicial review of the consolidated challenges to the final rules by the Court of Appeals for the Eighth Circuit. The final rules, as originally issued, would be effective for the Company in various fiscal years, starting with its Annual Report on Form 10-K for fiscal year 2025. Disclosures pursuant to the final rules, as originally issued, would be required prospectively, with information for prior periods required only to the extent it was previously disclosed in an SEC filing. The Company is currently evaluating the impact of the final rules on its Consolidated Financial Statements and disclosures.
2.    Correction of immaterial errors
During the three months ended March 31, 2024, we determined that an error existed in our previously issued consolidated financial statements. Specifically, we identified we had not properly accelerated stock compensation expense related to unvested shares of market-based awards of certain employees upon their termination during the fourth quarter of 2023. The error was evaluated under the U.S. Securities and Exchange Commission's ("SEC's") Staff Accounting Bulletin ("SAB")
15

Topic 1M, "Materiality," and SEC SAB Topic 1N, "Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in the Current Year Financial Statements" to determine the materiality of prior period misstatements to the Company’s financial statements. We evaluated the error and concluded that it was not material to the previously issued consolidated financial statements. Although the error was not material to any period, we corrected the accompanying historical consolidated financial statements for the year ended December 31, 2023 to reflect the additional stock compensation expense incurred within each period for comparative purposes.
The following table represents the adjustments to our Consolidated Balance Sheet as of December 31, 2023 in accordance with ASC 250. The adjustments to our Consolidated Statement of Shareholders’ Equity was limited to the adjustments outlined below.
The effect of the adjustments to our Consolidated Balance Sheet as of December 31, 2023 was as follows (in thousands):
December 31, 2023
(In thousands)As reportedAdjustmentAs corrected
Additional paid-in-capital$651,305 $1,575 $652,880 
Accumulated deficit(313,342)(1,575)(314,917)
3.     Discontinued operations
On April 17, 2024, the Company entered into the Purchase Agreement by and between the Company and GCI Holdings, which is wholly owned by a former consulting contractor of Global Cooling, for the sale of all of the issued and outstanding shares of common stock of Global Cooling to GCI Holdings. Upon the execution of the Purchase Agreement, the Global Cooling business is presented in the accompanying condensed financial statements as a discontinued operation for all periods presented.
As a condition of the Purchase Agreement, Global Cooling was required to have $7.0 million in cash on its balance sheet, of which, $6.7 million in cash was funded by the Company, and the Company was required to repay approximately $2.6 million of outstanding indebtedness of Global Cooling, and assume certain other liabilities of Global Cooling of $2.6 million. Following the execution of the Purchase Agreement, the divestiture of Global Cooling was consummated on April 17, 2024. The Company recognized a loss on disposal of Global Cooling, calculated as follows:
(In thousands)
Selling price: $1
$ 
Cash to Global Cooling funded by Company(6,652)
Costs to sell Global Cooling(1)
(582)
Negative selling price(7,234)
Global Cooling carrying basis as of April 17, 2024, inclusive of assumed liabilities(3,589)
Assumed liabilities: Accounts payable(2)
2,643 
Assumed liabilities: Debt(3)
2,596 
Global Cooling carrying basis as of April 17, 20241,650 
Release of Global Cooling currency translation adjustment(13)
Net loss on disposal$(8,897)
(1) Represents the costs incurred in connection with the divestiture of Global Cooling, including fees to be paid to the broker, attorneys, and other external parties.
(2) As a closing condition, the Company assumed certain accounts payable and accrued expenses from Global Cooling, totaling $0.5 million and $2.1 million, respectively.
(3) As a closing condition, the Company repaid the balance of the Global Cooling Amended Term Notes. For additional information on the terms of the Global Cooling Term Notes, see Note 13: Long-term debt.
In connection with the Company’s entry into the Purchase Agreement, the Company implemented a reduction in force (the “RIF”) related to the business of Global Cooling, which reduced the Company’s workforce by 47 employees (representing
16

approximately 11% of its full-time employees). The Company’s Board of Directors approved the RIF on March 29, 2024, and all affected employees were informed by April 18, 2024, following the execution of the Purchase Agreement. Additionally, the Company accelerated the unvested shares granted to both the employees impacted by the RIF and Global Cooling employees that remained with Global Cooling upon the closing of the GCI Divestiture. The Company recognized the following charges in connection with the RIF and stock compensation expense acceleration:
(In thousands)SeveranceStock CompensationTotal
RIF employee costs$291 $1,255 $1,546 
Former Global Cooling employees 1,925 1,925 
Total employment related divestiture expenditures$291 $3,180 $3,471 

In addition, upon the closing of the Transaction, the Company and Global Cooling entered into a transition services agreement ("TSA"), pursuant to which the Company agreed to provide certain transition services to Global Cooling for up to 90 days following the date of the closing of the Transaction. The TSA has since expired pursuant to its terms on the stated expiration date.

The following table summarizes the major classes of assets and liabilities of discontinued operations, which are summarized separately in the condensed consolidated balance sheets:
April 17,December 31,
(In thousands)20242023
Cash and cash equivalents$275 $2,090 
Accounts receivable, net2,430 1,728 
Inventories9,152 11,248 
Prepaid expenses and other current assets379 303 
Total current assets, discontinued operations12,236 15,369 
Property and equipment, net153 146 
Long-term deposits and other assets4 4 
Total assets, discontinued operations12,393 15,519 
Accounts payable1,425 3,367 
Accrued expenses and other current liabilities911 1,637 
Warranty liability7,193 7,507 
Lease liabilities, operating, current portion242 263 
Lease liabilities, financing, current portion16 22 
Total current liabilities, discontinued operations9,787 12,796 
Lease liabilities, operating, long-term948 1,016 
Lease liabilities, financing, long-term8 11 
Total liabilities, discontinued operations$10,743 $13,823 
Global Cooling had no remaining balances as of September 30, 2024.



17



The key components of loss from discontinued operations were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)2024202320242023
Revenue$ $9,755 $7,157 $28,546 
Cost of revenue 10,100 8,389 28,048 
Gross profit (345)(1,232)498 
Operating expenses (5,789)(9,418)(16,259)
Asset impairment charges (7,175) (7,175)
Other income (expense), net (19)(25)(63)
Loss on disposal  (8,897) 
Loss before income taxes (13,328)(19,572)(22,999)
Income tax expense  (10)(3)
Loss from discontinued operations, net of income taxes$ $(13,328)$(19,582)$(23,002)
During the three and nine months ended September 30, 2024, Global Cooling did not incur material depreciation, amortization, capital expenditure, or other noncash related costs. For the three months ended September 30, 2023, Global Cooling incurred depreciation and capital expenditure costs of $0.1 million and $0.2 million, respectively. During the nine months ended September 30, 2023, Global Cooling incurred depreciation, amortization, and capital expenditure costs of $0.4 million, $0.1 million, and $0.7 million, respectively.
We do not anticipate incurring any material additional charges in connection with the sale of Global Cooling.
4.    Fair value measurement
In accordance with FASB ASC Topic 820, Fair Value Measurements and Disclosures, (“ASC Topic 820”), the Company measures its financial instruments at fair value on a recurring basis. The carrying values of certain of our financial instruments including cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate fair value because of their short maturities. The carrying value of our marketable debt securities, which are accounted for as available-for-sale, are classified within either Level 1 or Level 2 in the fair value hierarchy because we use quoted market prices or alternative pricing sources and models utilizing market observable inputs to determine their fair value. The carrying values of our long-term debt, which is classified within Level 2 in the fair value hierarchy, approximates fair value as our borrowings with lenders are at interest rates that approximate market rates for comparable loans. The fair values of investments and contingent consideration classified as Level 3 were derived from management assumptions. The Company also measures certain assets and liabilities at fair value on a non-recurring basis when applying acquisition accounting. ASC Topic 820 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, ASC Topic 820 establishes a three-tier value fair hierarchy, which prioritizes the inputs used in measuring fair value as follows:
Level 1 – Observable inputs that reflect quoted prices (unadjusted) in active markets for identical assets or liabilities.
Level 2 – Observable inputs other than quoted prices included in Level 1 for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.
Level 3 – Unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability.
18

The fair value of the SciSafe contingent consideration liability was valued based on unobservable inputs using a Monte Carlo simulation. These inputs included the estimated amount and timing of projected future revenue, a discount rate of 4.5%, a risk-free rate of approximately 0.2%, asset volatility of 60%, and revenue volatility of 15%. Significant changes in any of those inputs in isolation would result in a significant change in the fair value measurement of the liability. Generally, changes used in the assumptions for projected future revenue and revenue volatility would be accompanied by a directionally similar change in the fair value measurement. Conversely, changes in the discount rate would be accompanied by a directionally opposite change in the related fair value measurement. However, due to the contingent consideration having a maximum payout amount, changes in these assumptions would not affect the fair value of the contingent consideration if they increase (decrease) beyond certain amounts. At the acquisition date, the contingent consideration was determined to have a fair value of $3.7 million. Subsequent to the acquisition date, the SciSafe contingent consideration liability was re-measured to fair value with changes recorded in the Change in fair value of contingent consideration in the Unaudited Condensed Consolidated Statements of Operations.
During the most recent re-measurement of the contingent consideration liability as of December 31, 2023, the Company determined it appropriate to write-off the remaining balance of the SciSafe contingent consideration liability. The target revenue required for earnout was not met during the year ended December 31, 2023 and had been determined to not be probable to achieve in future years. The change in fair value of contingent consideration of $1.6 million and $1.8 million associated with the contingent consideration liability was included within the Change in fair value of contingent consideration in the Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2023, respectively.
There were no remeasurements to fair value during the three and nine months ended September 30, 2024 of financial assets and liabilities that are not measured at fair value on a recurring basis.
The following tables set forth the Company’s financial assets and liabilities measured at fair value on a recurring basis as of September 30, 2024 and December 31, 2023, based on the three-tier fair value hierarchy:
(In thousands)
As of September 30, 2024Level 1Level 2Level 3Total
Assets:
Cash equivalents:
Money market accounts$13,731 $- $- $13,731 
Available-for-sale securities:    
U.S. government securities2,679 - - 2,679 
Corporate debt securities395 8,735 - 9,130 
Other debt securities- 3,286 - 3,286 
Total$16,805 $12,021 $- $28,826 
As of December 31, 2023
Assets:
Cash equivalents:
Money market accounts$25,034 $- $- $25,034 
Available-for-sale securities:
U.S. government securities5,170 - - 5,170 
Corporate debt securities- 9,674 - 9,674 
Other debt securities- 1,992 - 1,992 
Total$30,204 $11,666 $- $41,870 
There have been no transfers of assets or liabilities between the fair value measurement levels.
19

The following table presents the changes in fair value of contingent consideration liabilities that are measured using Level 3 inputs for the three and nine months ended September 30, 2023. There was no contingent consideration liability outstanding as of September 30, 2024.
Nine Months Ended September 30,
(In thousands)2023
Balance at beginning of period$4,456 
Change in fair value recognized in net loss(1,778)
Payment of contingent consideration earned$(2,263)
Balance at end of period$415 

5.    Investments
Available-for-sale securities
The Company’s portfolio of available-for-sale marketable securities consists of the following:
September 30, 2024
Amortized
Cost
Gross unrealizedEstimated
Fair Value
(In thousands)GainsLosses
Available-for-sale securities, current portion    
U.S. government securities$2,676 $3 $- $2,679 
Corporate debt securities6,149 16 - 6,165 
Other debt securities1,363 4 - 1,367 
Total short-term10,188 23 - 10,211 
     
Available-for-sale securities, long-term    
Corporate debt securities2,944 21 - 2,965 
Other debt securities1,910 9 - 1,919 
Total marketable securities$15,042 $53 $- $15,095 
December 31, 2023
Amortized
Cost
Gross unrealizedEstimated
Fair Value
(In thousands)GainsLosses
Available-for-sale securities, current portion
U.S. government securities$5,169 $1 $- $5,170 
Corporate debt securities9,673 5 (4)9,674 
Other debt securities1,443 1 - 1,444 
Total short-term16,285 7 (4)16,288 
Available-for-sale securities, long-term
Other debt securities545 3 - 548 
Total marketable securities$16,830 $10 $(4)$16,836 
20

September 30, 2024
(In thousands)Amortized
Cost
Estimated
Fair Value
Due in one year or less$10,188 $10,211 
Due after one year through five years4,854 4,884 
Total$15,042 $15,095 
Equity investments
The Company periodically invests in non-marketable equity securities of private companies without a readily determinable fair value to promote business and strategic objectives. The Company has adopted the measurement alternative whereby equity securities are carried at cost minus impairment, if any, plus or minus changes resulting from observable process changes in orderly transactions for identical or similar transactions of the same issuer. These securities included Series E Preferred Stock in PanTHERA CryoSolutions, Inc. carried at $1.0 million as of September 30, 2024 and December 31, 2023.
The Company also owns securities of Series A-1 and A-2 Preferred Stock in iVexSol, Inc. carried at $4.1 million for the period ending December 31, 2023. During the six months ended June 30, 2024, the Company received communications that triggered a going concern for the investment. As of June 30, 2024, the Company determined that the fair value of its equity interest was less than its carrying amount, and no longer recoverable, triggering an impairment charge of $4.1 million. The carrying value was zero as of September 30, 2024.
6.    Inventories
Inventories consist of the following as of September 30, 2024 and December 31, 2023:
September 30,December 31,
(In thousands)20242023
Raw materials$12,722 $16,932 
Work in progress6,647 5,890 
Finished goods12,810 9,386 
Total inventories$32,179 $32,208 
7.    Leases
The Company has various operating lease agreements for office space, warehouses, manufacturing, and production locations as well as vehicles and other equipment. Our real estate leases had original lease terms of three to eleven years and have remaining lease terms of one to eight years. We exclude options that are not reasonably certain to be exercised from our lease terms, ranging from one to five years. Our lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms, with all other lease payments consisting of variable lease costs. For certain leases, we receive incentives from our landlords, such as rent abatements, which effectively reduce the total lease payments owed for these leases. Vehicle and other equipment operating leases had original lease terms of four to five years and have remaining terms between one and five years.
Our financing leases relate to research equipment, machinery, and other equipment.
21

The table below presents certain information related to the weighted average discount rate and weighted average remaining lease term for the Company’s leases as of September 30, 2024 and December 31, 2023:
September 30,December 31,
(In thousands)20242023
Weighted average discount rate - operating leases5.8 %4.4 %
Weighted average discount rate - finance leases8.4 %8.3 %
Weighted average remaining lease term in years - operating leases6.16.6
Weighted average remaining lease term in years - finance leases3.54.1
The components of lease expense for the three and nine months ended September 30, 2024 and 2023 were as follows:
Three Months Ended
September 30,
Nine Months Ended
September 30,
(In thousands)2024202320242023
Operating lease costs$1,018 $810 $2,639 $2,460 
Financing lease costs57 - 173 - 
Short-term lease costs452 510 1,263 1,266 
Total operating lease costs1,527 1,320 4,075 3,726 
   
Variable lease costs446 299 1,166 903 
Total lease costs$1,973 $1,619 5,241 4,629 
Maturities of our lease liabilities as of September 30, 2024 are as follows:
(In thousands)Operating
Leases
Financing
Leases
2024 (3 months remaining)$857 $103 
20253,630 413 
20263,249 389 
20272,970 387 
20283,021 134 
Thereafter7,794 - 
Total lease payments21,521 1,426 
Less: interest(3,544)(190)
Total present value of lease liabilities$17,977 $1,236 
22

8.     Assets held for rent
Assets held for rent consist of the following as of September 30, 2024 and December 31, 2023:
September 30,December 31,
(In thousands)20242023
Shippers placed in service$9,862 $9,866 
Fixed assets held for rent6,538 1,468 
Accumulated depreciation(8,813)(6,272)
Subtotal7,587 5,062 
Shippers and related components in production3,235 2,651 
Total$10,822 $7,713 
Shippers and related components in production include shippers complete and ready to be deployed and placed in service upon a customer order, shippers in the process of being assembled, and components available to build shippers. We recognized $0.8 million and $2.3 million in depreciation expense related to assets held for rent during the three and nine months ended September 30, 2024, respectively, and $0.9 million and $2.8 million during the three and nine months ended September 30, 2023, respectively.
9.    Property and equipment
Property and equipment consist of the following as of September 30, 2024 and December 31, 2023:
September 30,December 31,
(In thousands)20242023
Property and equipment  
Leasehold improvements$5,982 $5,913 
Furniture and computer equipment769 773 
Manufacturing and other equipment17,084 19,893 
Construction in-progress4,105 3,807 
Subtotal27,940 30,386 
Less: Accumulated depreciation(10,231)(9,456)
Property and equipment, net$17,709 $20,930 
Depreciation expense for property and equipment was $0.6 million and $1.9 million for the three and nine months ended September 30, 2024, respectively, and $1.0 million and $2.9 million during the three and nine months ended September 30, 2023, respectively.
10.    Goodwill and intangible assets
Goodwill
Goodwill represents the difference between the purchase price and the estimated fair value of identifiable assets acquired and liabilities assumed. Goodwill acquired in a business combination is determined to have an indefinite useful life and is not amortized but instead is tested for impairment at least annually in accordance with ASC 350.
Intangible assets
Intangible assets, net consisted of the following as of September 30, 2024 and December 31, 2023:
23

(In thousands, except weighted average useful life)September 30, 2024
Intangible assets:
Gross Carrying
Value
Accumulated
Amortization
Net Carrying
Value
Weighted
Average Useful
Life (in years)
Customer relationships$9,936 $(4,625)$5,311 9.9
Tradenames8,134 (2,543)5,591 10.5
Technology - acquired18,372 (10,859)7,513 3.3
Non-compete agreements750 (750) 0.0
Total intangible assets$37,192 $(18,777)$18,415 6.6
(In thousands, except weighted average useful life)December 31, 2023
Intangible assets:
Gross Carrying
Value
Accumulated
Amortization
Net Carrying
Value
Weighted
Average Useful
Life (in years)
Customer relationships$9,936 $(4,217)$5,719 10.7
Tradenames8,134 (2,077)6,057 11.3
Technology - acquired18,372 (9,123)9,249 4.1
Non-compete agreements750 (626)124 0.8
Total intangible assets$37,192 $(16,043)$21,149 7.3
Amortization expense for definite-lived intangible assets was $0.9 million and $2.7 million for the three and nine months ended September 30, 2024, respectively, and $1.3 million and $4.1 million for the three and nine months ended September 30, 2023, respectively. As of September 30, 2024, the Company expects to record the following amortization expense for definite-lived intangible assets:
(In thousands)Amortization
Expense
For the Years Ending December 31,
2024 (3 months remaining)$868 
20253,468 
20263,358 
20272,605 
20281,500 
Thereafter6,616 
Total$18,415 

24

11.    Accrued expenses and other current liabilities
Accrued expenses and other current liabilities consist of the following as of September 30, 2024 and December 31, 2023:
September 30,December 31,
(In thousands)20242023
Accrued expenses$2,864 $6,667 
Accrued taxes373 551 
Accrued compensation4,777 2,902 
Deferred revenue, current435 655 
Total accrued expenses and other current liabilities$8,449 $10,775 
12.    Commitments and contingencies
Employment agreements
We have employment agreements with certain key employees. None of these employment agreements is for a definitive period, but rather each will continue indefinitely until terminated in accordance with its terms. The agreements provide for a base annual salary, payable in monthly (or shorter) installments. Under certain conditions and for certain of these officers, we may be required to pay additional amounts upon terminating the employee or upon the employee resigning for good reason.
Litigation
From time to time, the Company is subject to various legal proceedings that arise in the ordinary course of business, as our industry is characterized by frequent claims and litigation, including claims regarding intellectual property. Management does not believe any of the current claims are material to the Company’s business. Future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors. The Company carries certain insurance policies that may cover the aforementioned costs. The probability of claims that could result in a loss are evaluated and disclosed, as needed, individually and on a gross basis. Management is not aware of any significant pending or threatened litigation that is anticipated to result in unfavorable judgments against the Company other than those listed below.
Pending litigation claims
Two lawsuits have been filed by previous customers seeking payment for losses allegedly related to commercial freezer products from Global Cooling prior to its divestiture. These lawsuits are in various stages, and we continue to defend vigorously against the claims made in them. An estimate for a reasonably possible loss or range of loss cannot be made, though we expect any potential losses incurred to be covered by insurance.
Indemnification
As permitted under Delaware law and in accordance with the Company’s bylaws, the Company is required to indemnify its officers and directors for certain errors and occurrences while the officer or director is or was serving in such capacity. The Company is also party to indemnification agreements with its directors. The Company believes the fair value of the indemnification rights and agreements is minimal. Accordingly, the Company has not recorded any liabilities for these indemnification rights and agreements as of September 30, 2024 and December 31, 2023.
Purchase obligations
Purchase obligations are defined as agreements to purchase goods or services that are enforceable and legally binding and that specify all significant terms, including fixed or minimum quantities to be purchased, fixed, minimum, or variable pricing provisions and the approximate timing of the transactions. As of September 30, 2024, our total short-term obligations were $4.2 million.
25

Non-income related taxes
Companies are required to collect and remit sales tax from certain customers if the company is determined to have nexus in a particular state. Upon the determination of nexus, which varies by state, companies are additionally required to maintain detailed record of specific product and customer information within each jurisdiction in which it has established nexus to appropriately determine their sales tax liability, requiring technical knowledge of each jurisdiction’s tax case law. During the year ended December 31, 2023, the Company determined that a sales tax liability related to the periods of 2019 through 2023 was probable and determined an estimated liability. The estimated liability was approximately $3.8 million and $4.8 million as of September 30, 2024 and December 31, 2023, respectively. Due to the variety of jurisdictions in which this estimated liability relates to and our ongoing assessment of sales taxes owed, we cannot predict when final liabilities will be satisfied. We will reevaluate the estimated liability and timing of satisfaction each reporting period.
13.    Long-term debt
Term Loan
On September 20, 2022, the Company and certain of its subsidiaries entered into a term loan agreement (the “Loan Agreement”), which provides for a term loan in an aggregate maximum principal amount of up to $60 million in the increments and upon the dates and milestones described below (the “Term Loan”). The Term Loan matures on June 1, 2026. The Loan Agreement permitted the Company to borrow up to $30 million upon the initial closing of the transactions contemplated by the Loan Agreement (the “Term Loan Closing”), and provided options to borrow (i) up to $10 million between the Term Loan Closing and June 30, 2023, (ii) up to $10 million upon the achievement of certain revenue milestones by the Company, and (iii) an additional $10 million at the discretion of the lender. The Company borrowed $20 million at the Term Loan Closing and accounts for the Term Loan at cost. As of December 31, 2023, the Company had not drawn additional funding nor had it met the revenue milestones outlined within the Loan Agreement. The Company had until December 31, 2023 to draw an additional $10 million, subject to approval from the lender, and therefore has no additional opportunities under the Loan Agreement. Payments on the borrowing are interest-only through June 2024, with additional criteria allowing for interest-only payments to continue through June 2025. Tranches borrowed under the Loan Agreement bear interest at the Wall Street Journal prime rate plus 0.5%. However, the interest rate is subject to a ceiling that restricts the interest rate for each tranche from exceeding 1.0% above the overall rate applicable to each tranche at their respective funding dates and has a balloon payment due at the earliest of term loan maturity, repayment of the Term Loan in full, or termination of the Loan Agreement at $1.2 million. As of September 30, 2024, the implied interest rate of the Term Loan is 7.5% and the implied value of the Term Loan is $18.2 million. The Loan Agreement contains customary representations and warranties as well as customary affirmative and negative covenants. As of September 30, 2024, the Company is in compliance with the covenants set forth in the Loan Agreement.
On April 17, 2024, the Company entered into a Consent and Second Amendment to the Term Loan (the “Amendment”) by and among Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (“Bank”) and the Company and its subsidiaries. Pursuant to the Amendment and subject to the conditions set forth therein, Bank consented to the transaction and released its security interests in the assets of Global Cooling and the Shares arising under the Loan and Security Agreement, dated September 20, 2022, by and among Bank and Borrower, as amended by that certain Waiver and First Amendment to Loan and Security Agreement, dated February 26, 2024 (the “Loan Agreement”). In addition, effective as of the closing of the transaction, the Amendment amended the Loan Agreement to remove Global Cooling as a party to the Loan Agreement and provide for a non-refundable termination fee in the amount of $500,000 payable by Borrower to Bank in the event that the Loan Agreement is terminated prior to the Term Loan Maturity Date (as defined in the Loan Agreement) for any reason. The Amendment also contains customary representations and warranties of Borrower and provides for a release of Bank by Borrower for any claims existing or arising through the date of the Amendment, including, without limitation, those arising out of or in any manner connected with or related to the Loan Agreement.
On November 11, 2024, the Company entered into a Consent and Third Amendment to Loan and Security Agreement (the “Amendment”) by and among Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (“Bank”) and the Company and its subsidiaries. For additional information on the Amendment, see Note 19: Subsequent events.
26

Long-term debt consisted of the following as of September 30, 2024 and December 31, 2023:
September 30,December 31,
(In thousands)Maturity DateInterest Rate20242023
Global Cooling Amended Term NotesVarious4.0 %$ $2,596 
Term LoanJun-267.0 %17,500 20,000 
Insurance premium financingJul-258.3 %1,712 1,348 
Freezer equipment loanDec-255.7 %200 317 
Manufacturing equipment loansOct-255.7 %97 172 
Freezer installation loanVarious6.3 %593 807 
Other loansVariousVarious1 2 
Total debt, excluding unamortized debt issuance costs20,103 25,242 
Less: unamortized debt issuance costs(49)(98)
Total debt20,054 25,144 
Less: current portion of debt(12,231)(6,833)
Total long-term debt$7,823 $18,311 
As of September 30, 2024, the Term Loan was secured by substantially all assets of BioLife, SAVSU, CBS, SciSafe, and Sexton, other than intellectual property. Equipment loans are secured by the financed equipment.
As of September 30, 2024, the scheduled maturities of loans payable for each of the next five years and thereafter were as follows:
(In thousands)Amount
2024 (3 months remaining)$3,177 
202511,659 
20265,218 
2027- 
2028- 
Thereafter- 
Total debt$20,054 
14.    Revenue
To determine revenue recognition for contractual arrangements that we determine are within the scope of FASB Topic 606, Revenue from Contracts with Customers, we perform the following five steps: (i) identify each contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to our performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the relevant performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. Contracts with customers may contain multiple performance obligations. For such arrangements, the transaction price is allocated to each performance obligation based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price, taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations. Payment terms and conditions vary, although terms generally include a requirement of payment within 30 to 90 days. As of September 30, 2024 and December 31, 2023, our deferred revenue balance totaled $0.4 million and $0.7 million, respectively. During the three and nine months ended September 30, 2024, the Company recognized approximately $0.1 million and $0.6 million, respectively, of revenue that was included in the deferred revenue balance at the beginning of the year. During the three and nine months ended
27

September 30, 2023, the Company had recognized $0.1 million and $0.4 million, respectively, of revenue that was included in the deferred revenue balance at the beginning of the year.
The Company primarily recognizes product revenues, service revenues, and rental revenues. Product revenues are generated from the sale of cell processing tools, freezers, thawing devices, and cold chain products. We recognize product revenue, including shipping and handling charges billed to customers, at a point in time when we transfer control of our products to our customers, which is upon shipment for substantially all transactions. Shipping and handling costs are classified as part of cost of product revenue in the Condensed Consolidated Statements of Operations. Service revenue is generated from the storage of biological and pharmaceutical materials. We recognize service revenue over time as services are performed or ratably over the contract term. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method or the most likely amount method, depending on the facts and circumstances relative to the contract. When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in ASC Topic 606, the Company does not assess whether a significant financing component exists if the period between when the Company performs its obligations under the contract and when the customer pays is one year or less. None of the Company’s contracts contained a significant financing component as of and during the three and nine months ended September 30, 2024.
The Company also generates revenue from the leasing of our property, plant, and equipment, operating right-of-use assets, and evo cold chain systems within its biostorage services product line to customers pursuant to service contracts or rental arrangements entered into with the customer. Revenue from these arrangements is not within the scope of FASB ASC Topic 606 as it is within the scope of FASB ASC Topic 842, Leases. All customers leasing shippers currently do so under annual rental arrangements. We account for these rental transactions as operating leases and record rental revenue on a straight-line basis over the rental term.
The Company enters into various customer service agreements (collectively, “Service Contracts”) with customers to provide biological and pharmaceutical storage services. In certain of these Service Contracts, the property, plant, and equipment or operating right-of-use assets used to store the customer product are used only for the benefit of one customer. This is primarily driven by the customer’s desire to ensure that sufficient storage capacity is available in a specific geographic location for a set period of time. These agreements may include extension and termination clauses. These Service Contracts do not allow for customers to purchase the underlying assets.
The Company has assessed its Service Contracts and concluded that certain of the contracts for the storage of customer products met the criteria to be considered a leasing arrangement (“Embedded Leases”), with the Company as the lessor. The specific Service Contracts that met the criteria were those that provided a single customer with the ability to substantially direct the use of the Company’s property, plant, and equipment or operating right-of-use assets.
Applying the practical expedient from ASC Topic 842, consistent with the previous guidance, the Company will continue to recognize operating right-of-use asset embedded lessor arrangements on its Unaudited Condensed Consolidated Balance Sheets in operating right-of-use assets.
None of the Embedded Leases identified by the Company qualify as a sales-type or direct finance lease. None of the operating leases for which the Company is the lessor include options for the lessee to purchase the underlying asset at the end of the lease term or residual value guarantees, nor are any such operating leases with related parties.
Embedded Leases may contain both lease and non-lease components. We have elected to utilize the practical expedient from ASC Topic 842 to account for lease and non-lease components together as a single combined lease component as the timing and pattern of transfer are the same for the non-lease components and associated lease component and, the lease component, if accounted for separately, would be classified as an operating lease. Non-lease components of the Company’s rental arrangements include reimbursements of lessor costs.
28

Total bioproduction tools and services revenue for the three and nine months ended September 30, 2024 and 2023 were composed of the following:
Three Months Ended
September 30,
Nine Months Ended
September 30,
(In thousands, except percentages)2024202320242023
Product revenue  
Cell processing$19,030 $13,338 $53,154 $51,004 
Biostorage services$543 $365 $970 $1,099 
Freezer and thaw3,884 3,434 10,500 11,341 
Service revenue  
Biostorage services4,526 4,186 13,708 12,166 
Freezer and thaw134 191 465 407 
Rental revenue  
Biostorage services2,454 2,059 6,881 5,975 
Total revenue$30,571 $23,573 $85,678 $81,992 
The following table includes estimated rental revenue expected to be recognized in the future related to Embedded Leases as well as estimated service revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting periods. The Company is electing not to disclose the value of the remaining unsatisfied performance obligation with a duration of one year or less as permitted by the practical expedient in ASU 2014-09, Revenue from Contracts with Customers. The estimated revenue in the following table does not include contracts with the original durations of one year or less, amounts of variable consideration attributable to royalties, or contract renewals that are unexercised as of September 30, 2024. As of September 30, 2024, we did not have service revenue expected to be recognized in greater than one year.
The balances in the table below are partially based on judgments involved in estimating future orders from customers pursuant to their respective contracts:
(In thousands)2024 (3 months remaining)20252026Total
Rental revenue$812 $3,249 $812 $4,873 
15.    Stock-based compensation
Service-based vesting stock options
The following is a summary of service-based vesting stock option activity for the September 30, 2024, and the status of service-based vesting stock options outstanding as of September 30, 2024:
Nine Months Ended
September 30, 2024
Options
Wtd. Avg. Exercise Price
Outstanding as of beginning of period217,250 $2.21 
Exercised(58,750)2.33 
Outstanding as of September 30, 2024158,500 $2.16 
Stock options exercisable as of September 30, 2024158,500 $2.16 
29

As of September 30, 2024, there was $3.6 million of aggregate intrinsic value of outstanding and exercisable service-based vesting stock options. Intrinsic value is the total pretax intrinsic value for all “in-the-money” options (i.e., the difference between the Company’s closing stock price on the last trading day of the reporting period and the exercise price, multiplied by the number of shares) that would have been received by the option holders had all option holders exercised their options on September 30, 2024. This amount will change based on the fair market value of the Company’s stock. We did not recognize stock compensation expense related to service-based options during the three and nine months ended September 30, 2024. The intrinsic value of service vesting-based awards exercised was $0.5 million and $1.1 million during the three and nine months ended September 30, 2024, respectively. There were no service-based vesting options granted during the three and nine months ended September 30, 2024. The weighted average remaining contractual life of service-based vesting stock options outstanding and exercisable as of September 30, 2024 is 1.5 years. There were no unrecognized compensation costs for service-based vesting stock options as of September 30, 2024.
Restricted stock
Service-based vesting restricted stock
The following is a summary of service-based vesting restricted stock activity for the nine months ended September 30, 2024, and the status of unvested service-based vesting restricted stock outstanding as of September 30, 2024:
Nine Months Ended
September 30, 2024
Shares
Wtd. Avg. Grant Date Fair Value
Outstanding as of beginning of period2,312,898 $18.32 
Granted484,886 20.53 
Vested(701,436)25.83 
Forfeited(116,386)17.33 
Non-vested as of September 30, 20241,979,962 $16.22 
The aggregate fair value of the service-based vesting awards granted was $6.7 million and $10.0 million during the three and nine months ended September 30, 2024, respectively. The aggregate fair value of the service-based vesting awards that vested was $2.3 million and $8.0 million during the three and nine months ended September 30, 2024, respectively.
We recognized stock compensation expense related to service-based vesting awards of $3.8 million and $11.7 million during the three and nine months ended September 30, 2024, respectively. As of September 30, 2024, there was $26.8 million in unrecognized compensation costs related to service-based vesting awards. We expect to recognize those costs over 2.7 years.
Performance-based restricted stock
On March 8, 2024, the Company granted 109,512 shares of performance-based stock to an executive in the form of restricted stock. The shares granted contain performance conditions based on Company metrics related to future performance. The grant date fair value of this award was $17.36 per share. The fair value of this award is being expensed on a straight-line basis over the requisite service period ending on December 31, 2025.
We recognized stock compensation expense of $0.2 million and $0.7 million related to performance-based restricted stock awards for the three and nine months ended September 30, 2024, respectively. As of September 30, 2024, there was $1.2 million in unrecognized non-cash compensation costs related to performance-based restricted stock awards expected to vest. We expect to recognize those costs over 1.2 years. Non-cash compensation costs are expensed over the period for which performance was measured.

The aggregate fair value of the performance-based awards granted during the three and nine months ended September 30, 2024 was $1.9 million. No performance-based awards vested during the three and nine months ended September 30, 2024.

30

No performance-based restricted stock awards were granted or vested during the three and nine months ended September 30, 2023.
Market-based restricted stock
The following is a summary of market-based restricted stock activity under our stock option plan for the nine months ended September 30, 2024 and the status of market-based restricted stock outstanding as of September 30, 2024:
Nine Months Ended
September 30, 2024
Shares
Wtd. Avg. Grant
Outstanding as of beginning of period509,166 $26.50 
Granted299,565 27.12 
Vested(300,529)27.97 
Non-vested as of September 30, 2024508,202 $25.70 
On February 24, 2022, the Company granted 240,428 shares of market-based stock to its executives in the form of restricted stock. The shares granted contain a market condition based on total shareholder return ("TSR"). The TSR market condition measures the Company’s performance against a peer group. On March 8, 2024, the Company’s Compensation Committee determined the TSR attainment was 125% of the targeted shares and 300,529 shares were granted and immediately vested to the executives of the Company based on our TSR during the period beginning on January 1, 2022 through December 31, 2023 as compared to the TSR of 20 of our peers. The fair value of this award was determined using a Monte Carlo simulation with the following assumptions: a historical volatility of 63%, 0% dividend yield and a risk-free interest rate of 1.5%. The historical volatility was based on the most recent 2-year period for the Company and correlated with the components of the peer group. The stock price projection for the Company and the components of the peer group assumes a 0% dividend yield. This is mathematically equivalent to reinvesting dividends in the issuing entity over the performance period. The risk-free interest rate is based on the yield on the U.S. Treasury Strips as of the Measurement Date with a maturity consistent with the 2-year term associated with the market condition of the award. The fair value of this award of $6.7 million was expensed on a straight-line basis over the grant date to the vesting date of December 31, 2023.
On January 3, 2023, the Company granted 268,738 shares of market-based stock to its executives in the form of restricted stock. The shares granted contain a market condition based on TSR. The TSR market condition measures the Company’s performance against a peer group. The market-based restricted stock awards will vest as to between 0% and 200% of the number of restricted shares granted to each recipient based on our TSR during the period beginning on January 1, 2023 through December 31, 2024 as compared to the TSR of 20 of our peers. The fair value of this award was determined using a Monte Carlo simulation with the following assumptions: a historical volatility of 78%, 0% dividend yield and a risk-free interest rate of 4.4%. The historical volatility was based on the most recent 2-year period for the Company and correlated with the components of the peer group. The stock price projection for the Company and the components of the peer group assumes a 0% dividend yield. This is mathematically equivalent to reinvesting dividends in the issuing entity over the performance period. The risk-free interest rate is based on the yield on the U.S. Treasury Strips as of the Measurement Date with a maturity consistent with the 2-year term associated with the market condition of the award. The fair value of this award of $6.8 million is being expensed on a straight-line basis over the grant date to the vesting date of December 31, 2024, excluding $1.6 million of expense recognized in 2023 to reflect accelerations in the vesting period of certain awards.
On March 8, 2024, the Company granted 239,464 shares of market-based stock to its executives in the form of restricted stock. The shares granted contain a market condition based on TSR. The TSR market condition measures the Company’s performance against a peer group. The market-based restricted stock awards will vest as to between 0% and 200% of the number of restricted shares granted to each recipient based on our TSR during the period beginning on January 1, 2024 through December 31, 2025 as compared to the TSR of 20 of our peers. The fair value of this award was determined using a Monte Carlo simulation with the following assumptions: a historical volatility of 80%, 0% dividend yield and a risk-free interest rate of 4.6%. The historical volatility was based on the most recent 2-year period for the Company and correlated with the components of the peer group. The stock price projection for the Company and the components of the peer group assumes a 0% dividend yield. This is mathematically equivalent to reinvesting dividends in the issuing entity over the performance period. The risk-free interest rate is based on the yield on the U.S. Treasury Strips as of the Measurement Date with a maturity consistent with the 2-year term associated with the market condition of the award. The fair value of this
31

award of $6.3 million is being expensed on a straight-line basis over the grant date to the vesting date of December 31, 2025.
We recognized stock compensation expense of $1.3 million and $3.7 million related to market-based restricted stock awards for the three and nine months ended September 30, 2024, respectively, and $1.6 million and $4.9 million during the three and nine months ended September 30, 2023, respectively. As of September 30, 2024, there was $4.4 million in unrecognized non-cash compensation costs related to market-based restricted stock awards expected to vest. We expect to recognize those costs over 1.1 years.
The aggregate fair value of the market-based awards granted was zero and $6.3 million during the three and nine months ended September 30, 2024, respectively, and zero and $6.5 million during the three and nine months ended September 30, 2023, respectively. The aggregate fair value of the market-based awards that vested was zero and $5.1 million during the three and nine months ended September 30, 2024, respectively, and zero and $0.7 million during the three and nine months ended September 30, 2023, respectively.
Total stock compensation expense
Compensation expense associated with equity-based awards is recognized on a straight-line basis over the requisite service period, with awards generally vesting over a 4-year period, and forfeitures recognized as incurred. We recorded total stock compensation expense for the three and nine months ended September 30, 2024 and 2023, as follows:
 Three Months Ended
September 30,
Nine Months Ended
September 30,
(In thousands)2024202320242023
Cost of revenue$826 $1,031 $2,482 $2,991 
General and administrative costs2,873 3,349 8,648 9,497 
Sales and marketing costs1,001 1,920 2,909 3,575 
Research and development costs624 1,684 1,983 3,652 
Total$5,324 $7,984 $16,022 $19,715 
16.    Income taxes
The Company accounts for income taxes under ASC Topic 740 – Income Taxes. Under this standard, deferred tax assets and liabilities are recognized for future tax benefits or consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.
The Company’s tax provision for interim periods is determined using an estimate of the annual effective income tax rate, adjusted for discrete items, if any, that occur in the relevant period. Income tax expense of $0.1 million for the nine months ended September 30, 2024 resulted in an effective income tax rate of negative 0.7%. Included in the $0.1 million of tax expense was discrete tax expense of $1.2 million related to stock compensation, which was offset by a change in the valuation allowance.
The Company’s projected effective income tax rate for the year ending December 31, 2024 excluding the impact, if any, of discrete items is negative 0.7%, which is lower than the U.S. federal statutory rate of 21% primarily due to the increase in the valuation allowance on deferred tax assets and non-deductible executive compensation offset by state tax benefits and research tax credits.
Realization of deferred tax assets is dependent upon the generation of future taxable income, the timing and amount of which are uncertain. In determining the need for a valuation allowance, the Company’s management evaluates all available positive and negative evidence to determine if it is more likely than not that its deferred tax assets are realizable. As of September 30, 2024, the Company continues to provide a full valuation allowance against its deferred tax assets as the realization of such assets is not considered to be more likely than not at this time. If the Company's conclusion about the realizability of its deferred tax assets and therefore the appropriateness of the valuation allowance changes in a future
32

period, the Company could record a substantial tax benefit in its Condensed Consolidated Statements of Operations when that occurs.
17.    Net loss from continuing operations per common share
The Company considers its unvested restricted shares, which contain non-forfeitable rights to dividends, as participating securities, and includes such participating securities in its computation of earnings per share pursuant to the two-class method. Basic earnings per share is calculated by dividing net loss by the weighted average number of shares of common stock outstanding during the reporting period. Diluted earnings per share is calculated using the weighted average number of shares of common stock plus the potentially dilutive effect of common equivalent shares outstanding determined under both the two-class method and the treasury stock method, whichever is more dilutive. In periods when we have a net loss, common stock equivalents are excluded from our calculation of earnings per share as their inclusion would have an antidilutive effect.
The following table presents computations of basic and diluted earnings per share:
Three Months Ended
September 30,
Nine Months Ended
September 30,
(In thousands, except share and earnings per share data)2024202320242023
Basic earnings (loss) per common share
Numerator:
Net loss from continuing operations$(1,703)$(15,804)$(13,061)$(30,043)
Net loss from continuing operations allocated to common shareholders(1,703)(15,804)(13,061)(30,043)
Denominator:
Weighted-average common shares issued and outstanding46,175,34543,570,43845,871,71543,348,412
Basic and diluted loss from continuing operations per common share$(0.04)$(0.36)$(0.28)$(0.69)
The following table sets forth the number of weighted-average shares of common stock excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:
Three Months Ended
September 30,
Nine Months Ended
September 30,
2024202320242023
Stock options and restricted stock awards3,939,4172,636,2833,774,6973,007,126
Total3,939,4172,636,2833,774,6973,007,126
18.    Employee benefit plan
The Company sponsors 401(k) defined contribution plan for its employees. This plan provides for pre-tax and post-tax contributions for all employees. Employee contributions are voluntary. Employees may contribute up to 100% of their annual compensation to this plan as limited by an annual maximum amount as determined by the Internal Revenue Service. The Company matches employee contributions in amounts to be determined at the Company’s sole discretion. The Company made $0.2 million and $0.7 million in contributions to this plan for the three and nine months ended September 30, 2024, respectively. During the three and nine months ended September 30, 2023, the Company made $0.2 million and $0.7 million, respectively, in contributions to this plan.
33

19.    Subsequent events
The Company has evaluated events subsequent to September 30, 2024 through the date of this filing to assess the need for potential recognition or disclosure.
Stock Purchase Agreement for SciSafe Divestiture
On November 12, 2024, the Company entered into a Stock Purchase Agreement, by and among the Company, Subzero Purchaser Corp., a Delaware corporation, SciSafe, Inc., a Delaware corporation and an indirect, wholly owned subsidiary of the Company, and SciSafe, Inc., a New Jersey corporation and an indirect wholly owned subsidiary of the Company, for the sale by Seller of all of the issued and outstanding shares of common stock of SciSafe to Buyer for an aggregate purchase price of $73.0 million (subject to adjustment as set forth in the Purchase Agreement) (the “Transaction”). Following the execution of the Purchase Agreement, the Transaction was consummated on November 12, 2024 (the “Closing Date”). We anticipate the divestiture to qualify and be presented as Discontinued Operations in our Annual Report on Form 10-K for the year ended December 31, 2024.
The Purchase Agreement contains customary representations, warranties, covenants and indemnities of the parties thereto, including customary covenants that prevent the Company from competing with SciSafe, soliciting its employees or interfering with its business relationships for five years after the Closing Date. In connection with the closing of the Transaction, the Company was required to repay approximately $0.9 million of outstanding indebtedness of SciSafe, estimates to incur approximately $1.8 million in fees to be paid for legal and other transaction services, and estimates to incur approximately $0.4 million in severance costs. The Company also paid the former stockholders of SciSafe approximately $3.3 million in cash to waive all rights with respect to certain potential earn-out payments that would have otherwise accelerated and become due in connection with the Transaction pursuant to the purchase agreement by which the Company acquired SciSafe in October 2020. Finally, the Company expects to recognize approximately $4.0 million in stock compensation expense in connection with the acceleration of unvested shares for all former employees of the Company that remained with SciSafe upon the closing of the Transaction.
In addition, upon the closing of the Transaction, the Company and SciSafe entered into a transition services agreement, pursuant to which the Company will provide certain transition services to SciSafe for up to six months following the Closing Date.

The Company expects to recognize a gain on the Transaction of approximately $39.6 million before $11.1 million of goodwill allocation.
The Company’s estimates are subject to a number of assumptions, and actual results may differ.
Consent and Third Amendment to Loan and Security Agreement with Silicon Valley Bank
November 11, 2024, the Company entered into a Consent and Third Amendment to Loan and Security Agreement, by and among Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (“Bank”), the Company, SAVSU Technologies, Inc., a Delaware corporation (“SAVSU”), Arctic Solutions, Inc., a Delaware corporation doing business as Custom Biogenic Systems (“Arctic”), SciSafe Holdings, Inc., a Delaware corporation (“SciSafe Parent”), and Sexton Biotechnologies, Inc., a Delaware corporation (“Sexton,” and together with the Company, SAVSU, Arctic and SciSafe Parent, “Borrower”). Pursuant to the Amendment and subject to the conditions set forth therein, Bank consented to the Transaction as required pursuant to the Loan and Security Agreement, dated September 20, 2022, by and among Bank and Borrower, as amended by that certain Waiver and First Amendment to Loan and Security Agreement, dated February 26, 2024, and that certain Consent and Second Amendment to Loan and Security Agreement, dated April 17, 2024 (the “Loan Agreement”). In addition, effective as of the closing of the Transaction, the Amendment amended the Loan Agreement to provide for a non-refundable termination fee in the amount of $750,000 payable by Borrower to Bank in the event that the Loan Agreement is terminated prior to the Term Loan Maturity Date (as defined in the Loan Agreement) for any reason. The Amendment also made certain other ministerial changes to the Loan Agreement, contains customary representations and warranties of Borrower and provides for a release of Bank by Borrower for any claims existing or arising through the date of the Amendment, including, without limitation, those arising out of or in any manner connected with or related to the Loan Agreement.
As announced during the second quarter of 2023, the Company has continued to actively seek the divestiture of its CBS business and anticipates Discontinued Operations treatment upon the closure of a deal.
34

Item 2. Managements discussion and analysis of financial condition and results of operations
Forward looking statements

Certain statements contained in this Quarterly Report on Form 10-Q are not historical facts and may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “plans,” “expects,” “believes,” “anticipates,” “designed,” and similar words are intended to identify forward-looking statements. Forward-looking statements are based on our current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. A description of certain of these risks, uncertainties and other matters can be found in filings we make with the U.S. Securities and Exchange Commission (the “SEC”), all of which are available at www.sec.gov, including our Annual Report on Form 10-K as of and for the fiscal year ended December 31, 2023, filed with the SEC on February 29, 2024, (the "Annual Report"). Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by us. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in its expectations with regard to these forward-looking statements or the occurrence of unanticipated events.

Overview
Management’s discussion and analysis provides additional insight into the Company and is provided as a supplement to, and should be read in conjunction with, our Annual Report.
We are a life sciences company that develops, manufactures and supplies bioproduction tools and services which are designed to improve quality and de-risk biologic manufacturing, storage, distribution, and transportation in the cell and gene therapy industry. Our products are used in basic and applied research and commercial manufacturing of biologic-based therapies. Customers use our products to maintain the health and function of biologic material during sourcing, manufacturing, storage, and distribution.
We currently operate as one bioproduction tools and services business which supports several steps in the biologic material manufacturing and delivery process. We have a diversified portfolio of tools and services that focus on biopreservation, cell processing, frozen biologic storage products and services, cold-chain transportation, and thawing of biologic materials. We have in-house expertise in cryobiology and continue to capitalize on opportunities to maximize the value of our product platform for our extensive customer base through both organic growth innovations and acquisitions.

On April 17, 2024, the Company sold all of the issued and outstanding shares of common stock of Global Cooling, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Global Cooling”), to GCI Holdings Company, LLC, an Ohio limited liability company (“GCI Holdings”), pursuant to a Stock Purchase Agreement, by and between the Company and GCI Holdings (the “Global Cooling Divestiture”). Upon the execution of the Purchase Agreement, the Global Cooling business is presented in the accompanying condensed financial statements as a discontinued operation for all periods presented. See Note 3: Discontinued operations, to the Unaudited Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q.for further details regarding the divestiture.
On November 12, 2024, the Company the Company entered into a Stock Purchase Agreement, by and among the Company, Subzero Purchaser Corp., a Delaware corporation, SciSafe, Inc., a Delaware corporation and an indirect, wholly owned subsidiary of the Company, and SciSafe, Inc., a New Jersey corporation and an indirect wholly owned subsidiary of the Company, for the sale by Seller of all of the issued and outstanding shares of common stock of SciSafe to Buyer. The divestiture of SciSafe was considered a subsequent event to the financial results presented as of September 30, 2024. SciSafe is therefore presented as a part of our continuing operations as of the three and nine months ended September 30, 2024. For additional information on the divestiture of SciSafe, see Note 19: Subsequent events, to the Unaudited Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q.
35

Our products
Our bioproduction tools and services are composed of two revenue lines that contain seven main offerings:
Cell processing
Biopreservation media
Human platelet lysate media (“hPL”), cryogenic vials, and automated cell-processing fill machines
Biostorage services
Biological and pharmaceutical material storage
Cloud connected “smart” shipping containers
Automated thawing devices
Critical accounting policies and estimates
A “critical accounting policy” is one which is both important to the portrayal of our financial condition and results and requires management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. For a description of our critical accounting policies that affect our more significant judgments and estimates used in the preparation of our Unaudited Condensed Consolidated Financial Statements, refer to Management’s Discussion and Analysis of Financial Condition and Results of Operations and our significant accounting policies in Note 1 to the Consolidated Financial Statements included in our Annual Report and Part I, Note 1 to the Unaudited Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q.
Results of operations
The following discussion of the financial condition and results of operations should be read in conjunction with the accompanying Unaudited Condensed Consolidated Financial Statements and the related footnotes thereto.
Revenues
Total revenue for three and nine months ended September 30, 2024 and 2023 consisted of the following:
Three Months Ended
September 30,
Nine Months Ended
September 30,
(In thousands, except percentages)20242023$ Change% Change20242023$ Change% Change
Product revenue
Cell processing$19,030 $13,338 $5,692 43 %$53,154 $51,004 $2,150 %
Biostorage services543 365 $178 49 %970 1,099 $(129)(12)%
Freezer and thaw3,884 3,434 $450 13 %10,500 11,341 $(841)(7)%
Service revenue
Biostorage services4,526 4,186 $340 %13,708 12,166 $1,542 13 %
Freezer and thaw134 191 $(57)(30)%465 407 $58 14 %
Rental revenue
Biostorage services2,454 2,059 $395 19 %6,881 5,975 $906 15 %
Total revenue$30,571 $23,573 $6,998 30 %$85,678 $81,992 $3,686 %
Product revenue
Product revenue was $23.5 million for the three months ended September 30, 2024, representing an increase of $6.3 million, or 37%, compared with the same period in 2023 and was $64.6 million for the nine months ended September 30, 2024, representing an increase of $1.2 million, or 2%, compared with the same period in 2023. The increase in product revenues for the three and nine months ended September 30, 2024 is largely driven by an increase in customer demand for our cell processing products compared to the prior year. During the third and fourth quarters of 2023, we experienced a decrease in our revenues from our customers destocking inventory levels in addition to decreases in broader biotech funding that we did not experience during the current period.
36

Product revenue: Cell processing
Product revenue from our cell processing products increased by $5.7 million and $2.2 million, or by 43% and 4%, during the three and nine months ended September 30, 2024, respectively, compared with the same period in 2023. The increase in revenue from cell processing products is driven by an overall market improvement compared to the prior year when our customers reduced safety stock levels in addition to the broader biotech industry experiencing decreases in funding.
Product revenue: Biostorage services
Product revenue from our biostorage services increased by $0.2 million, or 49%, and decreased $0.1 million, or or 12%, in the three and nine months ended September 30, 2024, respectively, compared with the same period in 2023. The increase in the three months ended September 30, 2024 is primarily due to new customer acquisitions and increased demand from existing customers. The decrease in the nine month period relates to lower volumes of consumable products sold from our evo product line.
Product revenue: Freezer and thaw
Product revenue from our freezer and thaw products increased by $0.5 million, or 13%, during the three months ended September 30, 2024 and decreased by $0.8 million, or 7%, in the nine months ended September 30, 2024, compared with the same period in 2023. The increase in the three months ended period was primarily driven by an increase in customer demand for our ThawSTAR product line compared to the prior year. The decrease in the nine months ended can be attributed to lower overall sales of our freezer products in the first half of 2024 compared to the prior year.
Service revenue
Service revenue was $4.7 million and $14.2 million for the three and nine months ended September 30, 2024, respectively, representing an increase of $0.3 million and $1.6 million, or 6% and 13%, compared with the same period in 2023. The increase in the three and nine month periods relates primarily to the expansion of service revenue generated by SciSafe storage services.
Rental revenue
Rental revenue was $2.5 million and $6.9 million for the three and nine months ended September 30, 2024, respectively, representing an increase of $0.4 million, or 19%, and $0.9 million, or 15%, compared with the same periods in 2023. The increase is associated with an increased demand from existing customers.
Costs and operating expenses
Total costs and operating expenses for three and nine months ended September 30, 2024 and 2023 were composed of the following:
Three Months Ended
September 30,
Nine Months Ended
September 30,
(In thousands, except percentages)20242023$ Change% Change20242023$ Change% Change
Cost of product, rental, and service revenue$14,276 $11,578 $2,698 23 %$40,278 $44,989 $(4,711)(10)%
General and administrative11,351 10,813 $538 %33,953 37,568 $(3,615)(10)%
Sales and marketing3,543 4,876 $(1,333)(27)%10,401 12,731 $(2,330)(18)%
Research and development2,050 3,739 $(1,689)(45)%6,827 10,772 $(3,945)(37)%
Asset impairment charges— 8,310 $(8,310)(100)%— 8,310 $(8,310)(100)%
Intangible asset amortization910 1,312 $(402)(31)%2,734 4,135 $(1,401)(34)%
Change in fair value of contingent consideration— (1,580)$1,580 NM— (1,778)$1,778 NM
Total operating expenses$32,130 $39,048 $(6,918)(18)%$94,193 $116,727 $(22,534)(19)%
Cost of product, rental, and service revenue
Cost of revenue increased $2.7 million, or 23%, for the three months ended September 30, 2024 and decreased $4.7 million, or 10%, for the nine months ended September 30, 2024, compared to the same periods in 2023. The increase during the three months ended September 30, 2024 is due primarily to increases in sales across multiple product lines
37

compared to the same period in the prior year. The decrease in cost of revenue during the nine months ended September 30, 2024 can be attributed to decreases in personnel expenses, a more favorable product mix, and increased operational efficiencies.
Cost of revenue inclusive of intangible amortization related to acquired technology was 49% as a percentage of revenue for both the three and nine months ended September 30, 2024, compared to 52% and 58% as a percentage of revenue for the three and nine months ended September 30, 2023, respectively. The decrease in cost of revenue inclusive of intangible amortization related to acquired technology as a percentage of sales for the three and nine months ended September 30, 2024 is a result of increased utilization at our biorepository facilities, operational efficiencies, and a more favorable product mix in our biopreservation media product line, in addition to decreases in personnel expenses, including stock-based compensation expenses.
General and administrative expenses
General and administrative (“G&A”) expense consists primarily of personnel-related expenses, stock-based compensation, professional fees, such as accounting and consulting fees, and corporate insurance.
G&A expenses for the three months ended September 30, 2024 increased $0.5 million, or 5%, and decreased $3.6 million, or 10%, during the nine months ended September 30, 2024. The increase for the three months ended September 30, 2024 consists primarily of an increase in lease expenses and legal fees compared to the same period in the prior year. The decrease in G&A expenses during the nine months ended September 30, 2024 is primarily due to decreases in consultation service fees, a decrease in severance expenses, and a decrease in headcount resulting in decreased salary and stock-based compensation.
Sales and marketing expenses
Sales and marketing expense (“S&M”) consists primarily of personnel-related costs, stock-based compensation, consulting, advertising, and travel expense.
S&M expense for the three and nine months ended September 30, 2024 decreased $1.3 million and $2.3 million, or 27% and 18%, respectively, compared with the same periods in 2023. The decrease is primarily due to a decrease in headcount compared to the prior year.
Research and development expenses
Research and development (“R&D”) expense consists primarily of personnel-related costs, consulting, research supplies, and milestone expenses related to third party research agreements.
R&D expense for the three and nine months ended September 30, 2024 decreased $1.7 million and $3.9 million, or 45% and 37%, respectively, compared with the same periods in 2023. The decrease is primarily due to a decrease in headcount compared to the prior year, and lower research milestone payments in relation to our investment in PanTHERA.
Intangible asset amortization expense
Intangible asset amortization expense consists of charges related to the amortization of intangible assets associated with the acquisitions of Astero, SAVSU, CBS, SciSafe, and Sexton in which we acquired definite-lived intangible assets. Decreases in our intangible asset amortization expenses for the three and nine months ended September 30, 2024 can be attributed to the write-off of intangible assets related to CBS during the third quarter of 2023.
Change in fair value of contingent consideration
Change in fair value of contingent consideration consists of changes in estimated fair value of our potential earnouts related to our SciSafe acquisition. The benefit recognized in the three and nine months ended September 30, 2023 relates primarily to changes in our estimated probability of achieving earnout targets set forth within the purchase agreements.
38

Other expense
Total other income and expenses for the three and nine months ended September 30, 2024 and 2023 were composed of the following:
Three Months Ended
September 30,
Nine Months Ended
September 30,
(In thousands, except percentages)20242023$ Change% Change20242023$ Change% Change
Change in fair value of equity investments$— $— $— NM$(4,074)$— $(4,074)NM
Gain on settlement of Global Cooling escrow$— $— $— NM$— $5,115 $(5,115)NM
Interest expense, net$(267)$(449)$182 41 %$(796)$(1,216)$420 35 %
Other income95 235 $(140)(60)%417 1,002 $(585)(58)%
Total other (expense) income, net$(172)$(214)$42 20 %$(4,453)$4,901 $(9,354)(191)%
Change in fair value of equity investments. Reflects the change in fair value of our equity investments. During the second quarter of 2024, the Company determined that the fair value of its equity interest in iVexSol was less than its carrying amount, and no longer recoverable. The equity investment was fully impaired as a result of the analysis. For further details, see Note 5: Investments in Part I, Item 1 of this Form 10-Q.
Gain on settlement of Global Cooling escrow. Reflects the non-cash gain associated with our settlement of the GCI General Escrow during the second quarter of 2023 upon indemnification of shares within the escrow.
Interest expense, net
Interest expense, net incurred during the three and nine months ended September 30, 2024 related primarily to the Term Loan (as defined in Note 13: Long-term debt, to the Unaudited Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q) obtained in September 2022, financed insurance premiums, and indirect tax liabilities. We also earn interest on cash held in our money market account. Decreases in interest expense, net during the three and nine months ended September 30, 2024 can be attributed to the increases in interest income from our available-for-sale securities compared to the same period in 2023.
Liquidity and capital resources
On September 30, 2024 and December 31, 2023, we had $39.3 million and $50.2 million in cash, cash equivalents, and available-for-sale securities, respectively, in our continuing operations.
On April 17, 2024, the Company consummated the Global Cooling Divestiture. The Company provided $6.7 million in cash funding to effectuate the transaction and paid $0.6 million to the brokers, attorneys, and other external parties. In addition, the Company recognized $6.1 million in cash expenditures from operations during the three months ended September 30, 2024 to meet certain post-closing requirements, costs to sell Global Cooling, the assumption of certain liabilities and debt, and severance expenses related to the RIF implemented on the business of Global Cooling, which reduced the Company’s workforce by 47 employees. For additional information on the details of the Transaction and its related costs, see Item I, Note 3: Discontinued operations to the Unaudited Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q.
On November 12, 2024, the Company consummated the SciSafe Divestiture. In connection with the closing of the Transaction, the Company was required to repay approximately $0.9 million of outstanding indebtedness of SciSafe, estimates to incur approximately $1.8 million in fees to be paid for legal and other transaction services, and estimates to incur approximately $0.4 million in severance costs. The Company also paid the former stockholders of SciSafe approximately $3.3 million in cash to waive all rights with respect to certain potential earn-out payments and expects to recognize approximately $4.0 million in stock compensation expense in connection with the acceleration of unvested shares for all former employees of the Company that remained with SciSafe upon the closing of the Transaction. For
39

additional information on the divestiture of SciSafe, see Note 19: Subsequent events, to the Unaudited Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q.
Based on our current expectations with respect to our future revenue and expenses, we believe that our current level of cash, cash equivalents, and other liquid assets will be sufficient to meet our liquidity needs for at least the next twelve months from the date of the filing of this Quarterly Report on Form 10-Q. However, the Company may choose to raise additional capital through a debt or equity financing for strategic purposes. Additional capital, if required, may not be available on reasonable terms, if at all.
Cash flows
Nine Months Ended
September 30,
(In thousands, except percentages)20242023$ Change
Operating activities$6,786 $(14,809)$21,595 
Investing activities(15,337)13,880 $(29,217)
Financing activities(2,697)$750 $(3,447)
Net decrease in cash and cash equivalents$(11,248)$(179)$(11,069)
Net cash provided by (used in) operating activities
Net cash provided by operating activities was $6.8 million during the nine months ended September 30, 2024 compared to $14.8 million used in operating activities during the nine months ended September 30, 2023. The increase in cash provided by operating activities was primarily due to a decrease in operating losses compared to the prior year in addition to the timing of collection and disbursement of working capital related items in accounts receivable, inventories, prepaid expenses, and accrued expenses.
Net cash (used in) provided by investing activities
Net cash used by investing activities totaled $15.3 million during the nine months ended September 30, 2024 compared to $13.9 million provided by investing activities for the nine months ended September 30, 2023. The increase in cash used by investing activities was primarily driven by the $13.0 million in payments made on the divestiture of Global Cooling in addition to a decrease of $20.5 million in purchases, proceeds, and maturities of our investments in available-for-sale marketable securities compared to the prior year. This was offset by a decrease of $4.4 million in capital expenditures compared to the prior year.
Net cash (used in) provided by financing activities
Net cash used by financing activities totaled $2.7 million during the nine months ended September 30, 2024, compared to $0.8 million provided by financing activities during the nine months ended September 30, 2023. The increase in cash used by financing activities was primarily the result of increases in payments on the Company's Term Loan compared to the prior year.
Contractual obligations
Our material cash requirements include contractual and other obligations which we previously disclosed within the financial statements and Management Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report. Other than the contractual obligation listed below, there have been no significant changes to these obligations in the three months ended September 30, 2024.
Purchase obligations
Purchase obligations are defined as agreements to purchase goods or services that are enforceable and legally binding and that specify all significant terms, including fixed or minimum quantities to be purchased, fixed, minimum, or variable pricing provisions and the approximate timing of the transactions. As of September 30, 2024, our total short-term obligations were $4.2 million.
40

Item 3. Quantitative and qualitative disclosures about market risk
Interest rate risk
Our exposure to market risk for changes in interest rates relates primarily to our long-term debt. Our long-term debt primarily bears interest at a fixed rate, with a variable component subject to an interest rate ceiling. Fluctuations in interest rates therefore do not materially impact our consolidated financial statements from long-term debt. For additional information, see Note 13, Long-term debt to the Unaudited Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q.
Foreign currency exchange risk
For a discussion of market risks related to foreign currency exchange rates, refer to Item 7A, “Quantitative and Qualitative Disclosures about Market Risk” in our Annual Report. During the nine months ended September 30, 2024, there were no material changes or developments that would materially alter the market risk assessment of our exposures to foreign currency exchange rates performed as of December 31, 2023.
Item 4. Controls and procedures
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q were not effective, due to the material weaknesses in our internal control over financial reporting. As previously reported, we identified material weaknesses in our internal control over financial reporting as of December 31, 2023 with regard to (i) inappropriately designed entity-level controls impacting the control environment, risk assessment procedures, and monitoring activities to prevent or detect material misstatements to the consolidated financial statements attributed to an insufficient number of qualified resources and inadequate oversight and accountability over the performance of controls, ineffective identification and assessment or risks impacting internal control over financial reporting, and ineffective monitoring controls; (ii) information system logical access within certain key financial systems; (iii) ineffective accounting procedures and related controls over certain financial statement areas; (iv) inadequate risk assessment, accounting policies, procedures and related controls performed over the procure to pay and revenue recognition processes in the consolidated financial statements in accordance with the applicable financial reporting requirements.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting that occurred during the quarter ended September 30, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Limitations on Effectiveness of Control
Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected.
Remediation
We are continuing to implement remediation plans outlined in our Part II, Item 9A of Annual Report. We also may implement additional changes to our internal control over financial reporting as may be appropriate in the course of remediating the material weaknesses. Management, with the oversight of the Audit Committee of the Board, will continue
41

to take steps necessary to remedy the material weaknesses to reinforce the overall design and capability of our control environment.
42

PART II: Other information
Item 1. LEGAL PROCEEDINGS
From time to time, we may be subject to legal proceedings and claims in the ordinary course of business. We are not currently aware of any such proceedings or claims that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.
Item 1A. RISK FACTORS
During the nine months ended September 30, 2024, there were no material changes to the risk factors described in Part I, Item 1A of our Annual Report.
Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
None.
Item 3. DEFAULTS UPON SENIOR SECURITIES
None.
Item 4. MINE SAFETY DISCLOSURES
None.
Item 5. OTHER INFORMATION
None.


43

Item 6. Exhibits
Exhibit No.Description
3.1
31.1
31.2
32.1#
32.2#
101.INS**XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH**Inline XBRL Taxonomy Extension Schema Document
101.CAL**Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF**Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB**Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE**Inline XBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101)
#The information in Exhibits 32.1 and 32.2 shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act (including this Quarterly Report on Form 10-Q), unless the Company specifically incorporates the foregoing information into those documents by reference.
**In accordance with Rule 402 of Regulation S-T, this interactive data file is deemed not filed or part of this Quarterly Report on Form 10-Q for purposes of Sections 11 or 12 of the Securities Act or Section 18 of the Exchange Act and otherwise is not subject to liability under these sections.
44

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
BIOLIFE SOLUTIONS, INC.
Date: November 12, 2024
/s/ Troy Wichterman
Troy Wichterman
Chief Financial Officer
(Duly authorized officer and principal
financial and accounting officer)
45
507324348.3 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF BIOLIFE SOLUTIONS, INC. Section 1. Law, Certificate of Incorporation and Bylaws 1.1. These Bylaws are subject to the certificate of incorporation of Biolife Solutions, Inc. (the “Corporation” and such certificate of incorporation, the “Certificate of Incorporation”). In these Bylaws (as amended, the “Bylaws”), references to law, the certificate of incorporation and Bylaws mean the law, the provisions of the certificate of incorporation and the Bylaws as from time to time in effect. Section 2. Stockholders 2.1. Annual Meeting. The annual meeting of stockholders shall be held at such date and time as shall be designated from time to time by the board of directors of the Corporation (the “Board of Directors”) and stated in the notice of the meeting, at which they shall elect a board of directors and transact such other business as may be required by law or these Bylaws or as may properly come before the meeting. Any annual meeting of stockholders may be postponed by action of the Board of Directors at any time in advance of such meeting. 2.2. Special Meetings. A special meeting of the stockholders may be called at any time by the Chairperson of the Board of Directors, the Chief Executive Officer or the directors entitled to cast a majority of the votes of the whole Board of Directors. A special meeting of the stockholders also shall be called by the Chief Executive Officer or Secretary upon written request of the holders of thirty five percent (35%) of the outstanding shares entitled to vote thereat, or as otherwise required by law. Any such application by the stockholders shall state the purpose or purposes of the proposed meeting. Notice of a special meeting shall state the place, date, hour, and purposes of the meeting. Business transacted at any special meeting of stockholders shall be limited to the purposes stated in the notice of the meeting. 2.3. Place of Meeting. All meetings of the stockholders for the election of directors or for any other purpose shall be held at such place within or without the State of Delaware as may be determined from time to time by the Chairperson of the Board of Directors, the Chief Executive Officer or the directors entitled to cast a majority of the votes of the whole Board of Directors. Any adjourned session of any meeting of the stockholders shall be held at the place designated in the vote of adjournment. 2.4. Notice of Meetings. Except as otherwise provided by law, notice of each meeting of stockholders shall be given that shall state the place, if any, date and hour of the meeting, the record date for determining stockholders entitled to vote at the meeting, if such date is different from the record date for determining stockholders entitled to notice of the meeting, and, in the case of a special meeting, the purpose or purposes for which the meeting is called. Unless otherwise provided by applicable law, the Certificate of Incorporation or these Bylaws, the notice of any meeting shall be given not less than ten (10) nor more than sixty (60) days before the date of the meeting to each stockholder entitled to vote at such meeting, as of the record date for determining the stockholders entitled to notice of the meeting. 2.5. Adjournments. Any meeting of stockholders, annual or special, may adjourn from time to time to reconvene at the same or some other place, if any, and notice need not be given of any such adjourned meeting if the time and place, if any, thereof, and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person or by proxy and vote at such adjourned meeting are (a) announced at the meeting at which the adjournment is taken, (b) displayed, during the time scheduled for the meeting, on the same electronic network used to enable stockholders and proxy holders to participate in the meeting by means of remote communication or (c) set forth in the notice of meeting in accordance with Section 2.4 of these Bylaws. At the adjourned meeting, the Corporation may transact any business which might have been transacted at the original meeting. If the adjournment is for more than thirty (30) days, a notice of the adjourned meeting shall be given to each


 
507324348.3 Exhibit 3.1 stockholder of record entitled to vote at the meeting. If after the adjournment a new record date for stockholders entitled to vote is fixed for the adjourned meeting, the Board of Directors shall fix a new record date for notice of such adjourned meeting in accordance with Section 2.11 of these Bylaws, and shall give notice of the adjourned meeting to each stockholder of record entitled to vote at such adjourned meeting as of the record date fixed for notice of such adjourned meeting. 2.6. Quorum of Stockholders. Except as otherwise provided by applicable law, by or pursuant to the Certificate of Incorporation or by these Bylaws, at each meeting of stockholders the presence in person or by proxy of the holders of one-third in voting power of the then outstanding shares of capital stock of the Corporation entitled to vote at the meeting shall be necessary and sufficient to constitute a quorum. In the absence of a quorum, the stockholders so present may, by a majority in voting power thereof, adjourn the meeting from time to time in the manner provided in Section 2.5 of these Bylaws until a quorum shall attend. Shares of the Corporation’s capital stock shall neither be entitled to vote nor be counted for quorum purposes if such shares belong to (a) the Corporation, (b) to another corporation, if a majority of the shares entitled to vote in the election of directors of such other corporation is held, directly or indirectly by the Corporation or (c) any other entity, if a majority of the voting power of such other entity is held, directly or indirectly by the Corporation or if such other entity is otherwise controlled, directly or indirectly, by the Corporation; provided, however, that the foregoing shall not limit the right of the Corporation to vote stock, including but not limited to its own capital stock, held by it in a fiduciary capacity. 2.7. Action by Vote. When a quorum is present at any meeting, a plurality of the votes properly cast for election of directors shall be sufficient to elect directors and a majority of the votes affirmatively cast in favor of any question other than the election of directors shall decide the question, except when a larger or different vote is required by law, by the Certificate of Incorporation, by these Bylaws or by the rules or regulations of any stock exchange applicable to the Corporation or its securities. No ballot shall be required for any election unless requested by a stockholder present or represented at the meeting and entitled to vote in the election. 2.8. Proxy Representation. Every stockholder may authorize another person or persons to act for him by proxy in all matters in which a stockholder is entitled to participate, whether by waiving notice of any meeting, objecting to or voting or participating at a meeting, or expressing consent or dissent without a meeting. Every proxy must be given by the stockholder or by his/her attorney-in-fact. No proxy shall be voted or acted upon after three years from its date unless such proxy provides for a longer period. A duly executed proxy shall be irrevocable if it states that it is irrevocable and, if, and only as long as, it is coupled with an interest sufficient in law to support an irrevocable power. A proxy may be made irrevocable regardless of whether the interest with which it is coupled is an interest in the stock itself or an interest in the Corporation generally. The authorization of a proxy may but need not be limited to specified action, provided, however, that if a proxy limits its authorization to a meeting or meetings of stockholders, unless otherwise specifically provided such proxy shall entitle the holder thereof to vote at any adjourned session but shall not be valid after the final adjournment thereof. 2.9. Inspectors. The directors or the person presiding at the meeting may, but need not, appoint one or more inspectors of election and any substitute inspectors to act at the meeting or any adjournment thereof. Each inspector, before entering upon the discharge of his/her duties, shall take and sign an oath faithfully to execute the duties of inspector at such meeting with strict impartiality and according to the best of his/her ability. The inspectors, if any, shall determine the number of shares of stock outstanding and the voting power of each, the shares of stock represented at the meeting, the existence of a quorum, the validity and effect of proxies, and shall receive votes, ballots or consents, hear and determine all challenges and questions arising in connection with the right to vote, count and tabulate all votes, ballots or consents, determine the result, and do such acts as are proper to conduct the election or vote with fairness to all stockholders. Notwithstanding the foregoing, in the event that a stockholder seeks to nominate one or more directors pursuant to Section 3.3 of these Bylaws, the directors shall appoint two inspectors, who shall not be affiliated with the Corporation, to determine whether a stockholder has complied with Section 3.3 of these Bylaws. If the inspector shall determine that a stockholder has not complied with Section 3.3 of these Bylaws, the inspectors shall direct the person presiding over the meeting to declare to the meeting that a nomination was not made in accordance with the procedures prescribed by the Bylaws; and the person presiding over the meeting shall so declare to the meeting and the defective nomination shall be disregarded. On request of the person presiding at the meeting, the inspectors shall make a report in writing of any challenge, question or matter determined by them and execute a certificate of any fact found by them.


 
507324348.3 Exhibit 3.1 2.10. List of Stockholders. The Secretary shall prepare and make, at least ten (10) days before every meeting of stockholders, a complete list of the stockholders entitled to vote at such meeting, arranged in alphabetical order and showing the address of each stockholder and the number of shares registered in his/her name; provided, however, if the record date for determining the stockholders entitled to vote is less than ten (10) days before the meeting date, the list shall reflect the stockholders entitled to vote as of the tenth (10th) day before the meeting date, arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder as of the tenth (10th) day before the meeting date. Such list shall be open to the examination of any stockholder for any purpose germane to the meeting for a period of 10 days ending on the day before the meeting date: (i) on a reasonably accessible electronic network, provided that the information required to gain access to such list is provided with the notice of the meeting, or (ii) during ordinary business hours, at the principal place of business of the corporation. The stock ledger shall be the only evidence as to who are stockholders entitled to examine such list or to vote in person or by proxy at such meeting. In the event that the Corporation determines to make the list available on an electronic network, the Corporation may take reasonable steps to ensure that such information is available only to stockholders of the Corporation. 2.11. Fixing Date for Determination of Stockholders of Record. In order that the Corporation may determine the stockholders entitled to notice of any meeting of stockholders or any adjournment thereof, or to consent to corporate action without a meeting (where permitted by or pursuant to the provisions of the Certificate of Incorporation), or entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date: (a) in the case of a determination of stockholders entitled to notice of any meeting of stockholders or any adjournment thereof, shall, unless otherwise required by applicable law, not be more than sixty (60) nor less than ten (10) days before the date of such meeting and, unless the Board of Directors determines, at the time it fixes such record date, that a later date on or before the date of the meeting shall be the date for determining the stockholders entitled to vote at such meeting, the record date for determining the stockholders entitled to notice of such meeting shall also be the record date for determining the stockholders entitled to vote at such meeting; (b) in the case of a determination of stockholders entitled to consent to corporate action without a meeting (where permitted by or pursuant to the provisions of the Certificate of Incorporation), shall not be more than ten (10) days from the date upon which the resolution fixing the record date is adopted by the Board of Directors; and (c) in the case of any other action, shall not be more than sixty (60) days prior to such other action. If no record date is fixed: (i) the record date for determining stockholders entitled to notice of and to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held; (ii) the record date for determining stockholders entitled to consent to corporate action without a meeting, if any, when no prior action of the Board of Directors is required by applicable law, shall be the first date on which a signed consent setting forth the action taken or proposed to be taken is delivered to the Corporation in accordance with applicable law, or, if prior action by the Board of Directors is required by applicable law, shall be at the close of business on the day on which the Board of Directors adopts the resolution taking such prior action; and (iii) the record date for determining stockholders for any other purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the Board of Directors may fix a new record date for the determination of stockholders entitled to vote at the adjourned meeting, and in such case shall also fix as the record date for the stockholders entitled to notice of such adjourned meeting the same or an earlier date as that fixed for the determination of stockholders entitled to vote in accordance with the foregoing provisions of this Section 2.11 at the adjourned meeting. 2.12. Conduct of Meetings. The date and time of the opening and the closing of the polls for each election, question or business upon which the stockholders will vote at a meeting of stockholders shall be announced at the meeting by the individual presiding over the meeting. The Board of Directors may adopt (by resolution or resolutions thereof) such rules and regulations for the conduct of the meeting of stockholders as it shall deem appropriate. Except to the extent inconsistent with such rules and regulations as adopted by the Board of Directors, the individual presiding over any meeting of stockholders shall have the right and authority to convene and to adjourn the meeting, to prescribe such rules, regulations and procedures and to do all such acts as, in the judgment of such individual, are appropriate for the proper conduct of the meeting of stockholders. Such rules, regulations or procedures, whether adopted by the Board of Directors or prescribed by the individual presiding over the meeting of stockholders, may include, without


 
507324348.3 Exhibit 3.1 limitation, the following: (a) the establishment of an agenda or order of business for the meeting of stockholders; (b) rules and procedures for maintaining order at the meeting of stockholders and the safety of those present; (c) limitations on attendance at or participation in the meeting of stockholders to stockholders of record of the Corporation, their duly authorized and constituted proxies or such other persons as the individual presiding over the meeting of stockholders shall determine; (d) restrictions on entry to the meeting of stockholders after the time fixed for the commencement thereof; and (e) limitations on the time allotted to questions or comments by participants in the meeting of stockholders. The Board of Directors or, in addition to making any other determinations that may be appropriate to the conduct of the meeting of stockholders, the individual presiding over any meeting of stockholders, in each case, shall have the power and duty to determine whether any election, question or business was or was not properly made, proposed or brought before the meeting of stockholders and therefore shall be disregarded and not be considered or transacted at the meeting, and, if the Board of Directors or the individual presiding over the meeting, as the case may be, determines that such election, question or business was not properly made, proposed or brought before the meeting of stockholders and shall be disregarded and not be considered or transacted at the meeting, the individual presiding over the meeting shall declare to the meeting that such election, question or business was not properly made, proposed or brought before the meeting and shall be disregarded and not be considered or transacted at the meeting, and any such election, question or business shall not be considered or transacted at the meeting. Unless and to the extent determined by the Board of Directors or the individual presiding over the meeting, meetings of stockholders shall not be required to be held in accordance with the rules of parliamentary procedure. 2.13. Notice of Stockholder Business and Nominations. (a) Annual Meetings of Stockholders. (i) Nominations of one or more individuals for election to the Board of Directors by the stockholders generally entitled to vote (each, a “Nomination,” and more than one, “Nominations”) and the proposal of any question or business other than a Nomination or Nominations to be considered by the stockholders generally entitled to vote (which, for the avoidance of doubt, shall exclude any question or business other than a Nomination or Nominations required by or pursuant to the provisions of the Certificate of Incorporation to be voted on solely and exclusively by the holders of any class (voting separately as a class) or series (voting separately as a series) of capital stock of the Corporation then outstanding) (collectively, “Business”) may be made at an annual meeting of stockholders only (A) pursuant to the Corporation’s notice of meeting (or any supplement thereto); provided, however, that reference in the Corporation’s notice of meeting to the election of directors or the election of members of the Board of Directors shall not include or be deemed to include a Nomination or Nominations, (B) by or at the direction of the Board of Directors or (C) by any stockholder of the Corporation who was a stockholder of record of the Corporation at the time the notice provided for in this Section 2.13 is delivered to the Secretary, who is entitled to vote at the meeting and who complies with the procedures set forth in this Section 2.13. (ii) For Nominations or Business to be properly brought before an annual meeting of stockholders by a stockholder pursuant to Section 2.13(a)(i)(C), the stockholder must have given timely notice thereof in writing to the Secretary and any proposed Business must constitute a proper matter for stockholder action. To be timely, a stockholder’s notice shall be delivered to the Secretary at the principal executive offices of the Corporation not later than the close of business on the ninetieth (90th) day nor earlier than the close of business on the one hundred twentieth (120th) day prior to the first anniversary of the preceding year’s annual meeting of stockholders; provided, however, that in the event that the date of the annual meeting is more than thirty (30) days before or more than seventy (70) days after such anniversary date, notice by the stockholder must be so delivered not earlier than the close of business on the one hundred twentieth (120th) day prior to such annual meeting and not later than the close of business on the later of the ninetieth (90th) day prior to such annual meeting or the tenth (10th) day following the day on which public announcement of the date of such meeting is first made by the Corporation. In no event shall the public announcement of an adjournment or postponement of an annual meeting of stockholders commence a new time period (or extend any time period) for the giving of a stockholder’s notice as described above. Such stockholder’s notice shall set forth: (A) as to each Nomination to be made by such stockholder, (1) all information relating to the individual subject to such Nomination that is required to be disclosed in solicitations of proxies for election of directors in an election contest, or is otherwise required, in each case pursuant to and in accordance with Regulation 14A under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), without regard to the application of the Exchange Act to either the Nomination or the Corporation, (2) such individual’s written consent to being named in any proxy statement as a nominee and to serving as director if elected, (3) a description of any direct or indirect compensation or benefit (including, without limitation, indemnification and/or advancement rights) to which the individual subject to such Nomination may be entitled under any agreement, arrangement or understanding with any person other than the


 
507324348.3 Exhibit 3.1 Corporation (including, without limitation, the amount of any such monetary compensation) in connection with such individual’s nomination or service as a director of the Corporation and (4) a description of any other material relationship or relationships between or among the individual subject to such Nomination and/or such individual’s affiliates and associates, on the one hand, and the stockholder giving the notice and the beneficial owner, if any, on whose behalf the Nomination or Nominations is/are made and/or such stockholder’s or beneficial owner’s respective affiliates and associates, or others acting in concert with such stockholder or beneficial owner or their respective affiliates and associates, on the other hand, including, without limitation, all information that would be required to be disclosed pursuant to Item 404 under Regulation S-K if such stockholder, beneficial owner, affiliate, associate or other person were the “registrant” for purposes of such rule and the individual subject to such Nomination was a director or officer of such registrant; (B) as to the Business proposed by such stockholder, a brief description of the Business, the text of the proposed Business (including the text of any resolution or resolutions proposed for consideration and in the event that such Business includes a proposal to amend these Bylaws, the text of the proposed amendment), the reason or reasons for conducting such Business at the meeting and any material interest or interests in such Business of such stockholder and of the beneficial owner, if any, on whose behalf the Business is proposed; and (C) as to the stockholder giving the notice and the beneficial owner, if any, on whose behalf the Nomination, Nominations or Business is/are made (1) the name and address of such stockholder, as they appear on the Corporation’s books, and of such beneficial owner, if any, and any of their respective affiliates or associates or others acting in concert with them, (2) the class, series and number of shares of capital stock of the Corporation which are owned beneficially and of record by such stockholder and such beneficial owner, if any, (3) a representation that the stockholder is a holder of record of shares of capital stock of the Corporation entitled to vote at such meeting and such stockholder (or a qualified representative of such stockholder) intends to appear in person or by proxy at the meeting to propose such Nomination, Nominations or Business and (4) a representation as to whether the stockholder or the beneficial owner, if any, intends or is part of a group which intends (x) to deliver by proxy statement and/or form of proxy to holders of at least the percentage of the Corporation’s outstanding capital stock required to approve or adopt the Business or elect the nominee or nominees subject to the Nomination or Nominations and/or (y) to otherwise solicit proxies from stockholders of the Corporation in support of such Nomination, Nominations or Business which representation must include a statement as to whether such holder or any beneficial owner intends to solicit the requisite percentage of the Corporation’s stock under Rule 14a-19 (“Rule 14a-19”) under the Exchange Act; provided, however, that if the Business is otherwise subject to Rule 14a-8 (or any successor thereto) promulgated under the Exchange Act (“Rule 14a-8”), the foregoing notice requirements shall be deemed satisfied by a stockholder if the stockholder has notified the Corporation of his, her or its intention to present such Business at an annual meeting of stockholders in compliance with Rule 14a-8, and such Business has been included in a proxy statement that has been prepared by the Corporation to solicit proxies for such annual meeting of stockholders. The Corporation may require (1) any individual subject to such Nomination to furnish such other information as the Corporation may reasonably require to determine the eligibility of such individual subject to such Nomination to serve as a director of the Corporation if elected and (2) the stockholder giving notice to furnish such other information as the Corporation may reasonably require to demonstrate that any Business is a proper matter for stockholder action at an annual meeting of stockholders. (iii) Notwithstanding anything in the second sentence of Section 2.13(a)(ii) to the contrary, in the event that the number of directors to be elected to the Board of Directors by the stockholders generally entitled to vote at an annual meeting of stockholders is increased and there is no public announcement by the Corporation naming the nominees for election to the additional directorships at least one hundred (100) days prior to the first (1st) anniversary of the preceding year’s annual meeting of stockholders, a stockholder’s notice required by this Section 2.13 shall also be considered timely, but only with respect to nominees for election to such additional directorships, if it shall be delivered to the Secretary at the principal executive offices of the Corporation not later than the close of business on the tenth (10th) day following the day on which such public announcement is first made by the Corporation. (b) Special Meetings of Stockholders. Only such Business shall be conducted at a special meeting of stockholders as shall have been brought before the meeting pursuant to the Corporation’s notice of meeting (or any supplement thereto); provided, however, that reference therein to the election of directors or the election of members of the Board of Directors shall not include or be deemed to include Nominations. Nominations may be made at a special meeting of stockholders at which one or more directors are to be elected by the stockholders generally entitled to vote pursuant to the Corporation’s notice of meeting (or any supplement thereto) as aforesaid (provided that the Board of Directors has determined that directors shall be elected at such meeting) (i) by or at the direction of the Board of Directors or (ii) by any stockholder of the Corporation who is a stockholder of record at the time the notice provided for in this Section 2.13 is delivered to the Secretary, who is entitled to vote at the meeting and upon such election and


 
507324348.3 Exhibit 3.1 who complies with the notice procedures set forth in this Section 2.13. In the event the Corporation calls a special meeting of stockholders for the purpose of electing one or more directors to the Board of Directors by the stockholders generally entitled to vote, any such stockholder entitled to vote in such election may make a Nomination or Nominations of one or more individuals (as the case may be) for election to such position(s) as specified in the Corporation’s notice of meeting pursuant to Section 2.13(a)(i)(A), if the stockholder’s notice required by Section 2.13(a)(ii) shall be delivered to the Secretary at the principal executive offices of the Corporation not earlier than the close of business on the one hundred twentieth (120th) day prior to such special meeting and not later than the close of business on the later of the ninetieth (90th) day prior to such special meeting or the tenth (10th) day following the day on which public announcement is first made of the date of such special meeting and of the nominee(s) proposed by the Board of Directors to be elected at such special meeting. In no event shall the public announcement of an adjournment or postponement of a special meeting of stockholders commence a new time period (or extend any time period) for the giving of a stockholder’s notice as described above. (c) General. (i) Only individuals subject to a Nomination made in compliance with the procedures set forth in this Section 2.13 shall be eligible for election at an annual or special meeting of stockholders, and only such Business shall be conducted at an annual or special meeting of stockholders as shall have been brought before such meeting in accordance with the procedures set forth in this Section 2.13. Except as otherwise provided by applicable law, the Board of Directors or the individual presiding over an annual or special meeting of stockholders shall have the power and duty to determine whether (A) a Nomination or any Business proposed to be brought before the meeting was or was not made, proposed or brought, as the case may be, in accordance with the procedures set forth in this Section 2.13 and (B) any proposed Nomination, Nominations or Business shall be disregarded or that such Nomination, Nominations or Business shall not be considered or transacted at the meeting. Notwithstanding the foregoing provisions of this Section 2.13, if the stockholder (or a qualified representative of the stockholder) does not appear at the annual or special meeting of stockholders to present a Nomination, Nominations or Business, such Nomination, Nominations or Business shall be disregarded and such Nomination, Nominations or Business shall not be considered or transacted at the meeting, notwithstanding that proxies in respect of such vote may have been received by the Corporation. (ii) For purposes of this Section 2.13, “public announcement” shall include disclosure in a press release reported by the Dow Jones News Service, Associated Press or comparable national news service or in a document publicly filed by the Corporation with or publicly furnished by the Corporation to the Securities and Exchange Commission pursuant to Section 13, 14 and 15(d) (or any successor thereto) of the Exchange Act. (iii) Nothing in this Section 2.13 shall be deemed to affect any (A) rights or obligations, if any, of stockholders with respect to inclusion of proposals in the Corporation’s proxy statement pursuant to Rule 14a-8 (to the extent the Corporation or such proposals are subject to Rule 14a-8), (B) rights or obligations, if any, of stockholders with respect to the inclusion of a nominee in a universal proxy card pursuant to Rule 14a-19 (or any successor thereto) promulgated under the Exchange Act or (C) rights, if any, of the holders of any class or series of capital stock of the Corporation as provided for or filed by or pursuant to the Certificate of Incorporation and then outstanding to, solely and exclusively, elect one or more directors outstanding. Section 3. Board of Directors 3.1. Number. The number of directors which shall constitute the whole Board of Directors shall not be less than three (3). The exact number of directors shall be fixed from time to time by a resolution adopted by a majority of directors. The number of directors may be increased at any time or from time to time by the directors by vote of a majority of the directors then in office. The number of directors may be decreased to any number permitted by the foregoing at any time by the directors by vote of a majority of the directors then in office, but only to eliminate vacancies existing by reason of the death, resignation or removal of one or more directors. Directors need not be stockholders. 3.2. Tenure. Except as otherwise provided by law, by the Certificate of Incorporation or by these Bylaws, each director shall hold office until the successors of such director’s class are elected and qualified, or until he sooner dies, resigns, is removed or becomes disqualified.


 
507324348.3 Exhibit 3.1 3.3. Nomination. Only persons who are nominated in accordance with the procedures set forth in this Section 3.3 shall be eligible for election as directors. Nominations of persons for election to the Board of Directors may be made by or at the direction of the Board of Directors or by any stockholder of the Corporation entitled to vote for the election of directors at the meeting who complies with the notice procedures set forth in Section 2.13. Such nominations, other than those made by or at the discretion of the Board of Directors, shall be made pursuant to timely notice in writing to the Secretary. 3.4. Powers. The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors who shall have and may exercise all the powers of the Corporation and do all such lawful acts and things as are not by law, the Certificate of Incorporation or these Bylaws directed or required to be exercised or done by the stockholders. 3.5. Vacancies. Any director may resign at any time upon notice to the Corporation. Subject to the rights, if any, of the holders of any class or series of capital stock of the Corporation as provided for or fixed by or pursuant to the provisions of the Certificate of Incorporation and then outstanding, newly created directorships resulting from an increase in the authorized number of directors or any vacancies on the Board of Directors resulting from the death, resignation, disqualification, removal or other cause, shall be filled solely and exclusively by a majority of the directors then in office, although less than a quorum, or by the sole remaining director. Any director so elected shall hold office until the expiration of the term of office of the director whom he or she has replaced and until his or her successor shall be elected and qualified, subject to such director’s earlier death, resignation, disqualification or removal. No decrease in the number of directors shall shorten the term of any incumbent director. The directors shall have and may exercise all their powers notwithstanding the existence of one or more vacancies in their number, subject to any requirements of law, the Certificate of Incorporation or these Bylaws as to the number of directors required for a quorum or for any vote or other actions. 3.6. Committees. The Board of Directors may, by vote of a majority of the whole Board of Directors, (a) designate, change the membership of or terminate the existence of any committee or committees, each committee to consist of one or more of the directors; (b) designate one or more directors as alternate members of any such committee who may replace any absent or disqualified member at any meeting of the committee; and (c) determine the extent to which each such committee shall have and may exercise the powers of the Board of Directors in the management of the business and affairs of the Corporation, including the power to authorize the seal of the Corporation to be affixed to all papers which require it and the power and authority to declare dividends or to authorize the issuance of stock; excepting, however, such powers which by law, by the Certificate of Incorporation or by these or by these Bylaws they are prohibited from so delegating. In the absence or disqualification of any member of such committee and his/her alternate, if any, the member or members thereof present at any meeting and not disqualified from voting, whether or not constituting a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in the place of any such absent or disqualified member. Except as the Board of Directors may otherwise determine, any committee may make rules for the conduct of its business, but unless otherwise provided by the Board of Directors or such rules, its business shall be conducted as nearly as may be in the same manner as is provided by these Bylaws for the conduct of business by the Board of Directors. Each committee shall keep regular minutes of its meetings and report the same to the board of directors upon request. 3.7. Regular Meetings. Regular meetings of the Board of Directors may be held without call or notice at such places within or without the State of Delaware and at such times as the board may from time to time determine, provided that notice of the first regular meeting following any such determination shall be given to absent directors. A regular meeting of the directors may be held without call or notice immediately after and at the same place as the annual meeting of the stockholders. 3.8. Special Meetings. Special meetings of the Board of Directors may be held at any time and at any place within or without the State of Delaware designated in the notice of the meeting, when called by the chairperson of the Board of Directors, the Chief Executive Officer, or by one-third or more in number of the directors, reasonable notice thereof being given to each director by the Secretary or by the Chairperson of the Board of Directors, the Chief Executive Officer or any one of the directors calling the meeting. 3.9. Notice. Any time it is necessary to give notice of a board of directors’ meeting, notice shall be given (i) in person or by telephone to the director at least 24 hours in advance of the meeting, (ii) by personally delivering


 
507324348.3 Exhibit 3.1 written notice to the director’s last known business or home address at least 24 hours in advance of the meeting, (iii) by delivering notice by electronic mail or other electronic transmission at least 24 hours in advance of the meeting, (iv) by depositing written notice with a reputable delivery service or overnight carrier addressed to the director’s last known business or home address for delivery to that address no later than the business day preceding the date of the meeting or (v) by depositing written notice in the U.S. mail, postage prepaid, addressed to the director’s last known business or home address no later than the third business day preceding the date of the meeting. Notice of a meeting need not be given to any director if a written waiver of notice, executed by him, or a waiver sent by electronic transmission by him, in either case before or after the meeting, is filed with the records of the meeting, or to any director who attends the meeting without protesting prior thereto or at its commencement the lack of notice to him. Neither notice of a meeting nor a waiver of a notice need specify the purposes of the meeting. 3.10. Quorum. Except as may be otherwise provided by law, by the Certificate of Incorporation or these Bylaws, at any meeting of the directors a majority of the directors then in office shall constitute a quorum; a quorum shall not in any case be less than one-third of the total number of directors constituting the whole Board of Directors, with a minimum of two directors constituting a quorum. Any meeting may be adjourned from time to time by a majority of the affirmative votes cast upon the question, whether or not a quorum is present, and the meeting may be held as adjourned without further notice. 3.11. Action by Vote. Except as may be otherwise provided by law, by the Certificate of Incorporation or by these Bylaws, when a quorum is present at any meeting the vote of a majority of the directors present shall be the act of the Board of Directors. 3.12. Action Without a Meeting. Any action required or permitted to be taken at any meeting of the Board of Directors or a committee thereof may be taken without a meeting if all the members of the board or of such committee, as the case may be, consent thereto in writing or by electronic transmission. 3.13. Participation in Meetings by Conference Telephone. Members of the Board of Directors, or any committee designated by such board, may participate in a meeting of such board or committee by means of conference telephone or similar communications equipment by means of which all persons participating in the meeting can hear each other or by any other means permitted by law. Such participation shall constitute presence in person at such meeting. 3.14. Compensation. In the discretion of the board of directors, each director may be paid such fees for his/her services as director and be reimbursed from his/her reasonable expenses incurred in the performance of his/her duties as director as the board of directors from time to time may determine. Nothing contained in this section shall be construed to preclude any director from serving the Corporation in any other capacity and receiving reasonable compensation therefor. 3.15. Interested Directors and Officers. (a) No contract or transaction between the Corporation and one or more of its directors or officers, or between the Corporation and any other corporation, partnership, association, or other organization in which one or more of the Corporation’s directors or officers are directors or officers, or have a financial interest, shall be void or voidable, solely for this reason, or solely because the director or officer is present at or participates in the meeting of the board or committee thereof which authorizes the contract or transaction, or solely because his/her or their votes are counted for such purpose, if: (1) The material facts as to his/her relationship or interest and as to the contract or transaction are disclosed or are known to the Board of Directors or the committee, and the board or committee in good faith authorizes the contract or transaction by the affirmative votes of majority of the disinterested directors, even though the disinterested directors be less than a quorum: or (2) The material facts as to his/her relationship or interest and as to the contract or transaction are disclosed or are known to the stockholder entitled to vote thereon, and the contract or transaction is specifically approved in good faith by vote of the stockholders; or


 
507324348.3 Exhibit 3.1 (3) The contract or transaction is fair as to the Corporation as of the time it is authorized, approved or ratified by the Board of Directors, a committee thereof, or the stockholders. (b) Common or interested directors may be counted in determining the presence of a quorum at a meeting of the Board of Directors or of a committee which authorized the contract or transaction. Section 4. Officers and Agents. 4.1. Enumeration: Qualification. The Board of Directors shall elect a Chief Executive Officer, Chief Scientific Officer, Chief Financial Officer and a Secretary, and shall choose a Chairperson of the Board of Directors from among its members. The Board of Directors may also choose a President, one or more Vice Presidents, one or more Assistant Secretaries, a Treasurer and one or more Assistant Treasurers and such other officers as it shall from time to time deem necessary or desirable. The Corporation may also have such agents, if any, as the Board of Directors from time to time may in its discretion choose. Any officer may be but none need be a director or stockholder. Any two or more offices may be held by the same person. Any officer may be required by the Board of Directors to secure the faithful performance of his/her duties to the Corporation by giving bond in such amount and with sureties or otherwise as the Board of Directors may determine. 4.2. Powers. Subject to law, to the Certificate of Incorporation and to the other provisions of these Bylaws, each officer shall have, in addition to the duties and powers herein set forth, such duties and powers as are commonly incident to his/her office and such additional duties and powers as the Board of Directors may from time to time designate. 4.3. Election. The officers may be elected by the Board of Directors at their first meeting following the annual meeting of the stockholders or at any other time. At any time or from time to time the directors may delegate to any officer their power to elect or appoint any other officer or any agents. 4.4. Tenure. Each officer shall hold office until the first meeting of the board of directors following the next annual meeting of the stockholders and until his/her respective successor is chosen and qualified unless a shorter period shall have been specified by the terms of his/her election or appointment, or in each case until he sooner dies, resigns, is removed or becomes disqualified. Each agent shall retain his/her authority at the pleasure of the directors, or the officer by whom he was appointed or by the officer who then holds agent appointive power. 4.5. Chairperson of the Board of Directors, Chief Executive Officer. The Chairperson of the Board of Directors shall have such duties and powers as shall be designated from time to time by the Board of Directors. Unless the Board of Directors otherwise specifies, the Chairperson of the Board of Directors, or if there is none the Chief Executive Officer, if such person also is a director, shall preside, or designate the person who shall preside, at all meetings of the stockholders and of the Board of Directors. Unless the Board of Directors otherwise specifies, the Chief Executive Officer shall have direct charge of all business operations of the Corporation and, subject to the control of the Board of Directors, shall have general charge and supervision of the business of the corporation. 4.6. Chief Financial Officer and Assistant Treasurers. Unless the Board of Directors otherwise specifies, the Chief Financial Officer shall be the Treasurer of the Corporation and shall be in charge of its funds and valuable papers, and shall have such other duties and powers as may be designated from time to time by the Board of Directors or by the Chief Executive Officer. If no Controller is elected, the Chief Financial Officer shall, unless the Board of Directors otherwise specifies, also have the duties and powers of the Controller. Any Assistant Treasurers shall have such duties and powers as shall be designated from time to time by the Board of Directors, the Chief Executive Officer or the Chief Financial Officer. 4.7. Controller and Assistant Controller. If a Controller is elected, he shall, unless the Board of Directors otherwise specifies, be the Chief Accounting Officer of the Corporation and be in charge of its books of account and accounting records, and of its accounting procedures. He shall have such other duties and powers and may be designated from time to time by the Board of Directors, the Chief Executive Officer or the Chief Financial Officer.


 
507324348.3 Exhibit 3.1 Any Assistant Controller shall have such duties and powers as shall be designated from time to time by the Board of Directors, the Chief Executive Officer, the Chief Financial Officer or the Controller. 4.8. Secretary and Assistant Secretaries. The Secretary shall record all proceedings of the stockholders, of the Board of Directors and of committees of the Board of Directors in a book or series of books to be kept therefore and shall file therein all actions by written consent of stockholders or directors. In the absence of the Secretary from any meeting, an Assistant Secretary, or if there be none or he/she is absent, a temporary secretary chosen at the meeting, shall record the proceedings thereof. Unless a transfer agent has been appointed the Secretary shall keep or cause to be kept the stock and transfer records of the Corporation, which shall contain the names and record addresses of all stockholders and the number of shares registered in the name of each stockholder. He or she shall have such other duties and powers as may from time to time be designated by the Board of Directors or the Chief Executive Officer. Any Assistant Secretaries shall have such duties and powers as shall be designated from time to time by the Board of Directors, the Chief Executive Officer or the Secretary. Section 5. Resignations and Removals. 5.1. Any director or officer may resign at any time by delivering his/her resignation in writing or by electronic transmission to the Chairperson of the Board of Directors, the Chief Executive Officer, or the Secretary or to a meeting of the Board of Directors. Such resignation shall be effective upon receipt unless specified to be effective at some other time, and without in either case the necessity of its being accepted unless the resignation shall so state. A director (including persons elected by directors to fill vacancies in the board) may be removed from office with or without cause by the vote of the holders of a majority of the shares issued and outstanding and entitled to vote in the election of directors. The Board of Directors may at any time remove any officer either with or without cause. The Board of Directors may at any time terminate or modify the authority of any agent. No director of officer resigning and (except where a right to receive compensation shall be expressly provided in a duly authorized written agreement with the Corporation) no director or officer removed shall have any right to any compensation as such director or officer for any period following his/her resignation or removal, or any right to damages on account of such removal, whether his/her compensation be by the month or by the year or otherwise; unless, in the case of a resignation, the directors, or, in the case of removal, the body acting on the removal, shall in their or its discretion provide for compensation. Section 6. Vacancies. 6.1. If the office of Chief Executive Officer or Chief Financial Officer or the Treasurer or the Secretary becomes vacant, the directors may elect a successor by vote of a majority of the directors then in office. If the office of any other officer becomes vacant, any person or body empowered to elect or appoint that officer may choose a successor. Each such successor shall hold office for the unexpired term and until his/her successor is chosen and qualified or in each case he or she sooner dies, resigns, is removed or becomes disqualified. Any vacancy of a directorship shall be filled as specified in Section 3.5 of these Bylaws. Section 7. Capital Stock. 7.1. Stock Certificates. The shares of the Corporation shall be represented by certificates, provided that the Board of Directors of the Corporation may provide by resolution or resolutions that some or all of any or all classes or series of its stock shall be uncertificated shares. Any such resolution shall not apply to shares represented by a certificate until such certificate is surrendered to the Corporation. Notwithstanding the adoption of such a resolution by the Board of Directors, every holder of stock represented by certificates and upon request every holder of uncertificated shares shall be entitled to have a certificate signed by, or in the name of the Corporation by the Chairperson of the Board of Directors, the Chief Executive Officer or the Chief Financial Officer, and by the Treasurer or an Assistant Treasurer, or by the Secretary or an Assistant secretary of such Corporation representing the number of shares registered in certificate form. Any or all of the signatures on the certificate may be a facsimile. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate has


 
507324348.3 Exhibit 3.1 ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if he were such officer, transfer agent, or registrar at the time of issue. 7.2. Loss of Certificates. In the case of the alleged theft, loss, destruction or mutilation of a certificate of stock, a duplicate certificate may be issued in place thereof, upon such terms, including receipt of a bond sufficient to indemnify the Corporation against any claim on account thereof, as the board of directors may prescribe. Section 8. Transfer of Shares of Stock. 8.1. Transfer on Books. Subject to the restrictions, if any, stated or noted on the stock certificate, shares of stock may be transferred on the books of the Corporation by the surrender to the Corporation or its transfer agent of the certificate therefor properly endorsed or accompanied by a written assignment and power of attorney properly executed, with necessary transfer stamps affixed, and with such proof of the authenticity of signature as the Board of Directors or the transfer agent of the Corporation may reasonably require. Except as may be otherwise required by law, by the Certificate of Incorporation or by these Bylaws, the Corporation shall be entitled to treat the record holder of stock as shown on its books as the owner of such stock for all purposes, including the payment of dividends and the right to receive notice and to vote or to give any consent with respect thereto and to be held liable for such calls and assessments, if any, as may lawfully be made thereon, regardless of any transfer, pledge or other disposition of such stock until the shares have been properly transferred on the books of the corporation. It shall be the duty of each stockholder to notify the Corporation of his/her post office address. 8.2. Record Date and Closing Transfer Books. In order that the Corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof and in accordance with Section 2.11, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date shall not be more than sixty (60) nor less than ten (10) days before the date of such meeting. If no such record date is fixed by the Board of Directors, the record date for determining the stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the Board of Directors may fix a new record date for the adjourned meeting. In order that the Corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights or to exercise any rights in respect of any change, conversion or exchange of stock, or for the purpose of any other lawful action, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted, and which record date shall be not more than sixty (60) days prior to such payment, exercise or other action. If no such record date is fixed, the record date for determining stockholders for any such purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto. Section 9. Indemnification. 9.1. Right to Indemnification. The Corporation shall indemnify and hold harmless, to the fullest extent permitted by applicable law, any individual (a “Covered Person”) who was or is made or is threatened to be made a party or is otherwise involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative (a “proceeding”), by reason of the fact that he or she, or an individual for whom he or she is the legal representative, is or was a director or officer of the Corporation or, while a director or officer of the Corporation, is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust, other enterprise or nonprofit entity, including service with respect to employee benefit plans, its participants or beneficiaries against all expense, liability and loss (including attorneys’ fees, judgments, fines, ERISA excise taxes or penalties and amounts paid in settlement) reasonably incurred or suffered by such indemnitee in connection therewith and such indemnification shall continue as to an indemnitee who has ceased to be a director or officer and shall inure to the benefit of the indemnitee’s heirs, executors and administrators. Notwithstanding the preceding sentence, except as otherwise provided in Section 9.3, the Corporation shall be required to indemnify a


 
507324348.3 Exhibit 3.1 Covered Person in connection with a proceeding (or part thereof) commenced by such Covered Person only if the commencement of such proceeding (or part thereof) by the Covered Person was authorized in the specific case by the Board of Directors. 9.2. Prepayment of Expenses. The Corporation shall to the fullest extent not prohibited by applicable law, pay the expenses (including attorneys’ fees) incurred by a Covered Person in defending or otherwise participating in any proceeding in advance of its final disposition; provided, however, that, to the extent required by applicable law, such payment of expenses in advance of the final disposition of the proceeding shall be made only upon receipt of an undertaking by the Covered Person to repay all amounts advanced if it should be ultimately determined that the Covered Person is not entitled to be indemnified under this Section 9 or otherwise. 9.3. Claims. If (a) a claim for indemnification (following the final disposition of such proceeding) under this Section 9 is not paid in full within sixty (60) days after a written claim therefor by the Covered Person has been received by the Corporation or (b) a claim for advancement of expenses under this Section 9 is not paid in full within twenty (20) days after a written claim therefor by the Covered Person has been received by the Corporation, as applicable, the Covered Person may file suit to recover the unpaid amount of such claim and, if successful in whole or in part, shall be entitled to be paid the expense (including attorneys’ fees) of prosecuting such claim. In any such action the Corporation shall have the burden of proving that the Covered Person is not entitled to the requested indemnification or advancement of expenses under applicable law. In any such action to enforce a claim for indemnification under this Section 9, neither the failure of the Corporation to have made a determination prior to the commencement of such action that indemnification of the Covered Person is proper in the circumstances because the Covered Person has met the applicable standard of conduct set forth in the Delaware General Corporation Law, nor an actual determination by the Corporation that the Covered Person has not met such applicable standard of conduct, shall create a presumption that the Covered Person has not met such applicable standard of conduct. 9.4. Non-Exclusivity of Rights. The rights of indemnification and to the advancement of expenses conferred in this Section 9 shall not be exclusive of any other right which any person may have or thereafter acquire under any statue, provision of the Certificate of Incorporation, by-law agreement, vote of stockholders or disinterested directors or otherwise and shall inure to the benefit of the heirs and legal representatives of such person. 9.5. Insurance. The Corporation may maintain insurance, at its expense, to protect itself and any director, officer, employee or agent of the Corporation or another corporation, partnership, joint venture, trust or other enterprise against any expense, liability or loss, whether or not the Corporation would have the power to indemnify such person against such expense, liability or loss under the Delaware General Corporation Law. 9.6. Indemnification of Employees or Agents of the Corporation. The Corporation may, to the extent authorized from time to time by the Board of Directors, grant rights to indemnification and to the advancement of expenses, to any employee or agent of the Corporation to the fullest extent of the provisions of this Section 9 with respect to the indemnification and advancement of expenses of directors or officers of the Corporation. 9.7. Indemnification Contracts. The Board of Directors is authorized to enter into a contract with any director, officer, employee or agent of the Corporation, or any person serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, including employee benefit plans, providing for indemnification rights equivalent to or, if the Board of Directors so determines, greater than, those provided for in this Section 9. 9.8. Effect of Amendment. Any amendment, repeal or modification of any provision of this Section 9 by the stockholders or the directors of the Corporation shall not adversely affect any right or protection of a director or officer of the Corporation existing at the time of such amendment, repeal or modification. 9.9. Certain Terms. For purposes of this Section 9: (a) references to the “Corporation” shall include, in addition to the resulting corporation, any constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would have had power and authority to indemnify its directors, officers and employees or agents, so that any person who is or was a director, officer, employee or agent of such constituent corporation, or is or was serving at the request of such constituent corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, shall stand in


 
507324348.3 Exhibit 3.1 the same position under this Section 9 with respect to the resulting or surviving corporation as such person would have with respect to such constituent corporation as if its separate existence had continued; (b) references to “other enterprise” shall include employee benefit plans; (c) reference to “fines” shall include any excise taxes assessed on a person with respect to any employee benefit plan; and (d) references to “serving at the request of the Corporation or any of its consolidated subsidiaries” shall include any service as a director, officer, employee or agent of the Corporation which imposes duties on, or involves services by, such director, officer, employee or agent with respect to an employee benefit plan, its participants or beneficiaries. Section 10. General Provisions. 10.1. Corporate Seal. Subject to alteration by the directors, the seal of the Corporation shall consist of a flat-faced circular die with the word “Delaware” and the name of the Corporation cut or engraved thereon, together with such other words, dates or images as may be approved from time to time by the directors. 10.2. Execution of Papers. Except as the Board of Directors may generally or in particular cases authorize the execution thereof in some other manner, all deeds, leases, transfers, contracts, bonds, notes, checks, drafts or other obligations made, accepted or endorsed by the Corporation shall be signed by the Chairperson of the Board of Directors, the Chief Executive Officer, the Chief Financial Officer, the Secretary or the Treasurer. 10.3. Fiscal Year. The fiscal year of the Corporation shall be fixed by resolution of the Board of Directors. 10.4. Electronic Transmission. For purposes of these Bylaws, “electronic transmission” shall mean a form of communication not directly involving the physical transmission of paper that satisfies the requirements with respect to such communications contained in the Delaware General Corporation Law. 10.5. Amendments. These Bylaws may be adopted, amended or repealed by vote of a majority of the directors then in office or by vote of a majority of the stock outstanding and entitled to vote. Any by-law, whether adopted, amended or repealed by the stockholders or directors, may be amended or reinstated by the stockholders or the directors. 10.6. Manner of Notice. Except as otherwise provided in these Bylaws or permitted by applicable law, notices to directors and stockholders shall be in writing or electronic transmission and delivered by mail, courier service or electronic mail to the directors or stockholders at their addresses appearing on the records of the Corporation. 10.7. Waiver of Notice of Meetings of Stockholders, Directors and Committees. Any waiver of notice, given by the person entitled to notice, whether before or after the time stated therein, shall be deemed equivalent to notice. Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Neither the business to be transacted at nor the purpose of any regular or special meeting of the stockholders, directors, or members of a committee of directors need be specified in a waiver of notice. 10.8. Forum of Adjudication of Disputes. (a) Delaware Courts. Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the Corporation, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or employee of the Corporation to the Corporation or the Corporation’s stockholders, (iii) any civil action to interpret, apply or enforce any provision of the Delaware General Corporation Law, (iv) any civil action to interpret, apply, enforce or determine the validity of the provisions of the Certificate of Incorporation or these Bylaws or (v) any action asserting a claim governed by the internal affairs doctrine; provided, however, in the event that the Court of Chancery of the State of Delaware lacks jurisdiction over such action, the sole and exclusive forum for such action shall be another state or federal court located within the State of Delaware, in all cases, subject to such court having personal jurisdiction over the indispensable parties named as defendants. For the avoidance of doubt, this


 
507324348.3 Exhibit 3.1 Section 10.8(a) shall not apply to the resolution of any complaint asserting a cause of action arising under the Securities Act. (b) Federal Courts. Unless the Corporation consents in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by applicable law, be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. (c) Application. Failure to enforce the foregoing provisions of this Section 10.8 would cause the Corporation irreparable harm and the Corporation shall, to the fullest extent permitted by applicable law, be entitled to equitable relief, including injunctive relief and specific performance, to enforce the foregoing provisions. Any person purchasing or otherwise acquiring any interest in shares of capital stock of the Corporation shall be deemed to have notice of and consented to the provisions of this Section 10.8. This Section 10.8 shall not apply to any action asserting claims arising under the Exchange Act. Adopted effective as of November 12, 2024.


 

EXHIBIT 31.1
CERTIFICATION PURSUANT TO
RULE 13a-14(a) or RULE 13d-14(a) OF THE
SECURITIES EXCHANGE ACT OF 1934
I, Roderick de Greef, certify that:
1.I have reviewed this quarterly report on Form 10-Q of BioLife Solutions, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 12, 2024
/s/ Roderick de Greef
Roderick de Greef
Chief Executive Officer and Chairman of the Board


EXHIBIT 31.2
CERTIFICATION PURSUANT TO
RULE 13a-14(a) or RULE 13d-14(a) OF THE
SECURITIES EXCHANGE ACT OF 1934
I, Troy Wichterman, certify that:
1.I have reviewed this quarterly report on Form 10-Q of BioLife Solutions, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 12, 2024
/s/ Troy Wichterman
Troy Wichterman
Chief Financial Officer


EXHIBIT 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of BioLife Solutions, Inc. (the “Company”) on Form 10-Q for the period ending September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Roderick de Greef, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: November 12, 2024
/s/ Roderick de Greef
Roderick de Greef
Chief Executive Officer and Chairman of the Board


EXHIBIT 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of BioLife Solutions, Inc. (the “Company”) on Form 10-Q for the period ending September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Troy Wichterman, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: November 12, 2024
/s/ Troy Wichterman
Troy Wichterman
Chief Financial Officer

v3.24.3
Cover Page - shares
9 Months Ended
Sep. 30, 2024
Nov. 05, 2024
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2024  
Document Transition Report false  
Entity File Number 001-36362  
Entity Registrant Name BioLife Solutions, Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 94-3076866  
Entity Address, Address Line One 3303 Monte Villa Parkway, Suite 310  
Entity Address, City or Town Bothell  
Entity Address, State or Province WA  
Entity Address, Postal Zip Code 98021  
City Area Code 425  
Local Phone Number 402-1400  
Title of 12(b) Security Common stock, par value $0.001 per share  
Trading Symbol BLFS  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   46,387,214
Entity Central Index Key 0000834365  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q3  
Amendment Flag false  
v3.24.3
Unaudited Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 23,977 $ 33,317
Restricted cash 184 31
Available-for-sale securities, current portion 10,211 16,288
Accounts receivable, trade, net of allowance for credit losses of $955 and $1,707 as of September 30, 2024 and December 31, 2023, respectively 17,918 16,928
Inventories 32,179 32,208
Prepaid expenses and other current assets 4,914 6,463
Current assets, discontinued operations 0 15,369
Total current assets 89,383 120,604
Assets held for rent, net 10,822 7,713
Property and equipment, net 17,709 20,930
Operating lease right-of-use assets, net 14,402 11,446
Financing lease right-of-use assets, net 30 94
Long-term deposits and other assets 271 270
Available-for-sale securities, long-term 4,884 548
Equity investments 995 5,069
Intangible assets, net 18,415 21,149
Goodwill 224,741 224,741
Long-term assets, discontinued operations 0 150
Total assets 381,652 412,714
Current liabilities:    
Accounts payable 3,838 3,573
Accrued expenses and other current liabilities 8,449 10,775
Sales taxes payable 4,351 4,962
Warranty liability 186 350
Lease liabilities, operating, current portion 2,788 2,534
Lease liabilities, financing, current portion 323 355
Debt, current portion 12,231 6,833
Current liabilities, discontinued operations 0 12,796
Total current liabilities 32,166 42,178
Lease liabilities, operating, long-term 15,189 12,189
Lease liabilities, financing, long-term 913 1,158
Debt, long-term 7,823 18,311
Deferred tax liabilities 100 188
Long-term liabilities, discontinued operations 0 1,027
Total liabilities 56,191 75,051
Commitments and contingencies (Note 12)
Shareholders’ equity:    
Preferred stock, $0.001 par value; 1,000,000 shares authorized, Series A, 4,250 shares designated, and 0 shares issued and outstanding as of September 30, 2024 and December 31, 2023 0 0
Common stock, $0.001 par value; 150,000,000 shares authorized, 46,227,940 and 45,167,225 shares issued and outstanding, respectively, as of September 30, 2024 and December 31, 2023 46 45
Additional paid-in capital 673,183 652,880
Accumulated other comprehensive loss, net of taxes (208) (345)
Accumulated deficit (347,560) (314,917)
Total shareholders’ equity 325,461 337,663
Total liabilities and shareholders’ equity $ 381,652 $ 412,714
v3.24.3
Unaudited Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Allowance for doubtful accounts $ 955 $ 1,707
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, authorized (in shares) 1,000,000 1,000,000
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, authorized (in shares) 150,000,000 150,000,000
Common stock, issued (in shares) 46,227,940 45,167,225
Common stock, outstanding (in shares) 46,227,940 45,167,225
Series A Preferred Stock    
Preferred stock, designated (in shares) 4,250 4,250
Preferred stock, issued (in shares) 0 0
Preferred stock, outstanding (in shares) 0 0
v3.24.3
Unaudited Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Total product, rental, and service revenue $ 30,571 $ 23,573 $ 85,678 $ 81,992
Costs and operating expenses:        
General and administrative 11,351 10,813 33,953 37,568
Sales and marketing 3,543 4,876 10,401 12,731
Research and development 2,050 3,739 6,827 10,772
Asset impairment charges 0 8,310 0 8,310
Intangible asset amortization 910 1,312 2,734 4,135
Change in fair value of contingent consideration 0 (1,580) 0 (1,778)
Total operating expenses 32,130 39,048 94,193 116,727
Operating loss (1,559) (15,475) (8,515) (34,735)
Other (expense) income:        
Change in fair value of equity investments 0 0 (4,074) 0
Gain on settlement of Global Cooling escrow 0 0 0 5,115
Interest expense, net (267) (449) (796) (1,216)
Other income 95 235 417 1,002
Total other (expense) income, net (172) (214) (4,453) 4,901
Loss before income tax benefit (expense) (1,731) (15,689) (12,968) (29,834)
Income tax benefit (expense) 28 (115) (93) (209)
Net loss from continuing operations (1,703) (15,804) (13,061) (30,043)
Discontinued operations:        
Loss from discontinued operations 0 (13,328) (19,572) (22,999)
Income tax expense 0 0 (10) (3)
Loss from discontinued operations 0 (13,328) (19,582) (23,002)
Net loss (1,703) (29,132) (32,643) (53,045)
Loss from continuing operations, attributable to common shareholders:        
Basic (1,703) (15,804) (13,061) (30,043)
Diluted (1,703) (15,804) (13,061) (30,043)
Loss from discontinued operations, attributable to common shareholders:        
Basic 0 (13,328) (19,582) (23,002)
Diluted $ 0 $ (13,328) $ (19,582) $ (23,002)
Loss per share from continuing operations, attributable to common shareholders:        
Basic (in dollars per share) $ (0.04) $ (0.36) $ (0.28) $ (0.69)
Diluted (in dollars per share) (0.04) (0.36) (0.28) (0.69)
Loss per share from discontinued operations, attributable to common shareholders:        
Basic (in dollars per share) 0 (0.31) (0.43) (0.53)
Diluted (in dollars per share) $ 0 $ (0.31) $ (0.43) $ (0.53)
Net loss attributable to common shareholders:        
Basic $ (1,703) $ (29,132) $ (32,643) $ (53,045)
Diluted $ (1,703) $ (29,132) $ (32,643) $ (53,045)
Net loss per share attributable to common shareholders:        
Basic (in dollars per share) $ (0.04) $ (0.67) $ (0.71) $ (1.22)
Diluted (in dollars per share) $ (0.04) $ (0.67) $ (0.71) $ (1.22)
Weighted average shares used to compute loss per share attributable to common shareholders:        
Basic (in shares) 46,175,345 43,570,438 45,871,715 43,348,412
Diluted (in shares) 46,175,345 43,570,438 45,871,715 43,348,412
Product revenue        
Total product, rental, and service revenue $ 23,457 $ 17,137 $ 64,624 $ 63,444
Costs and operating expenses:        
Cost of goods and services sold (exclusive of intangible assets amortization) 8,765 6,572 25,163 29,223
Service revenue        
Total product, rental, and service revenue 4,660 4,377 14,173 12,573
Costs and operating expenses:        
Cost of goods and services sold (exclusive of intangible assets amortization) 3,401 3,937 10,247 11,624
Rental revenue        
Total product, rental, and service revenue 2,454 2,059 6,881 5,975
Costs and operating expenses:        
Cost of goods and services sold (exclusive of intangible assets amortization) $ 2,110 $ 1,069 $ 4,868 $ 4,142
v3.24.3
Unaudited Condensed Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Statement of Comprehensive Income [Abstract]        
Net loss $ (1,703) $ (29,132) $ (32,643) $ (53,045)
Other comprehensive income (loss):        
Foreign currency translation adjustment, net of tax 282 (165) 91 (25)
Unrealized gain on available-for-sale securities, net of tax 65 4 46 44
Comprehensive loss $ (1,356) $ (29,293) $ (32,506) $ (53,026)
v3.24.3
Unaudited Condensed Consolidated Statements of Shareholders' Equity - USD ($)
$ in Thousands
Total
Series A Preferred Stock
Preferred Stock
Series A Preferred Stock
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income
Accumulated Deficit
Beginning balance, preferred stock, outstanding (in shares) at Dec. 31, 2022     0        
Beginning balance at Dec. 31, 2022 $ 364,188   $ 0 $ 43 $ 611,739 $ (679) $ (246,915)
Beginning balance, common stock, outstanding (in shares) at Dec. 31, 2022       42,832,231      
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Stock-based compensation 23,337       23,337    
Stock option exercises (in shares)       175,043      
Stock option exercises 369       369    
Stock issued - on vested RSAs (in shares)       923,128      
Stock issued – on vested RSAs 1     $ 1      
Contingent consideration shares issued (in shares)       116,973      
Contingent consideration shares issued 2,263       2,263    
Settlement of Global Cooling escrow (in shares)       (216,024)      
Settlement of Global Cooling escrow (5,115)       (5,115)    
Foreign currency translation (25)         (25)  
Unrealized gain (loss) on available-for-sale securities 44         44  
Net loss (53,045)           (53,045)
Ending balance, preferred stock, outstanding (in shares) at Sep. 30, 2023     0        
Ending balance at Sep. 30, 2023 332,017   $ 0 $ 44 632,593 (660) (299,960)
Ending balance, common stock, outstanding (in shares) at Sep. 30, 2023       43,831,351      
Beginning balance, preferred stock, outstanding (in shares) at Jun. 30, 2023     0        
Beginning balance at Jun. 30, 2023 352,128   $ 0 $ 43 623,412 (499) (270,828)
Beginning balance, common stock, outstanding (in shares) at Jun. 30, 2023       43,442,250      
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Stock-based compensation 9,117       9,117    
Stock option exercises (in shares)       31,000      
Stock option exercises 64       64    
Stock issued - on vested RSAs (in shares)       358,101      
Stock issued – on vested RSAs 1     $ 1      
Foreign currency translation (165)         (165)  
Unrealized gain (loss) on available-for-sale securities 4         4  
Net loss (29,132)           (29,132)
Ending balance, preferred stock, outstanding (in shares) at Sep. 30, 2023     0        
Ending balance at Sep. 30, 2023 332,017   $ 0 $ 44 632,593 (660) (299,960)
Ending balance, common stock, outstanding (in shares) at Sep. 30, 2023       43,831,351      
Beginning balance, preferred stock, outstanding (in shares) at Dec. 31, 2023   0 0        
Beginning balance at Dec. 31, 2023 $ 337,663   $ 0 $ 45 652,880 (345) (314,917)
Beginning balance, common stock, outstanding (in shares) at Dec. 31, 2023 45,167,225     45,167,225      
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Stock-based compensation $ 20,231       20,231    
Stock option exercises (in shares) 58,750     58,750      
Stock option exercises $ 137       137    
Stock issued – on vested RSUs (in shares)       1,001,965      
Stock issued – on vested RSUs 1     $ 1      
Common stock shares issued (65)       (65)    
Foreign currency translation 91         91  
Unrealized gain (loss) on available-for-sale securities 46         46  
Net loss (32,643)           (32,643)
Ending balance, preferred stock, outstanding (in shares) at Sep. 30, 2024   0 0        
Ending balance at Sep. 30, 2024 $ 325,461   $ 0 $ 46 673,183 (208) (347,560)
Ending balance, common stock, outstanding (in shares) at Sep. 30, 2024 46,227,940     46,227,940      
Beginning balance, preferred stock, outstanding (in shares) at Jun. 30, 2024     0        
Beginning balance at Jun. 30, 2024 $ 321,442   $ 0 $ 46 667,808 (555) (345,857)
Beginning balance, common stock, outstanding (in shares) at Jun. 30, 2024       46,104,888      
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Stock-based compensation 5,329       5,329    
Stock option exercises (in shares)       22,500      
Stock option exercises 46       46    
Stock issued – on vested RSUs (in shares)       100,552      
Foreign currency translation 282         282  
Unrealized gain (loss) on available-for-sale securities 65         65  
Net loss (1,703)           (1,703)
Ending balance, preferred stock, outstanding (in shares) at Sep. 30, 2024   0 0        
Ending balance at Sep. 30, 2024 $ 325,461   $ 0 $ 46 $ 673,183 $ (208) $ (347,560)
Ending balance, common stock, outstanding (in shares) at Sep. 30, 2024 46,227,940     46,227,940      
v3.24.3
Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Cash flows from operating activities    
Net loss $ (32,643) $ (53,045)
Adjustments to reconcile net loss to net cash used in operating activities    
Impairment of intangible assets 0 5,758
Impairment of long-lived assets 0 9,727
Settlement of Global Cooling escrow 0 (5,115)
Depreciation 4,223 5,646
Amortization of intangible assets 2,734 4,266
Amortization of loan costs 0 13
Stock-based compensation 20,231 23,337
Non-cash lease expense 265 494
Deferred income tax (benefit) expense (88) 36
Change in fair value of contingent consideration 0 (1,778)
Change in fair value of equity investments 4,074 0
Accretion of available-for-sale investments (407) (1,049)
(Gain) loss on disposal of property and equipment, net (62) 227
Loss on disposal of assets held for rent, net 458 443
Loss on disposal of Global Cooling 8,897 0
Change in operating assets and liabilities, net of effects of acquisitions    
Accounts receivable, trade, net (1,666) 9,437
Inventories 2,124 (8,450)
Prepaid expenses and other assets 1,514 (1,045)
Accounts payable (1,139) (3,380)
Accrued expenses and other current liabilities (96) (1,692)
Warranty liability (478) (97)
Sales taxes payable (889) 1,330
Other (266) 128
Net cash provided by (used in) operating activities 6,786 (14,809)
Cash flows from investing activities    
Purchases of available-for-sale securities (16,014) (22,688)
Proceeds from sale of available-for-sale securities 2,609 2,971
Maturities of available-for-sale securities 15,600 42,450
Purchases of assets held for rent (2,028) (3,453)
Purchases of property and equipment (2,465) (5,400)
Payments on divestiture of Global Cooling (13,039) 0
Net cash (used in) provided by investing activities (15,337) 13,880
Cash flows from financing activities    
Payments on equipment loans (682) (383)
Proceeds from exercises of common stock options 137 370
Payments on term loans (2,500) (300)
Proceeds from financed insurance premium 2,094 2,639
Payments on financed insurance premium (1,730) (1,653)
Other (16) 77
Net cash (used in) provided by financing activities (2,697) 750
Net decrease in cash, cash equivalents, and restricted cash (11,248) (179)
Cash, cash equivalents, and restricted cash – beginning of period 35,438 19,473
Effects of currency translation on cash, cash equivalents, and restricted cash (29) (28)
Cash, cash equivalents, and restricted cash – end of period 24,161 19,266
Non-cash investing and financing activities    
Purchase of property and equipment not yet paid 97 4,064
Assets acquired under operating leases 5,302 880
Assets acquired under financing leases 0 1,682
Unrealized (losses) gains on currency translation 3 (11)
Unrealized gains on available-for-sale securities (46) (44)
Cashless issuance of SciSafe earnout shares 0 2,263
Cash interest paid 1,236 1,394
Returned shares from settlement of Global Cooling escrow $ 0 $ (5,115)
v3.24.3
Organization and significant accounting policies
9 Months Ended
Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and significant accounting policies Organization and significant accounting policies
Business
BioLife Solutions, Inc. (“BioLife”, “us”, “we”, “our”, or the “Company”) is a developer, manufacturer, and supplier of a portfolio of bioproduction tools and services including proprietary biopreservation media, automated thawing devices, cloud-connected shipping containers, and biological and pharmaceutical materials storage. Our CryoStor® freeze media and HypoThermosol® hypothermic storage media are optimized to preserve cells in the regenerative medicine market. These novel biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. Our Sexton cell processing product line includes human platelet lysates (“hPL”) for cell expansion, reducing risk and improving downstream performance over fetal bovine serum, human serum, and other chemically defined media, CellSeal® cryogenic vials that are purpose-built rigid containers used in cell and gene therapy (“CGT”) that can be filled manually or with high throughput systems, CryoCase™ cryo-compatible transparent rigid containers designed for closed-system fill and retrieval, and automated cell processing machines that bring multiple processes traditionally performed by manual techniques under a higher level of control to protect therapies from loss or contamination. Our ThawSTAR® product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. These products help administer temperature-sensitive biologic therapies to patients by standardizing the thawing process and reducing the risks of contamination and overheating, which are inherent with the use of traditional water baths. Our evo® shipping containers provide cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. Our biological and pharmaceutical materials storage services provide facilities that allow for real-time tracking of biologic materials and vaccines that can be stored at a wide range of temperatures.
On April 17, 2024, the Company sold all of the issued and outstanding shares of common stock of Global Cooling, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Global Cooling”), to GCI Holdings Company, LLC, an Ohio limited liability company (“GCI Holdings”) pursuant to a Stock Purchase Agreement (the “Purchase Agreement”), by and between the Company and GCI Holdings (the “Global Cooling Divestiture”). Upon the execution of the Purchase Agreement, on April 17, 2024, the Global Cooling business is presented in the accompanying unaudited condensed financial statements as a discontinued operation for all periods presented. See Note 3: Discontinued operations for further details regarding the divestiture.
On November 12, 2024, the Company entered into a Stock Purchase Agreement (the “Purchase Agreement”), by and among the Company, Subzero Purchaser Corp., a Delaware corporation (“Buyer”), SciSafe, Inc., a Delaware corporation and an indirect, wholly owned subsidiary of the Company (“Seller”), and SciSafe, Inc., a New Jersey corporation and an indirect wholly owned subsidiary of the Company (“SciSafe”), for the sale by Seller of all of the issued and outstanding shares of common stock (the “Shares”) of SciSafe to Buyer. The divestiture of SciSafe was considered a subsequent event to the financial results presented as of September 30, 2024. SciSafe is therefore presented as a part of our continuing operations as of the three and nine months ended September 30, 2024. For additional information on the divestiture of SciSafe, see Note 19: Subsequent events.
Use of estimates
The preparation of financial statements in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Significant estimates and assumptions by management affect the Company’s net realizable value of inventory, sales tax liabilities, valuation of market-based stock awards, valuations, fair value of marketable debt securities, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, estimated fair values of intangible assets and goodwill, amortization methods and periods, warranty reserves, certain accrued expenses, stock-based compensation, contingent consideration from business combinations, and provision for income taxes.
The Company regularly assesses these estimates; however, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.
Basis of presentation

The Unaudited Condensed Consolidated Financial Statements and related footnote disclosures as of and for the three and nine months ended September 30, 2024 are unaudited, and are not necessarily indicative of the Company’s operating results for a full year. The Unaudited Condensed Consolidated Financial Statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial results for the three and nine months ended September 30, 2024 in accordance with U.S. GAAP, however, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the U.S. Securities and Exchange Commission (the “SEC”) rules and regulations relating to interim financial statements. These Unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Audited Consolidated Financial Statements and accompanying notes thereto included in the Company’s Annual Report on Form 10-K as of and for the fiscal year ended December 31, 2023, filed with the SEC on February 29, 2024 (the “Annual Report”).
The Unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries, SAVSU Technologies, Inc. (“SAVSU”), Arctic Solutions, Inc. doing business as Custom Biogenic Systems (“CBS”), SciSafe Holdings, Inc. (“SciSafe”), BioLife Solutions B.V, and Sexton Biotechnologies, Inc. (“Sexton”). All intercompany accounts and transactions have been eliminated in consolidation.
Discontinued operations
On April 17, 2024, the Company sold all of the issued and outstanding shares of common stock of Global Cooling and the accounting requirements for reporting the Global Cooling subsidiary as a discontinued operation were met. Unless otherwise noted, amounts and disclosures throughout these Notes to Unaudited Condensed Consolidated Financial Statements relate to the Company's continuing operations. Refer to Note 3: Discontinued operations for further details.
In the opinion of management, the accompanying Unaudited Condensed Consolidated Financial Statements include all adjustments, consisting of only normal, recurring adjustments necessary for a fair presentation of the financial position, results of operations, and cash flows. The results of operations for the interim periods presented are not necessarily indicative of results to be expected for the entire year.
Foreign currency translation
The Company translates items presented on its Unaudited Condensed Consolidated Financial Statements into U.S. dollars. For the Company’s subsidiaries that operate in a local currency functional environment, all assets and liabilities are translated into U.S. dollars using current exchange rates at the balance sheet date; revenue and expenses are translated using average exchange rates in effect during each period. Resulting translation adjustments are reported as a separate component of Accumulated Other Comprehensive Loss in the Unaudited Condensed Consolidated Statements of Shareholders' Equity.
Segment reporting
The Company views its operations and makes decisions regarding how to allocate resources and manages its business as one reportable segment and one reporting unit. The Company’s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.
Significant accounting policies
The following describes an update to the Company’s accounting policies for discontinued operations during the three and nine months ended September 30, 2024. For a full discussion of significant accounting policies, refer to the Notes to the Consolidated Financial Statements described in Part II, Item 8 of our Annual Report.
In accordance with ASC 205-20: Presentation of Financial Statements: Discontinued Operations, a disposal of a component of an entity or a group of components of an entity is required to be reported as discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results. In
the period in which the component meets held-for-sale or discontinued operations criteria, the major current assets, non-current assets, current liabilities, and non-current liabilities shall be reported as components of total assets and liabilities separate from those balances of the continuing operations.
Our operations related to Global Cooling met the definition of a discontinued operation as of April 17, 2024. Accordingly, we retrospectively classified the results of our Global Cooling operations as discontinued operations in the Unaudited Condensed Consolidated Statements of Operations for all periods presented. The results of all discontinued operations, less applicable income taxes, are reported as components of net loss separate from the net loss of continuing operations. Certain assets and liabilities associated with our Global Cooling operations were classified as assets and liabilities of discontinued operations in the Unaudited Condensed Consolidated Balance Sheets for the periods presented. Additionally, the cash flows and comprehensive loss of our Global Cooling operations have not been segregated and are included in the interim Unaudited Condensed Consolidated Statements of Cash Flows and Unaudited Condensed Consolidated Statements of Comprehensive Loss, respectively, for all periods presented. All amounts included in the notes to the unaudited condensed consolidated financial statements relate to continuing operations unless otherwise noted. For additional information, see Note 3: Discontinued operations.
Liquidity and capital resources

On September 30, 2024 and December 31, 2023, we had $39.3 million and $50.2 million in cash, cash equivalents, and available-for-sale securities, respectively, in our continuing operations. Based on our current expectations with respect to our future revenue and expenses, we believe that our current level of cash, cash equivalents, and other liquid assets will be sufficient to meet our liquidity needs for at least the next twelve months from the date of the filing of this Quarterly Report on Form 10-Q (this “Form 10-Q”).
Risks and uncertainties
The preparation of financial statements requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities at the reporting date and revenues and expenses during the reporting periods. These estimates represent management's judgment about the outcome of future events. The global business environment continues to be impacted by cost pressure, the overall effects of economic uncertainty on customers' purchasing patterns, high interest rates, and other factors. It is not possible to accurately predict the future impact of such events and circumstances. Actual results could differ from our estimates.
For additional information, see caption “Risk Factors” identified in Part I, Item 1A of our Annual Report and in Part II, Item 1A of this Form 10-Q.
Concentrations of credit risk and business risk
Significant customers are those that represent more than 10% of the Company’s total revenue or gross accounts receivable balances for the periods and as of each balance sheet date presented. For each significant customer, revenue as a percentage of total revenue and gross accounts receivable as a percentage of total gross accounts receivable as of the periods presented were as follows:
Accounts ReceivableRevenue
September 30,December 31,Three Months Ended
September 30,
Nine Months Ended
September 30,
202420232024202320242023
Customer A16 %17 %****
Customer B****11 %11 %
Customer C**11 %***
*less than 10%
Revenue from foreign customers is denominated in United States dollars or euros.
The following table represents the Company’s products representing more than 10% of the Company’s total revenue:
Three Months Ended
September 30,
Nine Months Ended
September 30,
Product revenue concentration2024202320242023
CryoStor52 %46 %51 %53 %
The following table represents the Company’s total revenue by geographic area (based on the location of the customer):
Three Months Ended
September 30,
Nine Months Ended
September 30,
Revenue by customers geographic locations(1)
2024202320242023
United States(2)
76 %81 %77 %82 %
Europe, Middle East, Africa (EMEA)19 %15 %18 %14 %
Other%%%%
Total revenue100 %100 %100 %100 %
(1) As of the year ended December 31, 2023, the Company updated its methodology for determining the country of origin for its sales. Sales are now recorded by shipping country rather than billing country. The Company updated the methodology retrospectively, adjusting the prior year presentation for all regions presented.
(2) The line item presented above previously bifurcated sales between the United States and Canada. Due to the updated methodology for determining the country of origin for sales, it was noted that Canada no longer was a material location to separately disclose. Canada sales have been included within the "Other" line item in the table above and United States sales have been retained as a single line item to more accurately reflect origin of sales for material regions.
In the three and nine months ended September 30, 2024, no suppliers accounted for greater than 10% of purchases. In the three and nine months ended September 30, 2023, one supplier accounted for 19% and 16% of purchases, respectively.
As of September 30, 2024, one supplier accounted for 11% of our accounts payable. As of December 31, 2023, one supplier accounted for 11% of our accounts payable.
Recent accounting pronouncements
In March 2024, the SEC adopted final rules on the enhancement and standardization of climate-related disclosures of public companies. The final rules require disclosure of, among other things, material climate-related risks and their impact; activities to mitigate or adapt to material climate-related risks; governance and oversight of climate-related risks; and material Scope 1 and/or Scope 2 greenhouse gas emissions with an accompanying assurance report required following an initial transition period, at a limited assurance level, and then following an additional transition period, at a reasonable assurance level. In addition, the effects of severe weather events and other natural conditions, subject to certain thresholds, and amounts related to carbon offsets and renewable energy credits or certificates are required to be disclosed in the notes to the audited financial statements in certain circumstances.
On April 4, 2024, the SEC voluntarily stayed the implementation of the final rules pending the completion of judicial review of the consolidated challenges to the final rules by the Court of Appeals for the Eighth Circuit. The final rules, as originally issued, would be effective for the Company in various fiscal years, starting with its Annual Report on Form 10-K for fiscal year 2025. Disclosures pursuant to the final rules, as originally issued, would be required prospectively, with information for prior periods required only to the extent it was previously disclosed in an SEC filing. The Company is currently evaluating the impact of the final rules on its Consolidated Financial Statements and disclosures.
v3.24.3
Correction of immaterial errors
9 Months Ended
Sep. 30, 2024
Accounting Changes and Error Corrections [Abstract]  
Correction of immaterial errors Correction of immaterial errors
During the three months ended March 31, 2024, we determined that an error existed in our previously issued consolidated financial statements. Specifically, we identified we had not properly accelerated stock compensation expense related to unvested shares of market-based awards of certain employees upon their termination during the fourth quarter of 2023. The error was evaluated under the U.S. Securities and Exchange Commission's ("SEC's") Staff Accounting Bulletin ("SAB")
Topic 1M, "Materiality," and SEC SAB Topic 1N, "Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in the Current Year Financial Statements" to determine the materiality of prior period misstatements to the Company’s financial statements. We evaluated the error and concluded that it was not material to the previously issued consolidated financial statements. Although the error was not material to any period, we corrected the accompanying historical consolidated financial statements for the year ended December 31, 2023 to reflect the additional stock compensation expense incurred within each period for comparative purposes.
The following table represents the adjustments to our Consolidated Balance Sheet as of December 31, 2023 in accordance with ASC 250. The adjustments to our Consolidated Statement of Shareholders’ Equity was limited to the adjustments outlined below.
The effect of the adjustments to our Consolidated Balance Sheet as of December 31, 2023 was as follows (in thousands):
December 31, 2023
(In thousands)As reportedAdjustmentAs corrected
Additional paid-in-capital$651,305 $1,575 $652,880 
Accumulated deficit(313,342)(1,575)(314,917)
v3.24.3
Discontinued operations
9 Months Ended
Sep. 30, 2024
Discontinued Operations and Disposal Groups [Abstract]  
Discontinued operations Discontinued operations
On April 17, 2024, the Company entered into the Purchase Agreement by and between the Company and GCI Holdings, which is wholly owned by a former consulting contractor of Global Cooling, for the sale of all of the issued and outstanding shares of common stock of Global Cooling to GCI Holdings. Upon the execution of the Purchase Agreement, the Global Cooling business is presented in the accompanying condensed financial statements as a discontinued operation for all periods presented.
As a condition of the Purchase Agreement, Global Cooling was required to have $7.0 million in cash on its balance sheet, of which, $6.7 million in cash was funded by the Company, and the Company was required to repay approximately $2.6 million of outstanding indebtedness of Global Cooling, and assume certain other liabilities of Global Cooling of $2.6 million. Following the execution of the Purchase Agreement, the divestiture of Global Cooling was consummated on April 17, 2024. The Company recognized a loss on disposal of Global Cooling, calculated as follows:
(In thousands)
Selling price: $1
$— 
Cash to Global Cooling funded by Company(6,652)
Costs to sell Global Cooling(1)
(582)
Negative selling price(7,234)
Global Cooling carrying basis as of April 17, 2024, inclusive of assumed liabilities(3,589)
Assumed liabilities: Accounts payable(2)
2,643 
Assumed liabilities: Debt(3)
2,596 
Global Cooling carrying basis as of April 17, 20241,650 
Release of Global Cooling currency translation adjustment(13)
Net loss on disposal$(8,897)
(1) Represents the costs incurred in connection with the divestiture of Global Cooling, including fees to be paid to the broker, attorneys, and other external parties.
(2) As a closing condition, the Company assumed certain accounts payable and accrued expenses from Global Cooling, totaling $0.5 million and $2.1 million, respectively.
(3) As a closing condition, the Company repaid the balance of the Global Cooling Amended Term Notes. For additional information on the terms of the Global Cooling Term Notes, see Note 13: Long-term debt.
In connection with the Company’s entry into the Purchase Agreement, the Company implemented a reduction in force (the “RIF”) related to the business of Global Cooling, which reduced the Company’s workforce by 47 employees (representing
approximately 11% of its full-time employees). The Company’s Board of Directors approved the RIF on March 29, 2024, and all affected employees were informed by April 18, 2024, following the execution of the Purchase Agreement. Additionally, the Company accelerated the unvested shares granted to both the employees impacted by the RIF and Global Cooling employees that remained with Global Cooling upon the closing of the GCI Divestiture. The Company recognized the following charges in connection with the RIF and stock compensation expense acceleration:
(In thousands)SeveranceStock CompensationTotal
RIF employee costs$291 $1,255 $1,546 
Former Global Cooling employees— 1,925 1,925 
Total employment related divestiture expenditures$291 $3,180 $3,471 

In addition, upon the closing of the Transaction, the Company and Global Cooling entered into a transition services agreement ("TSA"), pursuant to which the Company agreed to provide certain transition services to Global Cooling for up to 90 days following the date of the closing of the Transaction. The TSA has since expired pursuant to its terms on the stated expiration date.

The following table summarizes the major classes of assets and liabilities of discontinued operations, which are summarized separately in the condensed consolidated balance sheets:
April 17,December 31,
(In thousands)20242023
Cash and cash equivalents$275 $2,090 
Accounts receivable, net2,430 1,728 
Inventories9,152 11,248 
Prepaid expenses and other current assets379 303 
Total current assets, discontinued operations12,236 15,369 
Property and equipment, net153 146 
Long-term deposits and other assets
Total assets, discontinued operations12,393 15,519 
Accounts payable1,425 3,367 
Accrued expenses and other current liabilities911 1,637 
Warranty liability7,193 7,507 
Lease liabilities, operating, current portion242 263 
Lease liabilities, financing, current portion16 22 
Total current liabilities, discontinued operations9,787 12,796 
Lease liabilities, operating, long-term948 1,016 
Lease liabilities, financing, long-term11 
Total liabilities, discontinued operations$10,743 $13,823 
Global Cooling had no remaining balances as of September 30, 2024.
The key components of loss from discontinued operations were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)2024202320242023
Revenue$— $9,755 $7,157 $28,546 
Cost of revenue— 10,100 8,389 28,048 
Gross profit— (345)(1,232)498 
Operating expenses— (5,789)(9,418)(16,259)
Asset impairment charges— (7,175)— (7,175)
Other income (expense), net— (19)(25)(63)
Loss on disposal— — (8,897)— 
Loss before income taxes— (13,328)(19,572)(22,999)
Income tax expense— — (10)(3)
Loss from discontinued operations, net of income taxes$— $(13,328)$(19,582)$(23,002)
During the three and nine months ended September 30, 2024, Global Cooling did not incur material depreciation, amortization, capital expenditure, or other noncash related costs. For the three months ended September 30, 2023, Global Cooling incurred depreciation and capital expenditure costs of $0.1 million and $0.2 million, respectively. During the nine months ended September 30, 2023, Global Cooling incurred depreciation, amortization, and capital expenditure costs of $0.4 million, $0.1 million, and $0.7 million, respectively.
We do not anticipate incurring any material additional charges in connection with the sale of Global Cooling.
v3.24.3
Fair value measurement
9 Months Ended
Sep. 30, 2024
Fair Value Disclosures [Abstract]  
Fair value measurement Fair value measurement
In accordance with FASB ASC Topic 820, Fair Value Measurements and Disclosures, (“ASC Topic 820”), the Company measures its financial instruments at fair value on a recurring basis. The carrying values of certain of our financial instruments including cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate fair value because of their short maturities. The carrying value of our marketable debt securities, which are accounted for as available-for-sale, are classified within either Level 1 or Level 2 in the fair value hierarchy because we use quoted market prices or alternative pricing sources and models utilizing market observable inputs to determine their fair value. The carrying values of our long-term debt, which is classified within Level 2 in the fair value hierarchy, approximates fair value as our borrowings with lenders are at interest rates that approximate market rates for comparable loans. The fair values of investments and contingent consideration classified as Level 3 were derived from management assumptions. The Company also measures certain assets and liabilities at fair value on a non-recurring basis when applying acquisition accounting. ASC Topic 820 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, ASC Topic 820 establishes a three-tier value fair hierarchy, which prioritizes the inputs used in measuring fair value as follows:
Level 1 – Observable inputs that reflect quoted prices (unadjusted) in active markets for identical assets or liabilities.
Level 2 – Observable inputs other than quoted prices included in Level 1 for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.
Level 3 – Unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability.
The fair value of the SciSafe contingent consideration liability was valued based on unobservable inputs using a Monte Carlo simulation. These inputs included the estimated amount and timing of projected future revenue, a discount rate of 4.5%, a risk-free rate of approximately 0.2%, asset volatility of 60%, and revenue volatility of 15%. Significant changes in any of those inputs in isolation would result in a significant change in the fair value measurement of the liability. Generally, changes used in the assumptions for projected future revenue and revenue volatility would be accompanied by a directionally similar change in the fair value measurement. Conversely, changes in the discount rate would be accompanied by a directionally opposite change in the related fair value measurement. However, due to the contingent consideration having a maximum payout amount, changes in these assumptions would not affect the fair value of the contingent consideration if they increase (decrease) beyond certain amounts. At the acquisition date, the contingent consideration was determined to have a fair value of $3.7 million. Subsequent to the acquisition date, the SciSafe contingent consideration liability was re-measured to fair value with changes recorded in the Change in fair value of contingent consideration in the Unaudited Condensed Consolidated Statements of Operations.
During the most recent re-measurement of the contingent consideration liability as of December 31, 2023, the Company determined it appropriate to write-off the remaining balance of the SciSafe contingent consideration liability. The target revenue required for earnout was not met during the year ended December 31, 2023 and had been determined to not be probable to achieve in future years. The change in fair value of contingent consideration of $1.6 million and $1.8 million associated with the contingent consideration liability was included within the Change in fair value of contingent consideration in the Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2023, respectively.
There were no remeasurements to fair value during the three and nine months ended September 30, 2024 of financial assets and liabilities that are not measured at fair value on a recurring basis.
The following tables set forth the Company’s financial assets and liabilities measured at fair value on a recurring basis as of September 30, 2024 and December 31, 2023, based on the three-tier fair value hierarchy:
(In thousands)
As of September 30, 2024Level 1Level 2Level 3Total
Assets:
Cash equivalents:
Money market accounts$13,731 $$$13,731 
Available-for-sale securities:    
U.S. government securities2,679 2,679 
Corporate debt securities395 8,735 9,130 
Other debt securities3,286 3,286 
Total$16,805 $12,021 $$28,826 
As of December 31, 2023
Assets:
Cash equivalents:
Money market accounts$25,034 $$$25,034 
Available-for-sale securities:
U.S. government securities5,170 5,170 
Corporate debt securities9,674 9,674 
Other debt securities1,992 1,992 
Total$30,204 $11,666 $$41,870 
There have been no transfers of assets or liabilities between the fair value measurement levels.
The following table presents the changes in fair value of contingent consideration liabilities that are measured using Level 3 inputs for the three and nine months ended September 30, 2023. There was no contingent consideration liability outstanding as of September 30, 2024.
Nine Months Ended September 30,
(In thousands)2023
Balance at beginning of period$4,456 
Change in fair value recognized in net loss(1,778)
Payment of contingent consideration earned$(2,263)
Balance at end of period$415 
v3.24.3
Investments
9 Months Ended
Sep. 30, 2024
Investments, Debt and Equity Securities [Abstract]  
Investments Investments
Available-for-sale securities
The Company’s portfolio of available-for-sale marketable securities consists of the following:
September 30, 2024
Amortized
Cost
Gross unrealizedEstimated
Fair Value
(In thousands)GainsLosses
Available-for-sale securities, current portion    
U.S. government securities$2,676 $$$2,679 
Corporate debt securities6,149 16 6,165 
Other debt securities1,363 1,367 
Total short-term10,188 23 10,211 
     
Available-for-sale securities, long-term    
Corporate debt securities2,944 21 2,965 
Other debt securities1,910 1,919 
Total marketable securities$15,042 $53 $$15,095 
December 31, 2023
Amortized
Cost
Gross unrealizedEstimated
Fair Value
(In thousands)GainsLosses
Available-for-sale securities, current portion
U.S. government securities$5,169 $$$5,170 
Corporate debt securities9,673 (4)9,674 
Other debt securities1,443 1,444 
Total short-term16,285 (4)16,288 
Available-for-sale securities, long-term
Other debt securities545 548 
Total marketable securities$16,830 $10 $(4)$16,836 
September 30, 2024
(In thousands)Amortized
Cost
Estimated
Fair Value
Due in one year or less$10,188 $10,211 
Due after one year through five years4,854 4,884 
Total$15,042 $15,095 
Equity investments
The Company periodically invests in non-marketable equity securities of private companies without a readily determinable fair value to promote business and strategic objectives. The Company has adopted the measurement alternative whereby equity securities are carried at cost minus impairment, if any, plus or minus changes resulting from observable process changes in orderly transactions for identical or similar transactions of the same issuer. These securities included Series E Preferred Stock in PanTHERA CryoSolutions, Inc. carried at $1.0 million as of September 30, 2024 and December 31, 2023.
The Company also owns securities of Series A-1 and A-2 Preferred Stock in iVexSol, Inc. carried at $4.1 million for the period ending December 31, 2023. During the six months ended June 30, 2024, the Company received communications that triggered a going concern for the investment. As of June 30, 2024, the Company determined that the fair value of its equity interest was less than its carrying amount, and no longer recoverable, triggering an impairment charge of $4.1 million. The carrying value was zero as of September 30, 2024.
v3.24.3
Inventories
9 Months Ended
Sep. 30, 2024
Inventory Disclosure [Abstract]  
Inventories Inventories
Inventories consist of the following as of September 30, 2024 and December 31, 2023:
September 30,December 31,
(In thousands)20242023
Raw materials$12,722 $16,932 
Work in progress6,647 5,890 
Finished goods12,810 9,386 
Total inventories$32,179 $32,208 
v3.24.3
Leases
9 Months Ended
Sep. 30, 2024
Leases [Abstract]  
Leases Leases
The Company has various operating lease agreements for office space, warehouses, manufacturing, and production locations as well as vehicles and other equipment. Our real estate leases had original lease terms of three to eleven years and have remaining lease terms of one to eight years. We exclude options that are not reasonably certain to be exercised from our lease terms, ranging from one to five years. Our lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms, with all other lease payments consisting of variable lease costs. For certain leases, we receive incentives from our landlords, such as rent abatements, which effectively reduce the total lease payments owed for these leases. Vehicle and other equipment operating leases had original lease terms of four to five years and have remaining terms between one and five years.
Our financing leases relate to research equipment, machinery, and other equipment.
The table below presents certain information related to the weighted average discount rate and weighted average remaining lease term for the Company’s leases as of September 30, 2024 and December 31, 2023:
September 30,December 31,
(In thousands)20242023
Weighted average discount rate - operating leases5.8 %4.4 %
Weighted average discount rate - finance leases8.4 %8.3 %
Weighted average remaining lease term in years - operating leases6.16.6
Weighted average remaining lease term in years - finance leases3.54.1
The components of lease expense for the three and nine months ended September 30, 2024 and 2023 were as follows:
Three Months Ended
September 30,
Nine Months Ended
September 30,
(In thousands)2024202320242023
Operating lease costs$1,018 $810 $2,639 $2,460 
Financing lease costs57 173 
Short-term lease costs452 510 1,263 1,266 
Total operating lease costs1,527 1,320 4,075 3,726 
   
Variable lease costs446 299 1,166 903 
Total lease costs$1,973 $1,619 5,241 4,629 
Maturities of our lease liabilities as of September 30, 2024 are as follows:
(In thousands)Operating
Leases
Financing
Leases
2024 (3 months remaining)$857 $103 
20253,630 413 
20263,249 389 
20272,970 387 
20283,021 134 
Thereafter7,794 
Total lease payments21,521 1,426 
Less: interest(3,544)(190)
Total present value of lease liabilities$17,977 $1,236 
Leases Leases
The Company has various operating lease agreements for office space, warehouses, manufacturing, and production locations as well as vehicles and other equipment. Our real estate leases had original lease terms of three to eleven years and have remaining lease terms of one to eight years. We exclude options that are not reasonably certain to be exercised from our lease terms, ranging from one to five years. Our lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms, with all other lease payments consisting of variable lease costs. For certain leases, we receive incentives from our landlords, such as rent abatements, which effectively reduce the total lease payments owed for these leases. Vehicle and other equipment operating leases had original lease terms of four to five years and have remaining terms between one and five years.
Our financing leases relate to research equipment, machinery, and other equipment.
The table below presents certain information related to the weighted average discount rate and weighted average remaining lease term for the Company’s leases as of September 30, 2024 and December 31, 2023:
September 30,December 31,
(In thousands)20242023
Weighted average discount rate - operating leases5.8 %4.4 %
Weighted average discount rate - finance leases8.4 %8.3 %
Weighted average remaining lease term in years - operating leases6.16.6
Weighted average remaining lease term in years - finance leases3.54.1
The components of lease expense for the three and nine months ended September 30, 2024 and 2023 were as follows:
Three Months Ended
September 30,
Nine Months Ended
September 30,
(In thousands)2024202320242023
Operating lease costs$1,018 $810 $2,639 $2,460 
Financing lease costs57 173 
Short-term lease costs452 510 1,263 1,266 
Total operating lease costs1,527 1,320 4,075 3,726 
   
Variable lease costs446 299 1,166 903 
Total lease costs$1,973 $1,619 5,241 4,629 
Maturities of our lease liabilities as of September 30, 2024 are as follows:
(In thousands)Operating
Leases
Financing
Leases
2024 (3 months remaining)$857 $103 
20253,630 413 
20263,249 389 
20272,970 387 
20283,021 134 
Thereafter7,794 
Total lease payments21,521 1,426 
Less: interest(3,544)(190)
Total present value of lease liabilities$17,977 $1,236 
v3.24.3
Assets held for rent
9 Months Ended
Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Assets held for rent Assets held for rent
Assets held for rent consist of the following as of September 30, 2024 and December 31, 2023:
September 30,December 31,
(In thousands)20242023
Shippers placed in service$9,862 $9,866 
Fixed assets held for rent6,538 1,468 
Accumulated depreciation(8,813)(6,272)
Subtotal7,587 5,062 
Shippers and related components in production3,235 2,651 
Total$10,822 $7,713 
Shippers and related components in production include shippers complete and ready to be deployed and placed in service upon a customer order, shippers in the process of being assembled, and components available to build shippers. We recognized $0.8 million and $2.3 million in depreciation expense related to assets held for rent during the three and nine months ended September 30, 2024, respectively, and $0.9 million and $2.8 million during the three and nine months ended September 30, 2023, respectively.
v3.24.3
Property and equipment
9 Months Ended
Sep. 30, 2024
Property, Plant and Equipment [Abstract]  
Property and equipment Property and equipment
Property and equipment consist of the following as of September 30, 2024 and December 31, 2023:
September 30,December 31,
(In thousands)20242023
Property and equipment  
Leasehold improvements$5,982 $5,913 
Furniture and computer equipment769 773 
Manufacturing and other equipment17,084 19,893 
Construction in-progress4,105 3,807 
Subtotal27,940 30,386 
Less: Accumulated depreciation(10,231)(9,456)
Property and equipment, net$17,709 $20,930 
Depreciation expense for property and equipment was $0.6 million and $1.9 million for the three and nine months ended September 30, 2024, respectively, and $1.0 million and $2.9 million during the three and nine months ended September 30, 2023, respectively.
v3.24.3
Goodwill and intangible assets
9 Months Ended
Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and intangible assets Goodwill and intangible assets
Goodwill
Goodwill represents the difference between the purchase price and the estimated fair value of identifiable assets acquired and liabilities assumed. Goodwill acquired in a business combination is determined to have an indefinite useful life and is not amortized but instead is tested for impairment at least annually in accordance with ASC 350.
Intangible assets
Intangible assets, net consisted of the following as of September 30, 2024 and December 31, 2023:
(In thousands, except weighted average useful life)September 30, 2024
Intangible assets:
Gross Carrying
Value
Accumulated
Amortization
Net Carrying
Value
Weighted
Average Useful
Life (in years)
Customer relationships$9,936 $(4,625)$5,311 9.9
Tradenames8,134 (2,543)5,591 10.5
Technology - acquired18,372 (10,859)7,513 3.3
Non-compete agreements750 (750)— 0.0
Total intangible assets$37,192 $(18,777)$18,415 6.6
(In thousands, except weighted average useful life)December 31, 2023
Intangible assets:
Gross Carrying
Value
Accumulated
Amortization
Net Carrying
Value
Weighted
Average Useful
Life (in years)
Customer relationships$9,936 $(4,217)$5,719 10.7
Tradenames8,134 (2,077)6,057 11.3
Technology - acquired18,372 (9,123)9,249 4.1
Non-compete agreements750 (626)124 0.8
Total intangible assets$37,192 $(16,043)$21,149 7.3
Amortization expense for definite-lived intangible assets was $0.9 million and $2.7 million for the three and nine months ended September 30, 2024, respectively, and $1.3 million and $4.1 million for the three and nine months ended September 30, 2023, respectively. As of September 30, 2024, the Company expects to record the following amortization expense for definite-lived intangible assets:
(In thousands)Amortization
Expense
For the Years Ending December 31,
2024 (3 months remaining)$868 
20253,468 
20263,358 
20272,605 
20281,500 
Thereafter6,616 
Total$18,415 
v3.24.3
Accrued expenses and other current liabilities
9 Months Ended
Sep. 30, 2024
Investments, Debt and Equity Securities [Abstract]  
Accrued expenses and other current liabilities Accrued expenses and other current liabilities
Accrued expenses and other current liabilities consist of the following as of September 30, 2024 and December 31, 2023:
September 30,December 31,
(In thousands)20242023
Accrued expenses$2,864 $6,667 
Accrued taxes373 551 
Accrued compensation4,777 2,902 
Deferred revenue, current435 655 
Total accrued expenses and other current liabilities$8,449 $10,775 
v3.24.3
Commitments and contingencies
9 Months Ended
Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]  
Commitments and contingencies Commitments and contingencies
Employment agreements
We have employment agreements with certain key employees. None of these employment agreements is for a definitive period, but rather each will continue indefinitely until terminated in accordance with its terms. The agreements provide for a base annual salary, payable in monthly (or shorter) installments. Under certain conditions and for certain of these officers, we may be required to pay additional amounts upon terminating the employee or upon the employee resigning for good reason.
Litigation
From time to time, the Company is subject to various legal proceedings that arise in the ordinary course of business, as our industry is characterized by frequent claims and litigation, including claims regarding intellectual property. Management does not believe any of the current claims are material to the Company’s business. Future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors. The Company carries certain insurance policies that may cover the aforementioned costs. The probability of claims that could result in a loss are evaluated and disclosed, as needed, individually and on a gross basis. Management is not aware of any significant pending or threatened litigation that is anticipated to result in unfavorable judgments against the Company other than those listed below.
Pending litigation claims
Two lawsuits have been filed by previous customers seeking payment for losses allegedly related to commercial freezer products from Global Cooling prior to its divestiture. These lawsuits are in various stages, and we continue to defend vigorously against the claims made in them. An estimate for a reasonably possible loss or range of loss cannot be made, though we expect any potential losses incurred to be covered by insurance.
Indemnification
As permitted under Delaware law and in accordance with the Company’s bylaws, the Company is required to indemnify its officers and directors for certain errors and occurrences while the officer or director is or was serving in such capacity. The Company is also party to indemnification agreements with its directors. The Company believes the fair value of the indemnification rights and agreements is minimal. Accordingly, the Company has not recorded any liabilities for these indemnification rights and agreements as of September 30, 2024 and December 31, 2023.
Purchase obligations
Purchase obligations are defined as agreements to purchase goods or services that are enforceable and legally binding and that specify all significant terms, including fixed or minimum quantities to be purchased, fixed, minimum, or variable pricing provisions and the approximate timing of the transactions. As of September 30, 2024, our total short-term obligations were $4.2 million.
Non-income related taxes
Companies are required to collect and remit sales tax from certain customers if the company is determined to have nexus in a particular state. Upon the determination of nexus, which varies by state, companies are additionally required to maintain detailed record of specific product and customer information within each jurisdiction in which it has established nexus to appropriately determine their sales tax liability, requiring technical knowledge of each jurisdiction’s tax case law. During the year ended December 31, 2023, the Company determined that a sales tax liability related to the periods of 2019 through 2023 was probable and determined an estimated liability. The estimated liability was approximately $3.8 million and $4.8 million as of September 30, 2024 and December 31, 2023, respectively. Due to the variety of jurisdictions in which this estimated liability relates to and our ongoing assessment of sales taxes owed, we cannot predict when final liabilities will be satisfied. We will reevaluate the estimated liability and timing of satisfaction each reporting period.
v3.24.3
Long-term debt
9 Months Ended
Sep. 30, 2024
Debt Disclosure [Abstract]  
Long-term debt Long-term debt
Term Loan
On September 20, 2022, the Company and certain of its subsidiaries entered into a term loan agreement (the “Loan Agreement”), which provides for a term loan in an aggregate maximum principal amount of up to $60 million in the increments and upon the dates and milestones described below (the “Term Loan”). The Term Loan matures on June 1, 2026. The Loan Agreement permitted the Company to borrow up to $30 million upon the initial closing of the transactions contemplated by the Loan Agreement (the “Term Loan Closing”), and provided options to borrow (i) up to $10 million between the Term Loan Closing and June 30, 2023, (ii) up to $10 million upon the achievement of certain revenue milestones by the Company, and (iii) an additional $10 million at the discretion of the lender. The Company borrowed $20 million at the Term Loan Closing and accounts for the Term Loan at cost. As of December 31, 2023, the Company had not drawn additional funding nor had it met the revenue milestones outlined within the Loan Agreement. The Company had until December 31, 2023 to draw an additional $10 million, subject to approval from the lender, and therefore has no additional opportunities under the Loan Agreement. Payments on the borrowing are interest-only through June 2024, with additional criteria allowing for interest-only payments to continue through June 2025. Tranches borrowed under the Loan Agreement bear interest at the Wall Street Journal prime rate plus 0.5%. However, the interest rate is subject to a ceiling that restricts the interest rate for each tranche from exceeding 1.0% above the overall rate applicable to each tranche at their respective funding dates and has a balloon payment due at the earliest of term loan maturity, repayment of the Term Loan in full, or termination of the Loan Agreement at $1.2 million. As of September 30, 2024, the implied interest rate of the Term Loan is 7.5% and the implied value of the Term Loan is $18.2 million. The Loan Agreement contains customary representations and warranties as well as customary affirmative and negative covenants. As of September 30, 2024, the Company is in compliance with the covenants set forth in the Loan Agreement.
On April 17, 2024, the Company entered into a Consent and Second Amendment to the Term Loan (the “Amendment”) by and among Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (“Bank”) and the Company and its subsidiaries. Pursuant to the Amendment and subject to the conditions set forth therein, Bank consented to the transaction and released its security interests in the assets of Global Cooling and the Shares arising under the Loan and Security Agreement, dated September 20, 2022, by and among Bank and Borrower, as amended by that certain Waiver and First Amendment to Loan and Security Agreement, dated February 26, 2024 (the “Loan Agreement”). In addition, effective as of the closing of the transaction, the Amendment amended the Loan Agreement to remove Global Cooling as a party to the Loan Agreement and provide for a non-refundable termination fee in the amount of $500,000 payable by Borrower to Bank in the event that the Loan Agreement is terminated prior to the Term Loan Maturity Date (as defined in the Loan Agreement) for any reason. The Amendment also contains customary representations and warranties of Borrower and provides for a release of Bank by Borrower for any claims existing or arising through the date of the Amendment, including, without limitation, those arising out of or in any manner connected with or related to the Loan Agreement.
On November 11, 2024, the Company entered into a Consent and Third Amendment to Loan and Security Agreement (the “Amendment”) by and among Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (“Bank”) and the Company and its subsidiaries. For additional information on the Amendment, see Note 19: Subsequent events.
Long-term debt consisted of the following as of September 30, 2024 and December 31, 2023:
September 30,December 31,
(In thousands)Maturity DateInterest Rate20242023
Global Cooling Amended Term NotesVarious4.0 %$— $2,596 
Term LoanJun-267.0 %17,500 20,000 
Insurance premium financingJul-258.3 %1,712 1,348 
Freezer equipment loanDec-255.7 %200 317 
Manufacturing equipment loansOct-255.7 %97 172 
Freezer installation loanVarious6.3 %593 807 
Other loansVariousVarious
Total debt, excluding unamortized debt issuance costs20,103 25,242 
Less: unamortized debt issuance costs(49)(98)
Total debt20,054 25,144 
Less: current portion of debt(12,231)(6,833)
Total long-term debt$7,823 $18,311 
As of September 30, 2024, the Term Loan was secured by substantially all assets of BioLife, SAVSU, CBS, SciSafe, and Sexton, other than intellectual property. Equipment loans are secured by the financed equipment.
As of September 30, 2024, the scheduled maturities of loans payable for each of the next five years and thereafter were as follows:
(In thousands)Amount
2024 (3 months remaining)$3,177 
202511,659 
20265,218 
2027
2028
Thereafter
Total debt$20,054 
v3.24.3
Revenue
9 Months Ended
Sep. 30, 2024
Revenue from Contract with Customer [Abstract]  
Revenue Revenue
To determine revenue recognition for contractual arrangements that we determine are within the scope of FASB Topic 606, Revenue from Contracts with Customers, we perform the following five steps: (i) identify each contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to our performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the relevant performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. Contracts with customers may contain multiple performance obligations. For such arrangements, the transaction price is allocated to each performance obligation based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price, taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations. Payment terms and conditions vary, although terms generally include a requirement of payment within 30 to 90 days. As of September 30, 2024 and December 31, 2023, our deferred revenue balance totaled $0.4 million and $0.7 million, respectively. During the three and nine months ended September 30, 2024, the Company recognized approximately $0.1 million and $0.6 million, respectively, of revenue that was included in the deferred revenue balance at the beginning of the year. During the three and nine months ended
September 30, 2023, the Company had recognized $0.1 million and $0.4 million, respectively, of revenue that was included in the deferred revenue balance at the beginning of the year.
The Company primarily recognizes product revenues, service revenues, and rental revenues. Product revenues are generated from the sale of cell processing tools, freezers, thawing devices, and cold chain products. We recognize product revenue, including shipping and handling charges billed to customers, at a point in time when we transfer control of our products to our customers, which is upon shipment for substantially all transactions. Shipping and handling costs are classified as part of cost of product revenue in the Condensed Consolidated Statements of Operations. Service revenue is generated from the storage of biological and pharmaceutical materials. We recognize service revenue over time as services are performed or ratably over the contract term. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method or the most likely amount method, depending on the facts and circumstances relative to the contract. When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in ASC Topic 606, the Company does not assess whether a significant financing component exists if the period between when the Company performs its obligations under the contract and when the customer pays is one year or less. None of the Company’s contracts contained a significant financing component as of and during the three and nine months ended September 30, 2024.
The Company also generates revenue from the leasing of our property, plant, and equipment, operating right-of-use assets, and evo cold chain systems within its biostorage services product line to customers pursuant to service contracts or rental arrangements entered into with the customer. Revenue from these arrangements is not within the scope of FASB ASC Topic 606 as it is within the scope of FASB ASC Topic 842, Leases. All customers leasing shippers currently do so under annual rental arrangements. We account for these rental transactions as operating leases and record rental revenue on a straight-line basis over the rental term.
The Company enters into various customer service agreements (collectively, “Service Contracts”) with customers to provide biological and pharmaceutical storage services. In certain of these Service Contracts, the property, plant, and equipment or operating right-of-use assets used to store the customer product are used only for the benefit of one customer. This is primarily driven by the customer’s desire to ensure that sufficient storage capacity is available in a specific geographic location for a set period of time. These agreements may include extension and termination clauses. These Service Contracts do not allow for customers to purchase the underlying assets.
The Company has assessed its Service Contracts and concluded that certain of the contracts for the storage of customer products met the criteria to be considered a leasing arrangement (“Embedded Leases”), with the Company as the lessor. The specific Service Contracts that met the criteria were those that provided a single customer with the ability to substantially direct the use of the Company’s property, plant, and equipment or operating right-of-use assets.
Applying the practical expedient from ASC Topic 842, consistent with the previous guidance, the Company will continue to recognize operating right-of-use asset embedded lessor arrangements on its Unaudited Condensed Consolidated Balance Sheets in operating right-of-use assets.
None of the Embedded Leases identified by the Company qualify as a sales-type or direct finance lease. None of the operating leases for which the Company is the lessor include options for the lessee to purchase the underlying asset at the end of the lease term or residual value guarantees, nor are any such operating leases with related parties.
Embedded Leases may contain both lease and non-lease components. We have elected to utilize the practical expedient from ASC Topic 842 to account for lease and non-lease components together as a single combined lease component as the timing and pattern of transfer are the same for the non-lease components and associated lease component and, the lease component, if accounted for separately, would be classified as an operating lease. Non-lease components of the Company’s rental arrangements include reimbursements of lessor costs.
Total bioproduction tools and services revenue for the three and nine months ended September 30, 2024 and 2023 were composed of the following:
Three Months Ended
September 30,
Nine Months Ended
September 30,
(In thousands, except percentages)2024202320242023
Product revenue  
Cell processing$19,030 $13,338 $53,154 $51,004 
Biostorage services$543 $365 $970 $1,099 
Freezer and thaw3,884 3,434 10,500 11,341 
Service revenue  
Biostorage services4,526 4,186 13,708 12,166 
Freezer and thaw134 191 465 407 
Rental revenue  
Biostorage services2,454 2,059 6,881 5,975 
Total revenue$30,571 $23,573 $85,678 $81,992 
The following table includes estimated rental revenue expected to be recognized in the future related to Embedded Leases as well as estimated service revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting periods. The Company is electing not to disclose the value of the remaining unsatisfied performance obligation with a duration of one year or less as permitted by the practical expedient in ASU 2014-09, Revenue from Contracts with Customers. The estimated revenue in the following table does not include contracts with the original durations of one year or less, amounts of variable consideration attributable to royalties, or contract renewals that are unexercised as of September 30, 2024. As of September 30, 2024, we did not have service revenue expected to be recognized in greater than one year.
The balances in the table below are partially based on judgments involved in estimating future orders from customers pursuant to their respective contracts:
(In thousands)2024 (3 months remaining)20252026Total
Rental revenue$812 $3,249 $812 $4,873 
v3.24.3
Stock-based compensation
9 Months Ended
Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]  
Stock-based compensation Stock-based compensation
Service-based vesting stock options
The following is a summary of service-based vesting stock option activity for the September 30, 2024, and the status of service-based vesting stock options outstanding as of September 30, 2024:
Nine Months Ended
September 30, 2024
Options
Wtd. Avg. Exercise Price
Outstanding as of beginning of period217,250 $2.21 
Exercised(58,750)2.33 
Outstanding as of September 30, 2024158,500 $2.16 
Stock options exercisable as of September 30, 2024158,500 $2.16 
As of September 30, 2024, there was $3.6 million of aggregate intrinsic value of outstanding and exercisable service-based vesting stock options. Intrinsic value is the total pretax intrinsic value for all “in-the-money” options (i.e., the difference between the Company’s closing stock price on the last trading day of the reporting period and the exercise price, multiplied by the number of shares) that would have been received by the option holders had all option holders exercised their options on September 30, 2024. This amount will change based on the fair market value of the Company’s stock. We did not recognize stock compensation expense related to service-based options during the three and nine months ended September 30, 2024. The intrinsic value of service vesting-based awards exercised was $0.5 million and $1.1 million during the three and nine months ended September 30, 2024, respectively. There were no service-based vesting options granted during the three and nine months ended September 30, 2024. The weighted average remaining contractual life of service-based vesting stock options outstanding and exercisable as of September 30, 2024 is 1.5 years. There were no unrecognized compensation costs for service-based vesting stock options as of September 30, 2024.
Restricted stock
Service-based vesting restricted stock
The following is a summary of service-based vesting restricted stock activity for the nine months ended September 30, 2024, and the status of unvested service-based vesting restricted stock outstanding as of September 30, 2024:
Nine Months Ended
September 30, 2024
Shares
Wtd. Avg. Grant Date Fair Value
Outstanding as of beginning of period2,312,898 $18.32 
Granted484,886 20.53 
Vested(701,436)25.83 
Forfeited(116,386)17.33 
Non-vested as of September 30, 20241,979,962 $16.22 
The aggregate fair value of the service-based vesting awards granted was $6.7 million and $10.0 million during the three and nine months ended September 30, 2024, respectively. The aggregate fair value of the service-based vesting awards that vested was $2.3 million and $8.0 million during the three and nine months ended September 30, 2024, respectively.
We recognized stock compensation expense related to service-based vesting awards of $3.8 million and $11.7 million during the three and nine months ended September 30, 2024, respectively. As of September 30, 2024, there was $26.8 million in unrecognized compensation costs related to service-based vesting awards. We expect to recognize those costs over 2.7 years.
Performance-based restricted stock
On March 8, 2024, the Company granted 109,512 shares of performance-based stock to an executive in the form of restricted stock. The shares granted contain performance conditions based on Company metrics related to future performance. The grant date fair value of this award was $17.36 per share. The fair value of this award is being expensed on a straight-line basis over the requisite service period ending on December 31, 2025.
We recognized stock compensation expense of $0.2 million and $0.7 million related to performance-based restricted stock awards for the three and nine months ended September 30, 2024, respectively. As of September 30, 2024, there was $1.2 million in unrecognized non-cash compensation costs related to performance-based restricted stock awards expected to vest. We expect to recognize those costs over 1.2 years. Non-cash compensation costs are expensed over the period for which performance was measured.

The aggregate fair value of the performance-based awards granted during the three and nine months ended September 30, 2024 was $1.9 million. No performance-based awards vested during the three and nine months ended September 30, 2024.
No performance-based restricted stock awards were granted or vested during the three and nine months ended September 30, 2023.
Market-based restricted stock
The following is a summary of market-based restricted stock activity under our stock option plan for the nine months ended September 30, 2024 and the status of market-based restricted stock outstanding as of September 30, 2024:
Nine Months Ended
September 30, 2024
Shares
Wtd. Avg. Grant
Outstanding as of beginning of period509,166 $26.50 
Granted299,565 27.12 
Vested(300,529)27.97 
Non-vested as of September 30, 2024508,202 $25.70 
On February 24, 2022, the Company granted 240,428 shares of market-based stock to its executives in the form of restricted stock. The shares granted contain a market condition based on total shareholder return ("TSR"). The TSR market condition measures the Company’s performance against a peer group. On March 8, 2024, the Company’s Compensation Committee determined the TSR attainment was 125% of the targeted shares and 300,529 shares were granted and immediately vested to the executives of the Company based on our TSR during the period beginning on January 1, 2022 through December 31, 2023 as compared to the TSR of 20 of our peers. The fair value of this award was determined using a Monte Carlo simulation with the following assumptions: a historical volatility of 63%, 0% dividend yield and a risk-free interest rate of 1.5%. The historical volatility was based on the most recent 2-year period for the Company and correlated with the components of the peer group. The stock price projection for the Company and the components of the peer group assumes a 0% dividend yield. This is mathematically equivalent to reinvesting dividends in the issuing entity over the performance period. The risk-free interest rate is based on the yield on the U.S. Treasury Strips as of the Measurement Date with a maturity consistent with the 2-year term associated with the market condition of the award. The fair value of this award of $6.7 million was expensed on a straight-line basis over the grant date to the vesting date of December 31, 2023.
On January 3, 2023, the Company granted 268,738 shares of market-based stock to its executives in the form of restricted stock. The shares granted contain a market condition based on TSR. The TSR market condition measures the Company’s performance against a peer group. The market-based restricted stock awards will vest as to between 0% and 200% of the number of restricted shares granted to each recipient based on our TSR during the period beginning on January 1, 2023 through December 31, 2024 as compared to the TSR of 20 of our peers. The fair value of this award was determined using a Monte Carlo simulation with the following assumptions: a historical volatility of 78%, 0% dividend yield and a risk-free interest rate of 4.4%. The historical volatility was based on the most recent 2-year period for the Company and correlated with the components of the peer group. The stock price projection for the Company and the components of the peer group assumes a 0% dividend yield. This is mathematically equivalent to reinvesting dividends in the issuing entity over the performance period. The risk-free interest rate is based on the yield on the U.S. Treasury Strips as of the Measurement Date with a maturity consistent with the 2-year term associated with the market condition of the award. The fair value of this award of $6.8 million is being expensed on a straight-line basis over the grant date to the vesting date of December 31, 2024, excluding $1.6 million of expense recognized in 2023 to reflect accelerations in the vesting period of certain awards.
On March 8, 2024, the Company granted 239,464 shares of market-based stock to its executives in the form of restricted stock. The shares granted contain a market condition based on TSR. The TSR market condition measures the Company’s performance against a peer group. The market-based restricted stock awards will vest as to between 0% and 200% of the number of restricted shares granted to each recipient based on our TSR during the period beginning on January 1, 2024 through December 31, 2025 as compared to the TSR of 20 of our peers. The fair value of this award was determined using a Monte Carlo simulation with the following assumptions: a historical volatility of 80%, 0% dividend yield and a risk-free interest rate of 4.6%. The historical volatility was based on the most recent 2-year period for the Company and correlated with the components of the peer group. The stock price projection for the Company and the components of the peer group assumes a 0% dividend yield. This is mathematically equivalent to reinvesting dividends in the issuing entity over the performance period. The risk-free interest rate is based on the yield on the U.S. Treasury Strips as of the Measurement Date with a maturity consistent with the 2-year term associated with the market condition of the award. The fair value of this
award of $6.3 million is being expensed on a straight-line basis over the grant date to the vesting date of December 31, 2025.
We recognized stock compensation expense of $1.3 million and $3.7 million related to market-based restricted stock awards for the three and nine months ended September 30, 2024, respectively, and $1.6 million and $4.9 million during the three and nine months ended September 30, 2023, respectively. As of September 30, 2024, there was $4.4 million in unrecognized non-cash compensation costs related to market-based restricted stock awards expected to vest. We expect to recognize those costs over 1.1 years.
The aggregate fair value of the market-based awards granted was zero and $6.3 million during the three and nine months ended September 30, 2024, respectively, and zero and $6.5 million during the three and nine months ended September 30, 2023, respectively. The aggregate fair value of the market-based awards that vested was zero and $5.1 million during the three and nine months ended September 30, 2024, respectively, and zero and $0.7 million during the three and nine months ended September 30, 2023, respectively.
Total stock compensation expense
Compensation expense associated with equity-based awards is recognized on a straight-line basis over the requisite service period, with awards generally vesting over a 4-year period, and forfeitures recognized as incurred. We recorded total stock compensation expense for the three and nine months ended September 30, 2024 and 2023, as follows:
 Three Months Ended
September 30,
Nine Months Ended
September 30,
(In thousands)2024202320242023
Cost of revenue$826 $1,031 $2,482 $2,991 
General and administrative costs2,873 3,349 8,648 9,497 
Sales and marketing costs1,001 1,920 2,909 3,575 
Research and development costs624 1,684 1,983 3,652 
Total$5,324 $7,984 $16,022 $19,715 
v3.24.3
Income taxes
9 Months Ended
Sep. 30, 2024
Income Tax Disclosure [Abstract]  
Income taxes Income taxes
The Company accounts for income taxes under ASC Topic 740 – Income Taxes. Under this standard, deferred tax assets and liabilities are recognized for future tax benefits or consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.
The Company’s tax provision for interim periods is determined using an estimate of the annual effective income tax rate, adjusted for discrete items, if any, that occur in the relevant period. Income tax expense of $0.1 million for the nine months ended September 30, 2024 resulted in an effective income tax rate of negative 0.7%. Included in the $0.1 million of tax expense was discrete tax expense of $1.2 million related to stock compensation, which was offset by a change in the valuation allowance.
The Company’s projected effective income tax rate for the year ending December 31, 2024 excluding the impact, if any, of discrete items is negative 0.7%, which is lower than the U.S. federal statutory rate of 21% primarily due to the increase in the valuation allowance on deferred tax assets and non-deductible executive compensation offset by state tax benefits and research tax credits.
Realization of deferred tax assets is dependent upon the generation of future taxable income, the timing and amount of which are uncertain. In determining the need for a valuation allowance, the Company’s management evaluates all available positive and negative evidence to determine if it is more likely than not that its deferred tax assets are realizable. As of September 30, 2024, the Company continues to provide a full valuation allowance against its deferred tax assets as the realization of such assets is not considered to be more likely than not at this time. If the Company's conclusion about the realizability of its deferred tax assets and therefore the appropriateness of the valuation allowance changes in a future
period, the Company could record a substantial tax benefit in its Condensed Consolidated Statements of Operations when that occurs.
v3.24.3
Net loss from continuing operations per common share
9 Months Ended
Sep. 30, 2024
Earnings Per Share [Abstract]  
Net loss from continuing operations per common share Net loss from continuing operations per common share
The Company considers its unvested restricted shares, which contain non-forfeitable rights to dividends, as participating securities, and includes such participating securities in its computation of earnings per share pursuant to the two-class method. Basic earnings per share is calculated by dividing net loss by the weighted average number of shares of common stock outstanding during the reporting period. Diluted earnings per share is calculated using the weighted average number of shares of common stock plus the potentially dilutive effect of common equivalent shares outstanding determined under both the two-class method and the treasury stock method, whichever is more dilutive. In periods when we have a net loss, common stock equivalents are excluded from our calculation of earnings per share as their inclusion would have an antidilutive effect.
The following table presents computations of basic and diluted earnings per share:
Three Months Ended
September 30,
Nine Months Ended
September 30,
(In thousands, except share and earnings per share data)2024202320242023
Basic earnings (loss) per common share
Numerator:
Net loss from continuing operations$(1,703)$(15,804)$(13,061)$(30,043)
Net loss from continuing operations allocated to common shareholders(1,703)(15,804)(13,061)(30,043)
Denominator:
Weighted-average common shares issued and outstanding46,175,34543,570,43845,871,71543,348,412
Basic and diluted loss from continuing operations per common share$(0.04)$(0.36)$(0.28)$(0.69)
The following table sets forth the number of weighted-average shares of common stock excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:
Three Months Ended
September 30,
Nine Months Ended
September 30,
2024202320242023
Stock options and restricted stock awards3,939,4172,636,2833,774,6973,007,126
Total3,939,4172,636,2833,774,6973,007,126
v3.24.3
Employee benefit plan
9 Months Ended
Sep. 30, 2024
Retirement Benefits [Abstract]  
Employee benefit plan Employee benefit plan
The Company sponsors 401(k) defined contribution plan for its employees. This plan provides for pre-tax and post-tax contributions for all employees. Employee contributions are voluntary. Employees may contribute up to 100% of their annual compensation to this plan as limited by an annual maximum amount as determined by the Internal Revenue Service. The Company matches employee contributions in amounts to be determined at the Company’s sole discretion. The Company made $0.2 million and $0.7 million in contributions to this plan for the three and nine months ended September 30, 2024, respectively. During the three and nine months ended September 30, 2023, the Company made $0.2 million and $0.7 million, respectively, in contributions to this plan.
v3.24.3
Subsequent events
9 Months Ended
Sep. 30, 2024
Subsequent Events [Abstract]  
Subsequent events Subsequent events
The Company has evaluated events subsequent to September 30, 2024 through the date of this filing to assess the need for potential recognition or disclosure.
Stock Purchase Agreement for SciSafe Divestiture
On November 12, 2024, the Company entered into a Stock Purchase Agreement, by and among the Company, Subzero Purchaser Corp., a Delaware corporation, SciSafe, Inc., a Delaware corporation and an indirect, wholly owned subsidiary of the Company, and SciSafe, Inc., a New Jersey corporation and an indirect wholly owned subsidiary of the Company, for the sale by Seller of all of the issued and outstanding shares of common stock of SciSafe to Buyer for an aggregate purchase price of $73.0 million (subject to adjustment as set forth in the Purchase Agreement) (the “Transaction”). Following the execution of the Purchase Agreement, the Transaction was consummated on November 12, 2024 (the “Closing Date”). We anticipate the divestiture to qualify and be presented as Discontinued Operations in our Annual Report on Form 10-K for the year ended December 31, 2024.
The Purchase Agreement contains customary representations, warranties, covenants and indemnities of the parties thereto, including customary covenants that prevent the Company from competing with SciSafe, soliciting its employees or interfering with its business relationships for five years after the Closing Date. In connection with the closing of the Transaction, the Company was required to repay approximately $0.9 million of outstanding indebtedness of SciSafe, estimates to incur approximately $1.8 million in fees to be paid for legal and other transaction services, and estimates to incur approximately $0.4 million in severance costs. The Company also paid the former stockholders of SciSafe approximately $3.3 million in cash to waive all rights with respect to certain potential earn-out payments that would have otherwise accelerated and become due in connection with the Transaction pursuant to the purchase agreement by which the Company acquired SciSafe in October 2020. Finally, the Company expects to recognize approximately $4.0 million in stock compensation expense in connection with the acceleration of unvested shares for all former employees of the Company that remained with SciSafe upon the closing of the Transaction.
In addition, upon the closing of the Transaction, the Company and SciSafe entered into a transition services agreement, pursuant to which the Company will provide certain transition services to SciSafe for up to six months following the Closing Date.

The Company expects to recognize a gain on the Transaction of approximately $39.6 million before $11.1 million of goodwill allocation.
The Company’s estimates are subject to a number of assumptions, and actual results may differ.
Consent and Third Amendment to Loan and Security Agreement with Silicon Valley Bank
November 11, 2024, the Company entered into a Consent and Third Amendment to Loan and Security Agreement, by and among Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (“Bank”), the Company, SAVSU Technologies, Inc., a Delaware corporation (“SAVSU”), Arctic Solutions, Inc., a Delaware corporation doing business as Custom Biogenic Systems (“Arctic”), SciSafe Holdings, Inc., a Delaware corporation (“SciSafe Parent”), and Sexton Biotechnologies, Inc., a Delaware corporation (“Sexton,” and together with the Company, SAVSU, Arctic and SciSafe Parent, “Borrower”). Pursuant to the Amendment and subject to the conditions set forth therein, Bank consented to the Transaction as required pursuant to the Loan and Security Agreement, dated September 20, 2022, by and among Bank and Borrower, as amended by that certain Waiver and First Amendment to Loan and Security Agreement, dated February 26, 2024, and that certain Consent and Second Amendment to Loan and Security Agreement, dated April 17, 2024 (the “Loan Agreement”). In addition, effective as of the closing of the Transaction, the Amendment amended the Loan Agreement to provide for a non-refundable termination fee in the amount of $750,000 payable by Borrower to Bank in the event that the Loan Agreement is terminated prior to the Term Loan Maturity Date (as defined in the Loan Agreement) for any reason. The Amendment also made certain other ministerial changes to the Loan Agreement, contains customary representations and warranties of Borrower and provides for a release of Bank by Borrower for any claims existing or arising through the date of the Amendment, including, without limitation, those arising out of or in any manner connected with or related to the Loan Agreement.
As announced during the second quarter of 2023, the Company has continued to actively seek the divestiture of its CBS business and anticipates Discontinued Operations treatment upon the closure of a deal.
v3.24.3
Organization and significant accounting policies (Policies)
9 Months Ended
Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Use of estimates
Use of estimates
The preparation of financial statements in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Significant estimates and assumptions by management affect the Company’s net realizable value of inventory, sales tax liabilities, valuation of market-based stock awards, valuations, fair value of marketable debt securities, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, estimated fair values of intangible assets and goodwill, amortization methods and periods, warranty reserves, certain accrued expenses, stock-based compensation, contingent consideration from business combinations, and provision for income taxes.
The Company regularly assesses these estimates; however, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.
Basis of presentation
Basis of presentation

The Unaudited Condensed Consolidated Financial Statements and related footnote disclosures as of and for the three and nine months ended September 30, 2024 are unaudited, and are not necessarily indicative of the Company’s operating results for a full year. The Unaudited Condensed Consolidated Financial Statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial results for the three and nine months ended September 30, 2024 in accordance with U.S. GAAP, however, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the U.S. Securities and Exchange Commission (the “SEC”) rules and regulations relating to interim financial statements. These Unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Audited Consolidated Financial Statements and accompanying notes thereto included in the Company’s Annual Report on Form 10-K as of and for the fiscal year ended December 31, 2023, filed with the SEC on February 29, 2024 (the “Annual Report”).
The Unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries, SAVSU Technologies, Inc. (“SAVSU”), Arctic Solutions, Inc. doing business as Custom Biogenic Systems (“CBS”), SciSafe Holdings, Inc. (“SciSafe”), BioLife Solutions B.V, and Sexton Biotechnologies, Inc. (“Sexton”). All intercompany accounts and transactions have been eliminated in consolidation.
Discontinued operations
On April 17, 2024, the Company sold all of the issued and outstanding shares of common stock of Global Cooling and the accounting requirements for reporting the Global Cooling subsidiary as a discontinued operation were met. Unless otherwise noted, amounts and disclosures throughout these Notes to Unaudited Condensed Consolidated Financial Statements relate to the Company's continuing operations. Refer to Note 3: Discontinued operations for further details.
In the opinion of management, the accompanying Unaudited Condensed Consolidated Financial Statements include all adjustments, consisting of only normal, recurring adjustments necessary for a fair presentation of the financial position, results of operations, and cash flows. The results of operations for the interim periods presented are not necessarily indicative of results to be expected for the entire year.
Foreign currency translation
Foreign currency translation
The Company translates items presented on its Unaudited Condensed Consolidated Financial Statements into U.S. dollars. For the Company’s subsidiaries that operate in a local currency functional environment, all assets and liabilities are translated into U.S. dollars using current exchange rates at the balance sheet date; revenue and expenses are translated using average exchange rates in effect during each period. Resulting translation adjustments are reported as a separate component of Accumulated Other Comprehensive Loss in the Unaudited Condensed Consolidated Statements of Shareholders' Equity.
Segment reporting
Segment reporting
The Company views its operations and makes decisions regarding how to allocate resources and manages its business as one reportable segment and one reporting unit. The Company’s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.
Concentrations of credit risk and business risk
Concentrations of credit risk and business risk
Significant customers are those that represent more than 10% of the Company’s total revenue or gross accounts receivable balances for the periods and as of each balance sheet date presented.
Recent accounting pronouncements
Recent accounting pronouncements
In March 2024, the SEC adopted final rules on the enhancement and standardization of climate-related disclosures of public companies. The final rules require disclosure of, among other things, material climate-related risks and their impact; activities to mitigate or adapt to material climate-related risks; governance and oversight of climate-related risks; and material Scope 1 and/or Scope 2 greenhouse gas emissions with an accompanying assurance report required following an initial transition period, at a limited assurance level, and then following an additional transition period, at a reasonable assurance level. In addition, the effects of severe weather events and other natural conditions, subject to certain thresholds, and amounts related to carbon offsets and renewable energy credits or certificates are required to be disclosed in the notes to the audited financial statements in certain circumstances.
On April 4, 2024, the SEC voluntarily stayed the implementation of the final rules pending the completion of judicial review of the consolidated challenges to the final rules by the Court of Appeals for the Eighth Circuit. The final rules, as originally issued, would be effective for the Company in various fiscal years, starting with its Annual Report on Form 10-K for fiscal year 2025. Disclosures pursuant to the final rules, as originally issued, would be required prospectively, with information for prior periods required only to the extent it was previously disclosed in an SEC filing. The Company is currently evaluating the impact of the final rules on its Consolidated Financial Statements and disclosures.
v3.24.3
Organization and significant accounting policies (Tables)
9 Months Ended
Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Concentrations of Credit Risk and Business Risk For each significant customer, revenue as a percentage of total revenue and gross accounts receivable as a percentage of total gross accounts receivable as of the periods presented were as follows:
Accounts ReceivableRevenue
September 30,December 31,Three Months Ended
September 30,
Nine Months Ended
September 30,
202420232024202320242023
Customer A16 %17 %****
Customer B****11 %11 %
Customer C**11 %***
*less than 10%
Schedule of Product Revenue Concentration
The following table represents the Company’s products representing more than 10% of the Company’s total revenue:
Three Months Ended
September 30,
Nine Months Ended
September 30,
Product revenue concentration2024202320242023
CryoStor52 %46 %51 %53 %
Schedule of Revenue by Geographic Areas
The following table represents the Company’s total revenue by geographic area (based on the location of the customer):
Three Months Ended
September 30,
Nine Months Ended
September 30,
Revenue by customers geographic locations(1)
2024202320242023
United States(2)
76 %81 %77 %82 %
Europe, Middle East, Africa (EMEA)19 %15 %18 %14 %
Other%%%%
Total revenue100 %100 %100 %100 %
(1) As of the year ended December 31, 2023, the Company updated its methodology for determining the country of origin for its sales. Sales are now recorded by shipping country rather than billing country. The Company updated the methodology retrospectively, adjusting the prior year presentation for all regions presented.
(2) The line item presented above previously bifurcated sales between the United States and Canada. Due to the updated methodology for determining the country of origin for sales, it was noted that Canada no longer was a material location to separately disclose. Canada sales have been included within the "Other" line item in the table above and United States sales have been retained as a single line item to more accurately reflect origin of sales for material regions.
v3.24.3
Correction of immaterial errors (Tables)
9 Months Ended
Sep. 30, 2024
Accounting Changes and Error Corrections [Abstract]  
Schedule of Effect of Adjustments to Financial Statements
The effect of the adjustments to our Consolidated Balance Sheet as of December 31, 2023 was as follows (in thousands):
December 31, 2023
(In thousands)As reportedAdjustmentAs corrected
Additional paid-in-capital$651,305 $1,575 $652,880 
Accumulated deficit(313,342)(1,575)(314,917)
v3.24.3
Discontinued operations (Tables)
9 Months Ended
Sep. 30, 2024
Discontinued Operations and Disposal Groups [Abstract]  
Schedule of Disposal Groups, Including Discontinued Operations The Company recognized a loss on disposal of Global Cooling, calculated as follows:
(In thousands)
Selling price: $1
$— 
Cash to Global Cooling funded by Company(6,652)
Costs to sell Global Cooling(1)
(582)
Negative selling price(7,234)
Global Cooling carrying basis as of April 17, 2024, inclusive of assumed liabilities(3,589)
Assumed liabilities: Accounts payable(2)
2,643 
Assumed liabilities: Debt(3)
2,596 
Global Cooling carrying basis as of April 17, 20241,650 
Release of Global Cooling currency translation adjustment(13)
Net loss on disposal$(8,897)
(1) Represents the costs incurred in connection with the divestiture of Global Cooling, including fees to be paid to the broker, attorneys, and other external parties.
(2) As a closing condition, the Company assumed certain accounts payable and accrued expenses from Global Cooling, totaling $0.5 million and $2.1 million, respectively.
(3) As a closing condition, the Company repaid the balance of the Global Cooling Amended Term Notes. For additional information on the terms of the Global Cooling Term Notes, see Note 13: Long-term debt.
The Company recognized the following charges in connection with the RIF and stock compensation expense acceleration:
(In thousands)SeveranceStock CompensationTotal
RIF employee costs$291 $1,255 $1,546 
Former Global Cooling employees— 1,925 1,925 
Total employment related divestiture expenditures$291 $3,180 $3,471 
The following table summarizes the major classes of assets and liabilities of discontinued operations, which are summarized separately in the condensed consolidated balance sheets:
April 17,December 31,
(In thousands)20242023
Cash and cash equivalents$275 $2,090 
Accounts receivable, net2,430 1,728 
Inventories9,152 11,248 
Prepaid expenses and other current assets379 303 
Total current assets, discontinued operations12,236 15,369 
Property and equipment, net153 146 
Long-term deposits and other assets
Total assets, discontinued operations12,393 15,519 
Accounts payable1,425 3,367 
Accrued expenses and other current liabilities911 1,637 
Warranty liability7,193 7,507 
Lease liabilities, operating, current portion242 263 
Lease liabilities, financing, current portion16 22 
Total current liabilities, discontinued operations9,787 12,796 
Lease liabilities, operating, long-term948 1,016 
Lease liabilities, financing, long-term11 
Total liabilities, discontinued operations$10,743 $13,823 
Global Cooling had no remaining balances as of September 30, 2024.
The key components of loss from discontinued operations were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)2024202320242023
Revenue$— $9,755 $7,157 $28,546 
Cost of revenue— 10,100 8,389 28,048 
Gross profit— (345)(1,232)498 
Operating expenses— (5,789)(9,418)(16,259)
Asset impairment charges— (7,175)— (7,175)
Other income (expense), net— (19)(25)(63)
Loss on disposal— — (8,897)— 
Loss before income taxes— (13,328)(19,572)(22,999)
Income tax expense— — (10)(3)
Loss from discontinued operations, net of income taxes$— $(13,328)$(19,582)$(23,002)
v3.24.3
Fair value measurement (Tables)
9 Months Ended
Sep. 30, 2024
Fair Value Disclosures [Abstract]  
Schedule of the Company's Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
The following tables set forth the Company’s financial assets and liabilities measured at fair value on a recurring basis as of September 30, 2024 and December 31, 2023, based on the three-tier fair value hierarchy:
(In thousands)
As of September 30, 2024Level 1Level 2Level 3Total
Assets:
Cash equivalents:
Money market accounts$13,731 $$$13,731 
Available-for-sale securities:    
U.S. government securities2,679 2,679 
Corporate debt securities395 8,735 9,130 
Other debt securities3,286 3,286 
Total$16,805 $12,021 $$28,826 
As of December 31, 2023
Assets:
Cash equivalents:
Money market accounts$25,034 $$$25,034 
Available-for-sale securities:
U.S. government securities5,170 5,170 
Corporate debt securities9,674 9,674 
Other debt securities1,992 1,992 
Total$30,204 $11,666 $$41,870 
Schedule of the Changes in Fair Value of Contingent Consideration Liabilities
The following table presents the changes in fair value of contingent consideration liabilities that are measured using Level 3 inputs for the three and nine months ended September 30, 2023. There was no contingent consideration liability outstanding as of September 30, 2024.
Nine Months Ended September 30,
(In thousands)2023
Balance at beginning of period$4,456 
Change in fair value recognized in net loss(1,778)
Payment of contingent consideration earned$(2,263)
Balance at end of period$415 
v3.24.3
Investments (Tables)
9 Months Ended
Sep. 30, 2024
Investments, Debt and Equity Securities [Abstract]  
Schedule of Available-for-Sale Marketable Securities
The Company’s portfolio of available-for-sale marketable securities consists of the following:
September 30, 2024
Amortized
Cost
Gross unrealizedEstimated
Fair Value
(In thousands)GainsLosses
Available-for-sale securities, current portion    
U.S. government securities$2,676 $$$2,679 
Corporate debt securities6,149 16 6,165 
Other debt securities1,363 1,367 
Total short-term10,188 23 10,211 
     
Available-for-sale securities, long-term    
Corporate debt securities2,944 21 2,965 
Other debt securities1,910 1,919 
Total marketable securities$15,042 $53 $$15,095 
December 31, 2023
Amortized
Cost
Gross unrealizedEstimated
Fair Value
(In thousands)GainsLosses
Available-for-sale securities, current portion
U.S. government securities$5,169 $$$5,170 
Corporate debt securities9,673 (4)9,674 
Other debt securities1,443 1,444 
Total short-term16,285 (4)16,288 
Available-for-sale securities, long-term
Other debt securities545 548 
Total marketable securities$16,830 $10 $(4)$16,836 
September 30, 2024
(In thousands)Amortized
Cost
Estimated
Fair Value
Due in one year or less$10,188 $10,211 
Due after one year through five years4,854 4,884 
Total$15,042 $15,095 
v3.24.3
Inventories (Tables)
9 Months Ended
Sep. 30, 2024
Inventory Disclosure [Abstract]  
Schedule of Inventory
Inventories consist of the following as of September 30, 2024 and December 31, 2023:
September 30,December 31,
(In thousands)20242023
Raw materials$12,722 $16,932 
Work in progress6,647 5,890 
Finished goods12,810 9,386 
Total inventories$32,179 $32,208 
v3.24.3
Leases (Tables)
9 Months Ended
Sep. 30, 2024
Leases [Abstract]  
Schedule of Operating and Finance Lease Terms and Discount Rates
The table below presents certain information related to the weighted average discount rate and weighted average remaining lease term for the Company’s leases as of September 30, 2024 and December 31, 2023:
September 30,December 31,
(In thousands)20242023
Weighted average discount rate - operating leases5.8 %4.4 %
Weighted average discount rate - finance leases8.4 %8.3 %
Weighted average remaining lease term in years - operating leases6.16.6
Weighted average remaining lease term in years - finance leases3.54.1
Schedule of Lease Expense
The components of lease expense for the three and nine months ended September 30, 2024 and 2023 were as follows:
Three Months Ended
September 30,
Nine Months Ended
September 30,
(In thousands)2024202320242023
Operating lease costs$1,018 $810 $2,639 $2,460 
Financing lease costs57 173 
Short-term lease costs452 510 1,263 1,266 
Total operating lease costs1,527 1,320 4,075 3,726 
   
Variable lease costs446 299 1,166 903 
Total lease costs$1,973 $1,619 5,241 4,629 
Schedule of Maturities of Operating Lease Liabilities
Maturities of our lease liabilities as of September 30, 2024 are as follows:
(In thousands)Operating
Leases
Financing
Leases
2024 (3 months remaining)$857 $103 
20253,630 413 
20263,249 389 
20272,970 387 
20283,021 134 
Thereafter7,794 
Total lease payments21,521 1,426 
Less: interest(3,544)(190)
Total present value of lease liabilities$17,977 $1,236 
Schedule of Maturities of Finance Lease Liabilities
Maturities of our lease liabilities as of September 30, 2024 are as follows:
(In thousands)Operating
Leases
Financing
Leases
2024 (3 months remaining)$857 $103 
20253,630 413 
20263,249 389 
20272,970 387 
20283,021 134 
Thereafter7,794 
Total lease payments21,521 1,426 
Less: interest(3,544)(190)
Total present value of lease liabilities$17,977 $1,236 
v3.24.3
Assets held for rent (Tables)
9 Months Ended
Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Assets Held For Rent
Assets held for rent consist of the following as of September 30, 2024 and December 31, 2023:
September 30,December 31,
(In thousands)20242023
Shippers placed in service$9,862 $9,866 
Fixed assets held for rent6,538 1,468 
Accumulated depreciation(8,813)(6,272)
Subtotal7,587 5,062 
Shippers and related components in production3,235 2,651 
Total$10,822 $7,713 
v3.24.3
Property and equipment (Tables)
9 Months Ended
Sep. 30, 2024
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment
Property and equipment consist of the following as of September 30, 2024 and December 31, 2023:
September 30,December 31,
(In thousands)20242023
Property and equipment  
Leasehold improvements$5,982 $5,913 
Furniture and computer equipment769 773 
Manufacturing and other equipment17,084 19,893 
Construction in-progress4,105 3,807 
Subtotal27,940 30,386 
Less: Accumulated depreciation(10,231)(9,456)
Property and equipment, net$17,709 $20,930 
v3.24.3
Goodwill and intangible assets (Tables)
9 Months Ended
Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Finite-Lived Intangible Assets
Intangible assets, net consisted of the following as of September 30, 2024 and December 31, 2023:
(In thousands, except weighted average useful life)September 30, 2024
Intangible assets:
Gross Carrying
Value
Accumulated
Amortization
Net Carrying
Value
Weighted
Average Useful
Life (in years)
Customer relationships$9,936 $(4,625)$5,311 9.9
Tradenames8,134 (2,543)5,591 10.5
Technology - acquired18,372 (10,859)7,513 3.3
Non-compete agreements750 (750)— 0.0
Total intangible assets$37,192 $(18,777)$18,415 6.6
(In thousands, except weighted average useful life)December 31, 2023
Intangible assets:
Gross Carrying
Value
Accumulated
Amortization
Net Carrying
Value
Weighted
Average Useful
Life (in years)
Customer relationships$9,936 $(4,217)$5,719 10.7
Tradenames8,134 (2,077)6,057 11.3
Technology - acquired18,372 (9,123)9,249 4.1
Non-compete agreements750 (626)124 0.8
Total intangible assets$37,192 $(16,043)$21,149 7.3
Schedule of Amortization Expense for Finite-Lived Intangible Assets As of September 30, 2024, the Company expects to record the following amortization expense for definite-lived intangible assets:
(In thousands)Amortization
Expense
For the Years Ending December 31,
2024 (3 months remaining)$868 
20253,468 
20263,358 
20272,605 
20281,500 
Thereafter6,616 
Total$18,415 
v3.24.3
Accrued expenses and other current liabilities (Tables)
9 Months Ended
Sep. 30, 2024
Investments, Debt and Equity Securities [Abstract]  
Schedule of Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities consist of the following as of September 30, 2024 and December 31, 2023:
September 30,December 31,
(In thousands)20242023
Accrued expenses$2,864 $6,667 
Accrued taxes373 551 
Accrued compensation4,777 2,902 
Deferred revenue, current435 655 
Total accrued expenses and other current liabilities$8,449 $10,775 
v3.24.3
Long-term debt (Tables)
9 Months Ended
Sep. 30, 2024
Debt Disclosure [Abstract]  
Schedule of Debt
Long-term debt consisted of the following as of September 30, 2024 and December 31, 2023:
September 30,December 31,
(In thousands)Maturity DateInterest Rate20242023
Global Cooling Amended Term NotesVarious4.0 %$— $2,596 
Term LoanJun-267.0 %17,500 20,000 
Insurance premium financingJul-258.3 %1,712 1,348 
Freezer equipment loanDec-255.7 %200 317 
Manufacturing equipment loansOct-255.7 %97 172 
Freezer installation loanVarious6.3 %593 807 
Other loansVariousVarious
Total debt, excluding unamortized debt issuance costs20,103 25,242 
Less: unamortized debt issuance costs(49)(98)
Total debt20,054 25,144 
Less: current portion of debt(12,231)(6,833)
Total long-term debt$7,823 $18,311 
Schedule of Maturities of Long-Term Debt
As of September 30, 2024, the scheduled maturities of loans payable for each of the next five years and thereafter were as follows:
(In thousands)Amount
2024 (3 months remaining)$3,177 
202511,659 
20265,218 
2027
2028
Thereafter
Total debt$20,054 
v3.24.3
Revenue (Tables)
9 Months Ended
Sep. 30, 2024
Revenue from Contract with Customer [Abstract]  
Schedule of Bioproduction Tools and Service Revenues
Total bioproduction tools and services revenue for the three and nine months ended September 30, 2024 and 2023 were composed of the following:
Three Months Ended
September 30,
Nine Months Ended
September 30,
(In thousands, except percentages)2024202320242023
Product revenue  
Cell processing$19,030 $13,338 $53,154 $51,004 
Biostorage services$543 $365 $970 $1,099 
Freezer and thaw3,884 3,434 10,500 11,341 
Service revenue  
Biostorage services4,526 4,186 13,708 12,166 
Freezer and thaw134 191 465 407 
Rental revenue  
Biostorage services2,454 2,059 6,881 5,975 
Total revenue$30,571 $23,573 $85,678 $81,992 
Schedule of Remaining Performance Obligations
The balances in the table below are partially based on judgments involved in estimating future orders from customers pursuant to their respective contracts:
(In thousands)2024 (3 months remaining)20252026Total
Rental revenue$812 $3,249 $812 $4,873 
v3.24.3
Stock-based compensation (Tables)
9 Months Ended
Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Service Vesting-Based Stock Option Activity
The following is a summary of service-based vesting stock option activity for the September 30, 2024, and the status of service-based vesting stock options outstanding as of September 30, 2024:
Nine Months Ended
September 30, 2024
Options
Wtd. Avg. Exercise Price
Outstanding as of beginning of period217,250 $2.21 
Exercised(58,750)2.33 
Outstanding as of September 30, 2024158,500 $2.16 
Stock options exercisable as of September 30, 2024158,500 $2.16 
Schedule of Service Vesting-Based and Market Based Restricted Stock Activity
The following is a summary of service-based vesting restricted stock activity for the nine months ended September 30, 2024, and the status of unvested service-based vesting restricted stock outstanding as of September 30, 2024:
Nine Months Ended
September 30, 2024
Shares
Wtd. Avg. Grant Date Fair Value
Outstanding as of beginning of period2,312,898 $18.32 
Granted484,886 20.53 
Vested(701,436)25.83 
Forfeited(116,386)17.33 
Non-vested as of September 30, 20241,979,962 $16.22 
The following is a summary of market-based restricted stock activity under our stock option plan for the nine months ended September 30, 2024 and the status of market-based restricted stock outstanding as of September 30, 2024:
Nine Months Ended
September 30, 2024
Shares
Wtd. Avg. Grant
Outstanding as of beginning of period509,166 $26.50 
Granted299,565 27.12 
Vested(300,529)27.97 
Non-vested as of September 30, 2024508,202 $25.70 
Schedule of Stock Compensation Expense We recorded total stock compensation expense for the three and nine months ended September 30, 2024 and 2023, as follows:
 Three Months Ended
September 30,
Nine Months Ended
September 30,
(In thousands)2024202320242023
Cost of revenue$826 $1,031 $2,482 $2,991 
General and administrative costs2,873 3,349 8,648 9,497 
Sales and marketing costs1,001 1,920 2,909 3,575 
Research and development costs624 1,684 1,983 3,652 
Total$5,324 $7,984 $16,022 $19,715 
v3.24.3
Net loss from continuing operations per common share (Tables)
9 Months Ended
Sep. 30, 2024
Earnings Per Share [Abstract]  
Schedule of Computations of Basic and Diluted Earnings Per Share
The following table presents computations of basic and diluted earnings per share:
Three Months Ended
September 30,
Nine Months Ended
September 30,
(In thousands, except share and earnings per share data)2024202320242023
Basic earnings (loss) per common share
Numerator:
Net loss from continuing operations$(1,703)$(15,804)$(13,061)$(30,043)
Net loss from continuing operations allocated to common shareholders(1,703)(15,804)(13,061)(30,043)
Denominator:
Weighted-average common shares issued and outstanding46,175,34543,570,43845,871,71543,348,412
Basic and diluted loss from continuing operations per common share$(0.04)$(0.36)$(0.28)$(0.69)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
The following table sets forth the number of weighted-average shares of common stock excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:
Three Months Ended
September 30,
Nine Months Ended
September 30,
2024202320242023
Stock options and restricted stock awards3,939,4172,636,2833,774,6973,007,126
Total3,939,4172,636,2833,774,6973,007,126
v3.24.3
Organization and significant accounting policies - Narrative (Details)
$ in Millions
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2023
Sep. 30, 2024
USD ($)
reportable_segment
reporting_unit
Sep. 30, 2023
Dec. 31, 2023
USD ($)
Short-Term Debt [Line Items]        
Number of reportable segments | reportable_segment   1    
Number of reporting units | reporting_unit   1    
Cash, cash equivalents, and available-for-sale securities | $   $ 39.3   $ 50.2
Supply Purchase | Supplier Concentration Risk | One Supplier        
Short-Term Debt [Line Items]        
Concentration risk, percent 19.00%   16.00%  
Accounts Payable | Supplier Concentration Risk | One Supplier        
Short-Term Debt [Line Items]        
Concentration risk, percent   11.00%   11.00%
v3.24.3
Organization and significant accounting policies - Schedule of Concentrations of Credit Risk and Business Risk (Details) - Customer Concentration Risk
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2024
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Customer A | Accounts Receivable        
Concentration Risk [Line Items]        
Concentration risk, percent   16.00%   17.00%
Customer B | Revenue        
Concentration Risk [Line Items]        
Concentration risk, percent   11.00% 11.00%  
Customer C | Revenue        
Concentration Risk [Line Items]        
Concentration risk, percent 11.00%      
v3.24.3
Organization and significant accounting policies - Schedule of Product Revenue Concentration (Details) - Revenue
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Revenue by customers' geographic locations        
Concentration Risk [Line Items]        
Concentration risk, percent 100.00% 100.00% 100.00% 100.00%
Revenue by customers' geographic locations | United States        
Concentration Risk [Line Items]        
Concentration risk, percent 76.00% 81.00% 77.00% 82.00%
Revenue by customers' geographic locations | Europe, Middle East, Africa (EMEA)        
Concentration Risk [Line Items]        
Concentration risk, percent 19.00% 15.00% 18.00% 14.00%
Revenue by customers' geographic locations | Other        
Concentration Risk [Line Items]        
Concentration risk, percent 5.00% 4.00% 5.00% 4.00%
CryoStor | Product revenue concentration        
Concentration Risk [Line Items]        
Concentration risk, percent 52.00% 46.00% 51.00% 53.00%
v3.24.3
Correction of immaterial errors (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Unaudited Condensed Consolidated Balance Sheet    
Additional paid-in-capital   $ 652,880
Accumulated deficit $ (347,560) (314,917)
As reported    
Unaudited Condensed Consolidated Balance Sheet    
Additional paid-in-capital   651,305
Accumulated deficit   (313,342)
Adjustment    
Unaudited Condensed Consolidated Balance Sheet    
Additional paid-in-capital   1,575
Accumulated deficit   $ (1,575)
v3.24.3
Discontinued operations - Narrative (Details)
$ in Thousands
3 Months Ended 9 Months Ended
Apr. 17, 2024
USD ($)
employee
Sep. 30, 2023
USD ($)
Sep. 30, 2023
USD ($)
Discontinued Operations, Disposed of by Sale | Global Cooling      
Discontinued Operations [Line Items]      
Cash required on closing date, funded by entity $ 6,652    
Repayment of indebtedness 2,600    
Other liabilities $ 2,643    
Expected reduction of workforce | employee 47    
Expected reduction of workforce (percent) 11.00%    
Period of transition services 90 days    
Depreciation   $ 100 $ 400
Capital expenditure cost   $ 200 700
Amortization     $ 100
Global Cooling      
Discontinued Operations [Line Items]      
Cash required on closing date $ 7,000    
v3.24.3
Discontinued operations - Loss on Disposal of Global Cooling (Details) - Discontinued Operations, Disposed of by Sale - Global Cooling
$ / shares in Units, $ in Thousands
Apr. 17, 2024
USD ($)
$ / shares
Discontinued Operations [Line Items]  
Selling price per share (in dollars per share) | $ / shares $ 1
Selling price: $1 $ 0
Cash to Global Cooling funded by Company (6,652)
Costs to sell Global Cooling (582)
Negative selling price (7,234)
Global Cooling carrying basis as of April 17, 2024, inclusive of assumed liabilities (3,589)
Assumed liabilities: Accounts payable 2,643
Assumed liabilities: Debt 2,596
Global Cooling carrying basis as of April 17, 2024 1,650
Release of Global Cooling currency translation adjustment (13)
Net loss on disposal (8,897)
Accounts payable 500
Accrued expenses $ 2,100
v3.24.3
Discontinued operations - RIF and Stock Compensation Expense Acceleration (Details)
$ in Thousands
9 Months Ended
Sep. 30, 2024
USD ($)
Discontinued Operations [Line Items]  
RIF employee costs $ 1,546
Former Global Cooling employees 1,925
Total employment related divestiture expenditures 3,471
Severance  
Discontinued Operations [Line Items]  
RIF employee costs 291
Former Global Cooling employees 0
Total employment related divestiture expenditures 291
Stock Compensation  
Discontinued Operations [Line Items]  
RIF employee costs 1,255
Former Global Cooling employees 1,925
Total employment related divestiture expenditures $ 3,180
v3.24.3
Discontinued operations - Assets and Liabilities of Discontinued Operations (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Apr. 17, 2024
Dec. 31, 2023
Discontinued Operations [Line Items]      
Total current assets, discontinued operations $ 0   $ 15,369
Total current liabilities, discontinued operations $ 0   12,796
Discontinued Operations, Disposed of by Sale | Global Cooling      
Discontinued Operations [Line Items]      
Cash and cash equivalents   $ 275 2,090
Accounts receivable, net   2,430 1,728
Inventories   9,152 11,248
Prepaid expenses and other current assets   379 303
Total current assets, discontinued operations   12,236 15,369
Property and equipment, net   153 146
Long-term deposits and other assets   4 4
Total assets, discontinued operations   12,393 15,519
Accounts payable   1,425 3,367
Accrued expenses and other current liabilities   911 1,637
Warranty liability   7,193 7,507
Lease liabilities, operating, current portion   242 263
Lease liabilities, financing, current portion   16 22
Total current liabilities, discontinued operations   9,787 12,796
Lease liabilities, operating, long-term   948 1,016
Lease liabilities, financing, long-term   8 11
Total liabilities, discontinued operations   $ 10,743 $ 13,823
v3.24.3
Discontinued operations - Components of Loss from Discontinued Operations (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Discontinued Operations [Line Items]        
Loss on disposal     $ (8,897) $ 0
Loss before income taxes $ 0 $ (13,328) (19,572) (22,999)
Income tax expense 0 0 (10) (3)
Loss from discontinued operations 0 (13,328) (19,582) (23,002)
Discontinued Operations, Disposed of by Sale | Global Cooling        
Discontinued Operations [Line Items]        
Revenue 0 9,755 7,157 28,546
Cost of revenue 0 10,100 8,389 28,048
Gross profit 0 (345) (1,232) 498
Operating expenses 0 (5,789) (9,418) (16,259)
Asset impairment charges 0 (7,175) 0 (7,175)
Other income (expense), net 0 (19) (25) (63)
Loss on disposal 0 0 (8,897) 0
Loss before income taxes 0 (13,328) (19,572) (22,999)
Income tax expense 0 0 (10) (3)
Loss from discontinued operations $ 0 $ (13,328) $ (19,582) $ (23,002)
v3.24.3
Fair value measurement - Narrative (Details)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Oct. 01, 2020
USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]          
Change in fair value of contingent consideration, increase (decrease) $ 0 $ (1,580) $ 0 $ (1,778)  
SciSafe Holdings, Inc          
Fair Value Measurement Inputs and Valuation Techniques [Line Items]          
Contingent consideration, liability         $ 3,700
Change in fair value of contingent consideration, increase (decrease)   $ (1,600)   $ (1,800)  
SciSafe Holdings, Inc | Discount Rate          
Fair Value Measurement Inputs and Valuation Techniques [Line Items]          
Contingent consideration, liability, measurement input         0.045
SciSafe Holdings, Inc | Risk Free Interest Rate          
Fair Value Measurement Inputs and Valuation Techniques [Line Items]          
Contingent consideration, liability, measurement input         0.002
SciSafe Holdings, Inc | Asset Price Volatility          
Fair Value Measurement Inputs and Valuation Techniques [Line Items]          
Contingent consideration, liability, measurement input         0.60
SciSafe Holdings, Inc | Revenue Volatility          
Fair Value Measurement Inputs and Valuation Techniques [Line Items]          
Contingent consideration, liability, measurement input         0.15
v3.24.3
Fair value measurement - Schedule of the Company's Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Assets:    
Available-for-sale securities $ 15,095 $ 16,836
Fair Value, Recurring    
Assets:    
Assets 28,826 41,870
Fair Value, Recurring | U.S. government securities    
Assets:    
Available-for-sale securities 2,679 5,170
Fair Value, Recurring | Corporate debt securities    
Assets:    
Available-for-sale securities 9,130 9,674
Fair Value, Recurring | Other debt securities    
Assets:    
Available-for-sale securities 3,286 1,992
Level 1 | Fair Value, Recurring    
Assets:    
Assets 16,805 30,204
Level 1 | Fair Value, Recurring | U.S. government securities    
Assets:    
Available-for-sale securities 2,679 5,170
Level 1 | Fair Value, Recurring | Corporate debt securities    
Assets:    
Available-for-sale securities 395 0
Level 1 | Fair Value, Recurring | Other debt securities    
Assets:    
Available-for-sale securities 0 0
Level 2 | Fair Value, Recurring    
Assets:    
Assets 12,021 11,666
Level 2 | Fair Value, Recurring | U.S. government securities    
Assets:    
Available-for-sale securities 0 0
Level 2 | Fair Value, Recurring | Corporate debt securities    
Assets:    
Available-for-sale securities 8,735 9,674
Level 2 | Fair Value, Recurring | Other debt securities    
Assets:    
Available-for-sale securities 3,286 1,992
Level 3 | Fair Value, Recurring    
Assets:    
Assets 0 0
Level 3 | Fair Value, Recurring | U.S. government securities    
Assets:    
Available-for-sale securities 0 0
Level 3 | Fair Value, Recurring | Corporate debt securities    
Assets:    
Available-for-sale securities 0 0
Level 3 | Fair Value, Recurring | Other debt securities    
Assets:    
Available-for-sale securities 0 0
Money market accounts | Fair Value, Recurring    
Assets:    
Cash equivalents 13,731 25,034
Money market accounts | Level 1 | Fair Value, Recurring    
Assets:    
Cash equivalents 13,731 25,034
Money market accounts | Level 2 | Fair Value, Recurring    
Assets:    
Cash equivalents 0 0
Money market accounts | Level 3 | Fair Value, Recurring    
Assets:    
Cash equivalents $ 0 $ 0
v3.24.3
Fair value measurement - Schedule of the Changes in Fair Value of Contingent Consideration Liabilities (Details) - Contingent Consideration Liabilities
$ in Thousands
9 Months Ended
Sep. 30, 2023
USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]  
Beginning balance $ 4,456
Change in fair value recognized in net loss (1,778)
Payment of contingent consideration earned (2,263)
Ending balance $ 415
v3.24.3
Investments - Schedule of Available-for-Sale Marketable Securities (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Debt Securities, Available-for-Sale [Line Items]    
Amortized Cost, current portion $ 10,188 $ 16,285
Gross unrealized Gains, current portion 23 7
Gross unrealized Losses, current portion 0 (4)
Available-for-sale securities, current portion 10,211 16,288
Amortized Cost, long term 4,854  
Available-for-sale securities, long-term 4,884 548
Total 15,042 16,830
Total marketable securities, Gross Unrealized Gains 53 10
Total marketable securities, Gross Unrealized Losses 0 (4)
Estimated Fair Value, Total marketable securities 15,095 16,836
Amortized Cost    
Due in one year or less 10,188 16,285
Due after one year through five years 4,854  
Total 15,042 16,830
Estimated Fair Value    
Due in one year or less 10,211 16,288
Due after one year through five years 4,884  
Total 15,095 16,836
U.S. government securities    
Debt Securities, Available-for-Sale [Line Items]    
Amortized Cost, current portion 2,676 5,169
Gross unrealized Gains, current portion 3 1
Gross unrealized Losses, current portion 0 0
Available-for-sale securities, current portion 2,679 5,170
Amortized Cost    
Due in one year or less 2,676 5,169
Estimated Fair Value    
Due in one year or less 2,679 5,170
Corporate debt securities    
Debt Securities, Available-for-Sale [Line Items]    
Amortized Cost, current portion 6,149 9,673
Gross unrealized Gains, current portion 16 5
Gross unrealized Losses, current portion 0 (4)
Available-for-sale securities, current portion 6,165 9,674
Amortized Cost, long term 2,944  
Gross unrealized Gains, long term 21  
Gross unrealized Losses, long term 0  
Available-for-sale securities, long-term 2,965  
Amortized Cost    
Due in one year or less 6,149 9,673
Due after one year through five years 2,944  
Estimated Fair Value    
Due in one year or less 6,165 9,674
Other debt securities    
Debt Securities, Available-for-Sale [Line Items]    
Amortized Cost, current portion 1,363 1,443
Gross unrealized Gains, current portion 4 1
Gross unrealized Losses, current portion 0 0
Available-for-sale securities, current portion 1,367 1,444
Amortized Cost, long term 1,910 545
Gross unrealized Gains, long term 9 3
Gross unrealized Losses, long term 0 0
Available-for-sale securities, long-term 1,919 548
Amortized Cost    
Due in one year or less 1,363 1,443
Due after one year through five years 1,910 545
Estimated Fair Value    
Due in one year or less $ 1,367 $ 1,444
v3.24.3
Investments - Narrative (Details) - USD ($)
6 Months Ended
Jun. 30, 2024
Sep. 30, 2024
Dec. 31, 2023
PanTHERA CryoSolutions, Inc. | Series E Preferred Stock      
Debt and Equity Securities, FV-NI [Line Items]      
Fair value of non-marketable equity securities without readily determinable fair value   $ 1,000,000.0 $ 1,000,000.0
iVexSol, Inc.      
Debt and Equity Securities, FV-NI [Line Items]      
Fair value of non-marketable equity securities without readily determinable fair value   $ 0  
Impairment charge $ 4,100,000    
iVexSol, Inc. | Series A-1 and A-2, Preferred Stock      
Debt and Equity Securities, FV-NI [Line Items]      
Fair value of non-marketable equity securities without readily determinable fair value     $ 4,100,000
v3.24.3
Inventories (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Inventory Disclosure [Abstract]    
Raw materials $ 12,722 $ 16,932
Work in progress 6,647 5,890
Finished goods 12,810 9,386
Total inventories $ 32,179 $ 32,208
v3.24.3
Leases - Narrative (Details)
Sep. 30, 2024
Minimum | Real Estate Lease  
Lessee, Lease, Description [Line Items]  
Operating lease, term of contract 3 years
Operating lease, remaining lease term 1 year
Operating lease, renewal term 1 year
Minimum | Vehicle and Other Equipment  
Lessee, Lease, Description [Line Items]  
Operating lease, term of contract 4 years
Operating lease, remaining lease term 1 year
Maximum | Real Estate Lease  
Lessee, Lease, Description [Line Items]  
Operating lease, term of contract 11 years
Operating lease, remaining lease term 8 years
Operating lease, renewal term 5 years
Maximum | Vehicle and Other Equipment  
Lessee, Lease, Description [Line Items]  
Operating lease, term of contract 5 years
Operating lease, remaining lease term 5 years
v3.24.3
Leases - Schedule of Operating and Finance Lease Terms and Discount Rates (Details)
Sep. 30, 2024
Dec. 31, 2023
Leases [Abstract]    
Weighted average discount rate - operating leases 5.80% 4.40%
Weighted average discount rate - finance leases 8.40% 8.30%
Weighted average remaining lease term in years - operating leases 6 years 1 month 6 days 6 years 7 months 6 days
Weighted average remaining lease term in years - finance leases 3 years 6 months 4 years 1 month 6 days
v3.24.3
Leases - Schedule of Lease Expense (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Leases [Abstract]        
Operating lease costs $ 1,018 $ 810 $ 2,639 $ 2,460
Financing lease costs 57 0 173 0
Short-term lease costs 452 510 1,263 1,266
Total operating lease costs 1,527 1,320 4,075 3,726
Variable lease costs 446 299 1,166 903
Total lease costs $ 1,973 $ 1,619 $ 5,241 $ 4,629
v3.24.3
Leases - Schedule of Maturities Operating and Finance Lease Liabilities (Details)
$ in Thousands
Sep. 30, 2024
USD ($)
Operating Leases  
2024 (3 months remaining) $ 857
2025 3,630
2026 3,249
2027 2,970
2028 3,021
Thereafter 7,794
Total lease payments 21,521
Less: interest (3,544)
Total present value of lease liabilities 17,977
Financing Leases  
2024 (3 months remaining) 103
2025 413
2026 389
2027 387
2028 134
Thereafter 0
Total lease payments 1,426
Less: interest (190)
Total present value of lease liabilities $ 1,236
v3.24.3
Assets held for rent - Schedule of Assets Held for Rent (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]    
Shippers placed in service $ 9,862 $ 9,866
Fixed assets held for rent 6,538 1,468
Accumulated depreciation (8,813) (6,272)
Subtotal 7,587 5,062
Shippers and related components in production 3,235 2,651
Total $ 10,822 $ 7,713
v3.24.3
Assets held for rent - Narrative (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]        
Assets held for rent, depreciation expense $ 0.8 $ 0.9 $ 2.3 $ 2.8
v3.24.3
Property and equipment - Schedule of Property and Equipment (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Property, Plant and Equipment [Line Items]    
Subtotal $ 27,940 $ 30,386
Less: Accumulated depreciation (10,231) (9,456)
Property and equipment, net 17,709 20,930
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Subtotal 5,982 5,913
Furniture and computer equipment    
Property, Plant and Equipment [Line Items]    
Subtotal 769 773
Manufacturing and other equipment    
Property, Plant and Equipment [Line Items]    
Subtotal 17,084 19,893
Construction in-progress    
Property, Plant and Equipment [Line Items]    
Subtotal $ 4,105 $ 3,807
v3.24.3
Property and equipment - Narrative (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Property, Plant and Equipment [Abstract]        
Property and equipment, depreciation expense $ 0.6 $ 1.0 $ 1.9 $ 2.9
v3.24.3
Goodwill and intangible assets - Schedule of Finite-Lived Intangible Assets (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]    
Accumulated Amortization $ (18,777) $ (16,043)
Net Carrying Value $ 18,415  
Weighted Average Useful Life (in years) 6 years 7 months 6 days 7 years 3 months 18 days
Intangible assets, gross $ 37,192 $ 37,192
Intangible assets, net 18,415 21,149
Customer relationships    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 9,936 9,936
Accumulated Amortization (4,625) (4,217)
Net Carrying Value $ 5,311 $ 5,719
Weighted Average Useful Life (in years) 9 years 10 months 24 days 10 years 8 months 12 days
Tradenames    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value $ 8,134 $ 8,134
Accumulated Amortization (2,543) (2,077)
Net Carrying Value $ 5,591 $ 6,057
Weighted Average Useful Life (in years) 10 years 6 months 11 years 3 months 18 days
Technology - acquired    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value $ 18,372 $ 18,372
Accumulated Amortization (10,859) (9,123)
Net Carrying Value $ 7,513 $ 9,249
Weighted Average Useful Life (in years) 3 years 3 months 18 days 4 years 1 month 6 days
Non-compete agreements    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value $ 750 $ 750
Accumulated Amortization (750) (626)
Net Carrying Value $ 0 $ 124
Weighted Average Useful Life (in years) 0 years 9 months 18 days
v3.24.3
Goodwill and intangible assets - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]        
Intangible asset amortization $ 910 $ 1,312 $ 2,734 $ 4,135
v3.24.3
Goodwill and intangible assets - Schedule of Amortization Expense for Finite-Lived Intangible Assets (Details)
$ in Thousands
Sep. 30, 2024
USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]  
2024 (3 months remaining) $ 868
2025 3,468
2026 3,358
2027 2,605
2028 1,500
Thereafter 6,616
Net Carrying Value $ 18,415
v3.24.3
Accrued expenses and other current liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Investments, Debt and Equity Securities [Abstract]    
Accrued expenses $ 2,864 $ 6,667
Accrued taxes 373 551
Accrued compensation 4,777 2,902
Deferred revenue, current 435 655
Total accrued expenses and other current liabilities $ 8,449 $ 10,775
v3.24.3
Commitments and contingencies (Details)
$ in Millions
Sep. 30, 2024
USD ($)
lawsuit
Dec. 31, 2023
USD ($)
Commitments and Contingencies Disclosure [Abstract]    
Number of pending litigation claims | lawsuit 2  
Short-term purchase obligations $ 4.2  
Sales and excise tax payable $ 3.8 $ 4.8
v3.24.3
Long-term debt - Narrative (Details) - USD ($)
$ in Thousands
Sep. 20, 2022
Sep. 30, 2024
Apr. 17, 2024
The 2023 Term Loan      
Debt Instrument [Line Items]      
Debt instrument, maximum borrowing capacity $ 60,000    
Maximum borrowing capacity 30,000    
Options to borrow 10,000    
Debt instrument, additional maximum amount upon certain milestone achievements 10,000    
Debt instrument, additional maximum at discretion of lender 10,000    
Proceeds from term loans $ 20,000    
Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration] Prime Rate [Member]    
Debt instrument, interest rate, maximum stated percentage for each tranche borrowed 1.00%    
Debt instrument, balloon payment due $ 1,200    
Interest rate   7.50%  
Debt instrument, face amount   $ 18,200  
The 2023 Term Loan | Variable Rate Component Two      
Debt Instrument [Line Items]      
Debt instrument, basis spread on variable rate 0.50%    
Second Amendment Term Loan      
Debt Instrument [Line Items]      
Termination fee, amount     $ 500
v3.24.3
Long-term debt - Schedule of Debt (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Debt Instrument [Line Items]    
Total debt, excluding unamortized debt issuance costs $ 20,103 $ 25,242
Less: unamortized debt issuance costs (49) (98)
Total debt 20,054 25,144
Less: current portion of debt (12,231) (6,833)
Total long-term debt $ 7,823 $ 18,311
Global Cooling Amended Term Notes    
Debt Instrument [Line Items]    
Interest Rate 4.00% 4.00%
Total debt, excluding unamortized debt issuance costs $ 0 $ 2,596
Term Loan    
Debt Instrument [Line Items]    
Interest Rate 7.00% 7.00%
Total debt, excluding unamortized debt issuance costs $ 17,500 $ 20,000
Insurance premium financing    
Debt Instrument [Line Items]    
Interest Rate 8.30% 8.30%
Total debt, excluding unamortized debt issuance costs $ 1,712 $ 1,348
Freezer equipment loan    
Debt Instrument [Line Items]    
Interest Rate 5.70% 5.70%
Total debt, excluding unamortized debt issuance costs $ 200 $ 317
Manufacturing equipment loans    
Debt Instrument [Line Items]    
Interest Rate 5.70% 5.70%
Total debt, excluding unamortized debt issuance costs $ 97 $ 172
Freezer installation loan    
Debt Instrument [Line Items]    
Interest Rate 6.30% 6.30%
Total debt, excluding unamortized debt issuance costs $ 593 $ 807
Other loans    
Debt Instrument [Line Items]    
Total debt, excluding unamortized debt issuance costs 1 2
Total long-term debt    
Debt Instrument [Line Items]    
Total long-term debt $ 7,823 $ 18,311
v3.24.3
Long-term debt - Schedule of Maturities of Long-Term Debt (Details) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Debt Disclosure [Abstract]    
2024 (3 months remaining) $ 3,177  
2025 11,659  
2026 5,218  
2027 0  
2028 0  
Thereafter 0  
Total debt $ 20,054 $ 25,144
v3.24.3
Revenue - Narrative (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]          
Deferred revenue $ 0.4   $ 0.4   $ 0.7
Deferred revenue, revenue recognized $ 0.1 $ 0.1 $ 0.6 $ 0.4  
v3.24.3
Revenue - Schedule of Bioproduction Tools and Service Revenues (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Disaggregation of Revenue [Line Items]        
Total product, rental, and service revenue $ 30,571 $ 23,573 $ 85,678 $ 81,992
Product revenue        
Disaggregation of Revenue [Line Items]        
Total product, rental, and service revenue 23,457 17,137 64,624 63,444
Cell processing        
Disaggregation of Revenue [Line Items]        
Total product, rental, and service revenue 19,030 13,338 53,154 51,004
Biostorage services        
Disaggregation of Revenue [Line Items]        
Total product, rental, and service revenue 543 365 970 1,099
Freezer and thaw        
Disaggregation of Revenue [Line Items]        
Total product, rental, and service revenue 3,884 3,434 10,500 11,341
Service revenue        
Disaggregation of Revenue [Line Items]        
Total product, rental, and service revenue 4,660 4,377 14,173 12,573
Biostorage services        
Disaggregation of Revenue [Line Items]        
Total product, rental, and service revenue 4,526 4,186 13,708 12,166
Freezer and thaw        
Disaggregation of Revenue [Line Items]        
Total product, rental, and service revenue 134 191 465 407
Rental revenue        
Disaggregation of Revenue [Line Items]        
Total product, rental, and service revenue 2,454 2,059 6,881 5,975
Biostorage services        
Disaggregation of Revenue [Line Items]        
Total product, rental, and service revenue $ 2,454 $ 2,059 $ 6,881 $ 5,975
v3.24.3
Revenue - Schedule of Remaining Performance Obligations (Details)
$ in Thousands
Sep. 30, 2024
USD ($)
Rental revenue  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue, remaining performance obligation, amount $ 4,873
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-10-01 | Rental revenue  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue, remaining performance obligation, amount $ 812
Revenue, remaining performance obligation, expected timing of satisfaction, period 3 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-10-01 | Service revenue  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue, remaining performance obligation, expected timing of satisfaction, period 3 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01 | Rental revenue  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue, remaining performance obligation, amount $ 3,249
Revenue, remaining performance obligation, expected timing of satisfaction, period 1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01 | Service revenue  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue, remaining performance obligation, expected timing of satisfaction, period 1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01 | Rental revenue  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue, remaining performance obligation, amount $ 812
Revenue, remaining performance obligation, expected timing of satisfaction, period 1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01 | Service revenue  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Revenue, remaining performance obligation, expected timing of satisfaction, period 1 year
v3.24.3
Stock-based compensation - Schedule of Service Vesting-Based Stock Option Activity (Details) - $ / shares
9 Months Ended
Sep. 30, 2024
Options  
Outstanding as of beginning of period (in shares) 217,250
Exercised (in shares) (58,750)
Outstanding as of end of period (in shares) 158,500
Stock options exercisable at end of period (in shares) 158,500
Wtd. Avg. Exercise Price  
Outstanding as of beginning of period (in dollars per share) $ 2.21
Exercised (in dollars per share) 2.33
Outstanding as of end of period (in dollars per share) 2.16
Stock options exercisable at end of period (in dollars per share) $ 2.16
v3.24.3
Stock-based compensation - Narrative (Details)
3 Months Ended 9 Months Ended 12 Months Ended
Mar. 08, 2024
USD ($)
peer
$ / shares
shares
Jan. 03, 2023
USD ($)
peer
shares
Feb. 24, 2022
USD ($)
peer
shares
Sep. 30, 2024
USD ($)
$ / shares
shares
Sep. 30, 2023
USD ($)
shares
Sep. 30, 2024
USD ($)
$ / shares
shares
Sep. 30, 2023
USD ($)
shares
Dec. 31, 2023
USD ($)
$ / shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Aggregate intrinsic value of exercisable service vesting-based stock options       $ 3,600,000   $ 3,600,000    
Intrinsic value of service vesting-based awards exercised       $ 500,000   $ 1,100,000    
Service based-vesting options granted (in shares) | shares       0   0    
Weighted average remaining contractual life (year)           1 year 6 months    
Share-based payment arrangement, expense       $ 5,324,000 $ 7,984,000 $ 16,022,000 $ 19,715,000  
Number of peers | peer 20 20 20          
Comprehensive loss       (1,356,000) $ (29,293,000) $ (32,506,000) $ (53,026,000)  
Vesting period (year)           4 years    
Adjustment                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Comprehensive loss               $ (1,600,000)
Options                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Unrecognized compensation costs for service vesting-based stock options       0   $ 0    
Restricted Stock                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Unrecognized compensation costs for service vesting-based stock options       26,800,000   26,800,000    
Aggregate fair value of the service vesting-based awards granted       6,700,000   10,000,000.0    
Aggregate fair value of the service vesting-based awards that vested       2,300,000   8,000,000.0    
Share-based payment arrangement, expense       $ 3,800,000   $ 11,700,000    
Period for recognition (year)           2 years 8 months 12 days    
Granted (in shares) | shares           484,886    
Grant date fair value (in dollars per share) | $ / shares       $ 16.22   $ 16.22   $ 18.32
Vested (in shares) | shares           701,436    
Performance Shares                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Unrecognized compensation costs for service vesting-based stock options       $ 1,200,000   $ 1,200,000    
Service based-vesting options granted (in shares) | shares         0   0  
Share-based payment arrangement, expense       200,000   $ 700,000    
Period for recognition (year)           1 year 2 months 12 days    
Granted (in shares) | shares 109,512              
Grant date fair value (in dollars per share) | $ / shares $ 17.36              
Aggregate fair value of the market-based awards granted       $ 1,900,000   $ 1,900,000    
Vested (in shares) | shares       0   0    
Market-based Restricted Stock                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Unrecognized compensation costs for service vesting-based stock options       $ 4,400,000   $ 4,400,000    
Share-based payment arrangement, expense       $ 1,300,000 $ 1,600,000 $ 3,700,000 $ 4,900,000  
Period for recognition (year)           1 year 1 month 6 days    
Granted (in shares) | shares 300,529         299,565    
Grant date fair value (in dollars per share) | $ / shares       $ 25.70   $ 25.70   $ 26.50
Aggregate fair value of the market-based awards granted       $ 0 0 $ 6,300,000 6,500,000  
Vested (in shares) | shares           300,529    
Total shareholder return attainment (percent) 125.00%              
Historical volatility (percent) 80.00% 78.00% 63.00%          
Dividend yield (percent) 0.00% 0.00% 0.00%          
Risk-free interest rate 4.60% 4.40% 1.50%          
Measurement date with a maturity period (year) 2 years 2 years 2 years          
Aggregate fair value of the market-based awards that vested       $ 0 $ 0 $ 5,100,000 $ 700,000  
Market-based Restricted Stock | Minimum                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Total shareholder return attainment (percent) 0.00% 0.00%            
Market-based Restricted Stock | Maximum                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Total shareholder return attainment (percent) 200.00% 200.00%            
Market-based Restricted Stock | Executive Officer                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Share-based payment arrangement, expense $ 6,300,000 $ 6,800,000 $ 6,700,000          
Granted (in shares) | shares 239,464 268,738 240,428          
v3.24.3
Stock-based compensation - Schedule of Service Vesting-Based and Market Based Restricted Stock Activity (Details) - $ / shares
9 Months Ended
Mar. 08, 2024
Sep. 30, 2024
Restricted Stock    
Shares    
Outstanding as of beginning of period (in shares)   2,312,898
Granted (in shares)   484,886
Vested (in shares)   (701,436)
Forfeited (in shares)   (116,386)
Outstanding as of end of period (in shares)   1,979,962
Wtd. Avg. Grant Date Fair Value    
Outstanding as of beginning of period (in dollars per share)   $ 18.32
Granted (in dollars per share)   20.53
Vested (in dollars per share)   25.83
Forfeited (in dollars per share)   17.33
Outstanding as of end of period (in dollars per share)   $ 16.22
Market-based Restricted Stock    
Shares    
Outstanding as of beginning of period (in shares)   509,166
Granted (in shares) 300,529 299,565
Vested (in shares)   (300,529)
Outstanding as of end of period (in shares)   508,202
Wtd. Avg. Grant Date Fair Value    
Outstanding as of beginning of period (in dollars per share)   $ 26.50
Granted (in dollars per share)   27.12
Vested (in dollars per share)   27.97
Outstanding as of end of period (in dollars per share)   $ 25.70
v3.24.3
Stock-based compensation - Schedule of Stock Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Total $ 5,324 $ 7,984 $ 16,022 $ 19,715
Cost of revenue        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Total 826 1,031 2,482 2,991
General and administrative costs        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Total 2,873 3,349 8,648 9,497
Sales and marketing costs        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Total 1,001 1,920 2,909 3,575
Research and development costs        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Total $ 624 $ 1,684 $ 1,983 $ 3,652
v3.24.3
Income taxes (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Income Tax Disclosure [Abstract]        
Income tax expense (benefit) $ (28) $ 115 $ 93 $ 209
Effective income tax rate reconciliation, percent     (0.70%)  
Effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount     $ 1,200  
Effective income tax rate reconciliation, at federal statutory income tax rate, without discrete items percent     (0.70%)  
Effective income tax rate reconciliation, at federal statutory income tax rate, percent     21.00%  
v3.24.3
Net loss from continuing operations per common share - Schedule of Computations of Basic and Diluted Earnings Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Numerator:        
Net loss from continuing operations $ (1,703) $ (15,804) $ (13,061) $ (30,043)
Net loss from continuing operations allocated to common shareholders (1,703) (15,804) (13,061) (30,043)
Net loss from continuing operations allocated to common shareholders $ (1,703) $ (15,804) $ (13,061) $ (30,043)
Denominator:        
Weighted-average common shares issued, basic (in shares) 46,175,345 43,570,438 45,871,715 43,348,412
Weighted-average common shares outstanding, basic (in shares) 46,175,345 43,570,438 45,871,715 43,348,412
Weighted-average common shares issued, diluted (in shares) 46,175,345 43,570,438 45,871,715 43,348,412
Weighted-average common shares outstanding, diluted (in shares) 46,175,345 43,570,438 45,871,715 43,348,412
Basic loss from continuing operations per common share (in dollars per share) $ (0.04) $ (0.36) $ (0.28) $ (0.69)
Diluted loss from continuing operations per common share (in dollars per share) $ (0.04) $ (0.36) $ (0.28) $ (0.69)
v3.24.3
Net loss from continuing operations per common share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of earnings per share, amount (in shares) 3,939,417 2,636,283 3,774,697 3,007,126
Stock options and restricted stock awards        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from computation of earnings per share, amount (in shares) 3,939,417 2,636,283 3,774,697 3,007,126
v3.24.3
Employee benefit plan (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Retirement Benefits [Abstract]        
Defined contribution plan, employer matching contribution, percent of employees' gross pay     100.00%  
Defined contribution plan, employer discretionary contribution amount $ 0.2 $ 0.2 $ 0.7 $ 0.7
v3.24.3
Subsequent events (Details) - USD ($)
$ in Thousands
9 Months Ended
Nov. 12, 2024
Sep. 30, 2024
Nov. 11, 2024
Subsequent Event [Line Items]      
Total employment related divestiture expenditures   $ 3,471  
Severance      
Subsequent Event [Line Items]      
Total employment related divestiture expenditures   291  
Stock Compensation      
Subsequent Event [Line Items]      
Total employment related divestiture expenditures   $ 3,180  
Disposal Group, Held-for-Sale, Not Discontinued Operations | SciSafe Holdings, Inc | Subsequent Event      
Subsequent Event [Line Items]      
Repayment of indebtedness $ 900    
Legal and other transaction services fees paid 1,800    
Gain on disposal of discontinued operation, net of tax 39,600    
Disposal group, including discontinued operation, goodwill 11,100    
Disposal Group, Held-for-Sale, Not Discontinued Operations | SciSafe Holdings, Inc | Subsequent Event | Severance      
Subsequent Event [Line Items]      
Total employment related divestiture expenditures 400    
Disposal Group, Held-for-Sale, Not Discontinued Operations | SciSafe Holdings, Inc | Subsequent Event | Earn-Out Payment      
Subsequent Event [Line Items]      
Total employment related divestiture expenditures 3,300    
Disposal Group, Held-for-Sale, Not Discontinued Operations | SciSafe Holdings, Inc | Subsequent Event | Stock Compensation      
Subsequent Event [Line Items]      
Total employment related divestiture expenditures $ 4,000    
SCI Holdings | Subsequent Event      
Subsequent Event [Line Items]      
Noncompete duration 5 years    
Transition services, duration 6 months    
SCI Holdings | Disposal Group, Held-for-Sale, Not Discontinued Operations | SciSafe Holdings, Inc | Subsequent Event      
Subsequent Event [Line Items]      
Transaction price $ 73,000    
Silicon Valley Bank (SVB) | Subsequent Event      
Subsequent Event [Line Items]      
Potential termination fee if agreement is terminated prior to maturity date     $ 750

BioLife Solutions (NASDAQ:BLFS)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025 BioLife Solutions 차트를 더 보려면 여기를 클릭.
BioLife Solutions (NASDAQ:BLFS)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025 BioLife Solutions 차트를 더 보려면 여기를 클릭.